CINXE.COM

<!DOCTYPE html> <html dir="ltr" lang="en-US"> <head> <script type='text/javascript' data-ot-ignore>const otAllowScripts = ['/init.js']; new MutationObserver(function (d) { Array.prototype.forEach.call(d, function (g) { Array.prototype.forEach.call(g.addedNodes, function (e) { try { if ('script' === e.tagName?.toLowerCase() && otAllowScripts.some(s => e.src?.includes(s))) { e.setAttribute('data-ot-ignore', ''); } } catch (err) { console.error(err); } }) }) }).observe(document.documentElement, { childList: !0, subtree: !0, attributes: !0, attributeFilter: ['src'] });</script>  <script type="text/javascript" src="https://cdn.cookielaw.org/consent/7537629c-faa0-40ce-a837-f7b14c0d4e70/OtAutoBlock.js"></script> <script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="7537629c-faa0-40ce-a837-f7b14c0d4e70"></script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/lww-cookiepro.js?v=05.24.00.023"> </script> <title> Hepatology </title>   <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.setAttributeNode(d.createAttribute('data-ot-ignore'));j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-NLR6H6W');</script>  <meta name="GENERATOR" content="Microsoft SharePoint" /><meta http-equiv="Content-type" content="text/html; charset=utf-8" /><meta http-equiv="X-UA-Compatible" content="IE=edge" /><script type="text/javascript">window.NREUM||(NREUM={});NREUM.info = {"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"NRJS-310e337bbb542715b7f","applicationID":"1029107228","transactionName":"ZgdWMRZUVkVSBUBbCl9NdTY0GlBTQ0lrUQRFA1gKA0YXW1IVQFcXQQNTAEtHXUVDCVpBDEcHRAQDUFRXSglBRktQEUQd","queueTime":0,"applicationTime":598,"agent":"","atts":""}</script><script type="text/javascript">(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"1103305545",accountID:"2792772",trustKey:"1191223",xpid:"VgEOU1FUChABVFNbBgEAVFYJ",licenseKey:"NRJS-310e337bbb542715b7f",applicationID:"1029107228"};;/*! For license information please see nr-loader-spa-1.285.0.min.js.LICENSE.txt */ (()=>{var e,t,r={8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{if(null===e[a]){r[a]=null;continue}Array.isArray(e[a])&&Array.isArray(t[a])?r[a]=Array.from(new Set([...e[a],...t[a]])):"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},2555:(e,t,r)=>{"use strict";r.d(t,{Vp:()=>c,fn:()=>s,x1:()=>u});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){try{const t=c(e);return!!t.licenseKey&&!!t.errorBeacon&&!!t.applicationID}catch(e){return!1}}function c(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function u(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.info=a[e])}},9417:(e,t,r)=>{"use strict";r.d(t,{D0:()=>h,gD:()=>g,xN:()=>p});var n=r(3333);const i=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var o=r(2614),a=r(944),s=r(384),c=r(8122);const u="[data-nr-mask]",d=()=>{const e={feature_flags:[],experimental:{marks:!1,measures:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{get capture_marks(){return e.feature_flags.includes(n.$v.MARKS)||e.experimental.marks},set capture_marks(t){e.experimental.marks=t},get capture_measures(){return e.feature_flags.includes(n.$v.MEASURES)||e.experimental.measures},set capture_measures(t){e.experimental.measures=t},capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(n.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:o.wk,inactiveMs:o.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){i(t)?e.mask_selector="".concat(t,",").concat(u):""===t||null===t?e.mask_selector=u:(0,a.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){i(t)?e.block_selector+=",".concat(t):""!==t&&(0,a.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,a.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}},l={},f="All configuration objects require an agent identifier!";function h(e){if(!e)throw new Error(f);if(!l[e])throw new Error("Configuration for ".concat(e," was never set"));return l[e]}function p(e,t){if(!e)throw new Error(f);l[e]=(0,c.a)(t,d());const r=(0,s.nY)(e);r&&(r.init=l[e])}function g(e,t){if(!e)throw new Error(f);var r=h(e);if(r){for(var n=t.split("."),i=0;i<n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}},5603:(e,t,r)=>{"use strict";r.d(t,{a:()=>c,o:()=>s});var n=r(384),i=r(8122);const o={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},a={};function s(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!a[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.loader_config=a[e])}},3371:(e,t,r)=>{"use strict";r.d(t,{V:()=>f,f:()=>l});var n=r(8122),i=r(384),o=r(6154),a=r(9324);let s=0;const c={buildEnv:a.F3,distMethod:a.Xs,version:a.xv,originTime:o.WN},u={customTransaction:void 0,disabled:!1,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,onerror:void 0,ptid:void 0,releaseIds:{},appMetadata:{},session:void 0,denyList:void 0,timeKeeper:void 0,obfuscator:void 0,harvester:void 0},d={};function l(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!d[e])throw new Error("Runtime for ".concat(e," was never set"));return d[e]}function f(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");d[e]={...(0,n.a)(t,u),...c},Object.hasOwnProperty.call(d[e],"harvestCount")||Object.defineProperty(d[e],"harvestCount",{get:()=>++s});const r=(0,i.nY)(e);r&&(r.runtime=d[e])}},9324:(e,t,r)=>{"use strict";r.d(t,{F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.285.0",i="PROD",o="CDN",a="^2.0.0-alpha.18"},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>s,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>a,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),a=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),s="complete"===a?.document?.readyState,c=Boolean("hidden"===a?.document?.visibilityState),u=""+a?.location,d=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>a,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(s(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function a(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,a;i>0?(o=r.substring(0,i),a=r.substring(i)):(o=r,a="");let[s]=o.split(":");n.push({hostname:s,pathname:a})}}function s(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>c,Ze:()=>l,x3:()=>u});var n=r(7836),i=r(3606),o=r(860),a=r(2646);const s={};function c(e,t){const r={staged:!1,priority:o.P3[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function u(e,t){e&&s[e]&&(s[e].get(t)&&s[e].delete(t),h(e,t,!1),s[e].size&&f(e))}function d(e){if(!e)throw new Error("agentIdentifier required");s[e]||(s[e]=new Map)}function l(e="",t="feature",r=!1){if(d(e),!e||!s[e].get(t)||r)return h(e,t);s[e].get(t).staged=!0,f(e)}function f(e){const t=Array.from(s[e]);t.every((([e,t])=>t.staged))&&(t.sort(((e,t)=>e[1].priority-t[1].priority)),t.forEach((([t])=>{s[e].delete(t),h(e,t)})))}function h(e,t,r=!0){const o=e?n.ee.get(e):n.ee,s=i.i.handlers;if(!o.aborted&&o.backlog&&s){if(r){const e=o.backlog[t],r=s[t];if(r){for(let t=0;e&&t<e.length;++t)p(e[t],r);Object.entries(r).forEach((([e,t])=>{Object.values(t||{}).forEach((t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])}))}))}}o.isolatedBacklog||delete s[t],o.backlog[t]=null,o.emit("drain-"+t,[])}}function p(e,t){var r=e[1];Object.values(t[r]||{}).forEach((t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}}))}},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>c,ee:()=>u});var n=r(384),i=r(8990),o=r(3371),a=r(2646),s=r(5607);const c="nr@context:".concat(s.W),u=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&(0,o.f)(r).isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(u.aborted&&!i)return;t&&o&&t.emit(e,r,n);for(var a=h(n),c=g(e),d=c.length,l=0;l<d;l++)c[l].apply(a,r);var p=v()[s[e]];p&&p.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach((([e,n])=>{s[n]=t,t in r||(r[t]=[])}))},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach((e=>{delete f.backlog[e]}))},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof a.y?e:e?(0,i.I)(e,c,(()=>new a.y(c))):new a.y(c)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),d=(0,n.Zm)();d.ee||(d.ee=u)},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.d,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>s,ZF:()=>c,bz:()=>a,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map((e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const a=[];for(var s=0;s<e;s++)a.push(o(r,i++).toString(16));return a.join("")}function c(){return s(16)}function u(){return s(32)}},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>a,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>s,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,a=18e5,s={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},944:(e,t,r)=>{"use strict";function n(e,t){"function"==typeof console.debug&&console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t)}r.d(t,{R:()=>n})},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>a,t:()=>s});var n=r(7836),i=r(3241);const o=new Set,a={};function s(e,t){const r=n.ee.get(t);a[t]??={},e&&"object"==typeof e&&(o.has(t)||(r.emit("rumresp",[e]),a[t]=e,o.add(t),(0,i.W)({agentIdentifier:t,loaded:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout((()=>{i=clearTimeout(i)}),t)),n||(clearTimeout(i),i=setTimeout((()=>{e.apply(this,r)}),t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,sB:()=>a});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function a(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}},384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>o,US:()=>d,Zm:()=>a,bQ:()=>c,dV:()=>s,nY:()=>u,pV:()=>l});var n=r(6154),i=r(1863);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function s(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket}),e}function c(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function u(e){let t=a();return t.initializedAgents?.[e]}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)}),r,i)}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),a=r(6154);const s={},c=a.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(s[t.debugId]++)return t;s[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(a.RI&&h(document,f),c&&h(c.prototype,f),h(a.gm,f)),t.on(u+"-start",(function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var i=(0,o.I)(n,l,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(d+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>c});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W);var a=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const a="-"===n.charAt(0);for(let s=0;s<t.length;s++){const c=t[s],u=e[c];d(u)||(e[c]=r(u,a?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,s,c){return d(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){u([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,d,l;try{a=this,o=[...arguments],d="function"==typeof n?n(o,a):n||{}}catch(t){u([t,"",[o,a,s],d],e)}i(r+"start",[o,a,s],d,c);try{return l=t.apply(a,o)}catch(e){throw i(r+"err",[o,a,e],d,c),e}finally{i(r+"end",[o,a,l],d,c)}}}function i(r,n,i,o){if(!s||t){var a=s;s=!0;try{e.emit(r,n,i,t,o)}catch(t){u([t,r,n,i],e)}s=a}}}function u(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function d(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},9414:(e,t,r)=>{"use strict";r.d(t,{J:()=>c});var n=r(7836),i=r(2646),o=r(944),a=r(3434);const s=new Map;function c(e,t,r,c){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,o.R)(29);const u=function(e){return(e||n.ee).get("logger")}(e),d=(0,a.YM)(u),l=new i.y(n.P);l.level=c.level,l.customAttributes=c.customAttributes;const f=t[r]?.[a.Jt]||t[r];return s.set(f,l),d.inPlace(t,[r],"wrap-logger-",(()=>s.get(f))),u}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>u,TZ:()=>n,Zp:()=>i,kd:()=>c,mq:()=>s,nf:()=>a,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],a=4,s=1e3,c=["PageAction","UserAction","BrowserPerformance"],u={MARKS:"experimental.marks",MEASURES:"experimental.measures",RESOURCES:"experimental.resources"}},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>a,TZ:()=>s,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},a="log",s=n.K7.logging},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),a=r(8154),s=r(993);function c(e,t,r={},c=s.p_.INFO){(0,n.p)(a.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(s.ET,[(0,i.t)(),t,r,c],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(s.p_).some((t=>t===e.toUpperCase().trim()))}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>s,TZ:()=>n,rs:()=>i,xV:()=>a});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,G4:()=>o,Qb:()=>l,TZ:()=>i,Ug:()=>a,_s:()=>s,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o={RECORD:"recordReplay",PAUSE:"pauseReplay",REPLAY_RUNNING:"replayRunning",ERROR_DURING_REPLAY:"errorDuringReplay"},a=.12,s={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api"}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>c,CT:()=>u,SR:()=>s,rF:()=>d});var n=r(384),i=r(9417),o=r(7767),a=r(6154);function s(e){return!!(0,n.dV)().o.MO&&(0,o.V)(e)&&!0===(0,i.gD)(e,"session_trace.enabled")}function c(e){return!0===(0,i.gD)(e,"session_replay.preload")&&s(e)}function u(e,t){const r=t.correctAbsoluteTimestamp(e);return{originalTimestamp:e,correctedTimestamp:r,timestampDiff:e-r,originTime:a.WN,correctedOriginTime:t.correctedOriginTime,originTimeDiff:Math.floor(a.WN-t.correctedOriginTime)}}function d(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>s,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>a,jx:()=>l,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState",l=1e3},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>o,O2:()=>c,Qu:()=>u,TZ:()=>s,ih:()=>d,pP:()=>a,tC:()=>i});var n=r(860);const i=["click","keydown","submit","popstate"],o="api",a="initialPageLoad",s=n.K7.softNav,c={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},u={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},d={IP:"in progress",FIN:"finished",CAN:"cancelled"}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>A,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>T,uP:()=>s,wW:()=>E,xq:()=>a});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",E="cb"+R,A="jsTime",T="fetch"},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>o});var n=r(9417),i=r(6154);const o=e=>i.RI&&!0===(0,n.gD)(e,"privacy.cookies_enabled")},8969:(e,t,r)=>{"use strict";r.d(t,{j:()=>I});var n=r(860),i=r(2555),o=r(3371),a=r(9908),s=r(7836),c=r(1687),u=r(5289),d=r(6154),l=r(944),f=r(8154),h=r(384),p=r(6344);const g=["setErrorHandler","finished","addToTrace","addRelease","recordCustomEvent","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start",p.G4.RECORD,p.G4.PAUSE,"log","wrapLogger"],m=["setErrorHandler","finished","addToTrace","addRelease"];var v=r(1863),b=r(2614),y=r(993),w=r(3785),R=r(9414),x=r(3241),E=r(5701);function A(){const e=(0,h.pV)();g.forEach((t=>{e[t]=(...r)=>function(t,...r){let n=[];return Object.values(e.initializedAgents).forEach((e=>{e&&e.api?e.exposed&&e.api[t]&&n.push(e.api[t](...r)):(0,l.R)(38,t)})),n.length>1?n:n[0]}(t,...r)}))}const T={};var S=r(9417),N=r(5603);const _=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};let O=!1;function I(e,t={},g,I){let{init:P,info:j,loader_config:C,runtime:k={},exposed:L=!0}=t;k.loaderType=g;const H=(0,h.pV)();j||(P=H.init,j=H.info,C=H.loader_config),(0,S.xN)(e.agentIdentifier,P||{}),(0,N.a)(e.agentIdentifier,C||{}),j.jsAttributes??={},d.bv&&(j.jsAttributes.isWorker=!0),(0,i.x1)(e.agentIdentifier,j);const M=(0,S.D0)(e.agentIdentifier),D=[j.beacon,j.errorBeacon];O||(M.proxy.assets&&(_(M.proxy.assets),D.push(M.proxy.assets)),M.proxy.beacon&&D.push(M.proxy.beacon),A(),(0,h.US)("activatedFeatures",E.B),e.runSoftNavOverSpa&&=!0===M.soft_navigations.enabled&&M.feature_flags.includes("soft_nav")),k.denyList=[...M.ajax.deny_list||[],...M.ajax.block_internal?D:[]],k.ptid=e.agentIdentifier,(0,o.V)(e.agentIdentifier,k),e.ee=s.ee.get(e.agentIdentifier),void 0===e.api&&(e.api=function(e,t,h=!1){t||(0,c.Ak)(e,"api");const g={};var A=s.ee.get(e),S=A.get("tracer");T[e]=b.g.OFF,A.on(p.G4.REPLAY_RUNNING,(t=>{T[e]=t}));var N="api-",_=N+"ixn-";function O(t,r,n,o){const a=(0,i.Vp)(e);return null===r?delete a.jsAttributes[t]:(0,i.x1)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),j(N,n,!0,o||null===r?"session":void 0)(t,r)}function I(){}g.log=function(e,{customAttributes:t={},level:r=y.p_.INFO}={}){(0,a.p)(f.xV,["API/log/called"],void 0,n.K7.metrics,A),(0,w.R)(A,e,t,r)},g.wrapLogger=(e,t,{customAttributes:r={},level:i=y.p_.INFO}={})=>{(0,a.p)(f.xV,["API/wrapLogger/called"],void 0,n.K7.metrics,A),(0,R.J)(A,e,t,{customAttributes:r,level:i})},m.forEach((e=>{g[e]=j(N,e,!0,"api")})),g.addPageAction=j(N,"addPageAction",!0,n.K7.genericEvents),g.recordCustomEvent=j(N,"recordCustomEvent",!0,n.K7.genericEvents),g.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,o.f)(e).customTransaction=(r||"http://custom.transaction")+t,j(N,"setPageViewName",!0)()},g.setCustomAttribute=function(e,t,r=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof t)||null===t)return O(e,t,"setCustomAttribute",r);(0,l.R)(40,typeof t)}else(0,l.R)(39,typeof e)},g.setUserId=function(e){if("string"==typeof e||null===e)return O("enduser.id",e,"setUserId",!0);(0,l.R)(41,typeof e)},g.setApplicationVersion=function(e){if("string"==typeof e||null===e)return O("application.version",e,"setApplicationVersion",!1);(0,l.R)(42,typeof e)},g.start=()=>{try{(0,a.p)(f.xV,["API/start/called"],void 0,n.K7.metrics,A),A.emit("manual-start-all")}catch(e){(0,l.R)(23,e)}},g[p.G4.RECORD]=function(){(0,a.p)(f.xV,["API/recordReplay/called"],void 0,n.K7.metrics,A),(0,a.p)(p.G4.RECORD,[],void 0,n.K7.sessionReplay,A)},g[p.G4.PAUSE]=function(){(0,a.p)(f.xV,["API/pauseReplay/called"],void 0,n.K7.metrics,A),(0,a.p)(p.G4.PAUSE,[],void 0,n.K7.sessionReplay,A)},g.interaction=function(e){return(new I).get("object"==typeof e?e:{})};const P=I.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(f.xV,["API/createTracer/called"],void 0,n.K7.metrics,A),h||(0,a.p)(_+"tracer",[(0,v.t)(),e,r],i,n.K7.spa,A),function(){if(S.emit((o?"":"no-")+"fn-start",[(0,v.t)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){const t="string"==typeof e?new Error(e):e;throw S.emit("fn-err",[arguments,this,t],r),t}finally{S.emit("fn-end",[(0,v.t)()],r)}}}};function j(t,r,i,o){return function(){return(0,a.p)(f.xV,["API/"+r+"/called"],void 0,n.K7.metrics,A),(0,x.W)({agentIdentifier:e,loaded:!!E.B?.[e],type:"data",name:"api",feature:t+r,data:{notSpa:i,bufferGroup:o}}),o&&(0,a.p)(t+r,[i?(0,v.t)():performance.now(),...arguments],i?null:this,o,A),i?void 0:this}}function C(){r.e(478).then(r.bind(r,8778)).then((({setAPI:t})=>{t(e),(0,c.Ze)(e,"api")})).catch((e=>{(0,l.R)(27,e),A.abort()}))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{P[e]=j(_,e,void 0,h?n.K7.softNav:n.K7.spa)})),g.setCurrentRouteName=h?j(_,"routeName",void 0,n.K7.softNav):j(N,"routeName",!0,n.K7.spa),g.noticeError=function(t,r){"string"==typeof t&&(t=new Error(t)),(0,a.p)(f.xV,["API/noticeError/called"],void 0,n.K7.metrics,A),(0,a.p)("err",[t,(0,v.t)(),!1,r,!!T[e]],void 0,n.K7.jserrors,A)},d.RI?(0,u.GG)((()=>C()),!0):C(),g}(e.agentIdentifier,I,e.runSoftNavOverSpa)),void 0===e.exposed&&(e.exposed=L),O||(0,x.W)({agentIdentifier:e.agentIdentifier,loaded:!!E.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:{init:M,info:j,loader_config:C,runtime:k}}),O=!0}},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>s,df:()=>o,qY:()=>n,v4:()=>a});const n="events",i="jserrors",o="browser/blobs",a="rum",s="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:a,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:s,[c.genericEvents]:"ins"}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.285.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.285.0.PROD:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){s=l;break}}if(!s){c=!0;var f={478:"sha512-73OmviyU40lnC5NZHvj5egb1Dktz4of17DYc4nbj2RduD/YSRadVPKgqV4pTV++UKRfMh1kiyzvZ3EZ9+nCVRA==",249:"sha512-K0uLsDVOs99bSE/U1/+N3dF9ugBMgNxv9bGCDosl/OYQ9Vbh3OEiiDdoeJ2Jyez+MV++R54r9pGP4l89pkOgrw==",212:"sha512-xpg2N/nVV3R+2dh1bNPkgU4MdEfsSknhvWWYRI9zgj8nuzl1HP8n4T1tr6iNK7k+LC8m/kDrZH58sW6X5daNDQ=="};(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r,0!==s.src.indexOf(window.location.origin+"/")&&(s.crossOrigin="anonymous"),f[a]&&(s.integrity=f[a])}e[r]=[n];var h=(t,n)=>{s.onerror=s.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=h.bind(null,s.onerror),s.onload=h.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.285.0.PROD"]=self["webpackChunk:NRBA-1.285.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(944),t=i(6344),r=i(9566);class n{agentIdentifier;constructor(){this.agentIdentifier=(0,r.LA)(16)}#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}addPageAction(e,t){return this.#e("addPageAction",e,t)}recordCustomEvent(e,t){return this.#e("recordCustomEvent",e,t)}setPageViewName(e,t){return this.#e("setPageViewName",e,t)}setCustomAttribute(e,t,r){return this.#e("setCustomAttribute",e,t,r)}noticeError(e,t){return this.#e("noticeError",e,t)}setUserId(e){return this.#e("setUserId",e)}setApplicationVersion(e){return this.#e("setApplicationVersion",e)}setErrorHandler(e){return this.#e("setErrorHandler",e)}addRelease(e,t){return this.#e("addRelease",e,t)}log(e,t){return this.#e("log",e,t)}}class o extends n{#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}start(){return this.#e("start")}finished(e){return this.#e("finished",e)}recordReplay(){return this.#e(t.G4.RECORD)}pauseReplay(){return this.#e(t.G4.PAUSE)}addToTrace(e){return this.#e("addToTrace",e)}setCurrentRouteName(e){return this.#e("setCurrentRouteName",e)}interaction(){return this.#e("interaction")}wrapLogger(e,t,r){return this.#e("wrapLogger",e,t,r)}}var a=i(860),s=i(9417);const c=Object.values(a.K7);function u(e){const t={};return c.forEach((r=>{t[r]=function(e,t){return!0===(0,s.gD)(t,"".concat(e,".enabled"))}(r,e)})),t}var d=i(8969);var l=i(1687),f=i(4234),h=i(5289),p=i(6154),g=i(5270),m=i(7767),v=i(6389);class b extends f.W{constructor(e,t,r=!0){super(e.agentIdentifier,t),this.auto=r,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===e.init[this.featureName].autoStart&&(this.auto=!1),this.auto?(0,l.Ak)(e.agentIdentifier,t):this.ee.on("manual-start-all",(0,v.J)((()=>{(0,l.Ak)(e.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator(e)})))}importAggregator(t,r={}){if(this.featAggregate||!this.auto)return;let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let o;try{if((0,m.V)(this.agentIdentifier)){const{setupAgentSession:e}=await i.e(478).then(i.bind(i,6526));o=e(t)}}catch(t){(0,e.R)(20,t),this.ee.emit("internal-error",[t]),this.featureName===a.K7.sessionReplay&&this.abortHandler?.()}try{if(!this.#t(this.featureName,o))return(0,l.Ze)(this.agentIdentifier,this.featureName),void n(!1);const{lazyFeatureLoader:e}=await i.e(478).then(i.bind(i,6103)),{Aggregate:a}=await e(this.featureName,"aggregate");this.featAggregate=new a(t,r),t.runtime.harvester.initializedAggregates.push(this.featAggregate),n(!0)}catch(t){(0,e.R)(34,t),this.abortHandler?.(),(0,l.Ze)(this.agentIdentifier,this.featureName,!0),n(!1),this.ee&&this.ee.abort()}};p.RI?(0,h.GG)((()=>o()),!0):o()}#t(e,t){switch(e){case a.K7.sessionReplay:return(0,g.SR)(this.agentIdentifier)&&!!t;case a.K7.sessionTrace:return!!t;default:return!0}}}var y=i(6630);class w extends b{static featureName=y.T;constructor(e,t=!0){super(e,y.T,t),this.importAggregator(e)}}var R=i(384);var x=i(9908),E=i(2843),A=i(3878),T=i(782),S=i(1863);class N extends b{static featureName=T.T;constructor(e,t=!0){super(e,T.T,t),p.RI&&((0,E.u)((()=>(0,x.p)("docHidden",[(0,S.t)()],void 0,T.T,this.ee)),!0),(0,A.sp)("pagehide",(()=>(0,x.p)("winPagehide",[(0,S.t)()],void 0,T.T,this.ee))),this.importAggregator(e))}}var _=i(8154);class O extends b{static featureName=_.TZ;constructor(e,t=!0){super(e,_.TZ,t),p.RI&&document.addEventListener("securitypolicyviolation",(e=>{(0,x.p)(_.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)})),this.importAggregator(e)}}var I=i(6774),P=i(3304);class j{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,P.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function C(e){return H(e)?e:new j(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic)}function k(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(H(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return C(e.reason)}const r=C(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function L(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new j(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic);return t.name=SyntaxError.name,t}return H(e.error)?e.error:C(e)}function H(e){return e instanceof Error&&!!e.stack}class M extends b{static featureName=I.T;#r=!1;constructor(e,r=!0){super(e,I.T,r);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",((e,t)=>{this.abortHandler&&(0,x.p)("ierr",[C(e),(0,S.t)(),!0,{},this.#r,t],void 0,this.featureName,this.ee)})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.#r=e})),p.gm.addEventListener("unhandledrejection",(e=>{this.abortHandler&&(0,x.p)("err",[k(e),(0,S.t)(),!1,{unhandledPromiseRejection:1},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),p.gm.addEventListener("error",(e=>{this.abortHandler&&(0,x.p)("err",[L(e),(0,S.t)(),!1,{},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var D=i(8990);let K=1;const U="nr@id";function V(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===p.gm?0:(0,D.I)(e,U,(function(){return K++}))}function G(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,P.A)(e).length}catch(e){return}}}var F=i(8139),B=i(7836),W=i(3434);const z={},q=["open","send"];function Z(t){var r=t||B.ee;const n=function(e){return(e||B.ee).get("xhr")}(r);if(void 0===p.gm.XMLHttpRequest)return n;if(z[n.debugId]++)return n;z[n.debugId]=1,(0,F.u)(r);var i=(0,W.YM)(n),o=p.gm.XMLHttpRequest,a=p.gm.MutationObserver,s=p.gm.Promise,c=p.gm.setInterval,u="readystatechange",d=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],l=[],f=p.gm.XMLHttpRequest=function(t){const r=new o(t),a=n.context(r);try{n.emit("new-xhr",[r],a),r.addEventListener(u,(s=a,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,n.emit("xhr-resolved",[],e)),i.inPlace(e,d,"fn-",y)}),(0,A.jT)(!1))}catch(t){(0,e.R)(15,t);try{n.emit("internal-error",[t])}catch(e){}}var s;return r};function h(e,t){i.inPlace(t,["onreadystatechange"],"fn-",y)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,f),f.prototype=o.prototype,i.inPlace(f.prototype,q,"-xhr-",y),n.on("send-xhr-start",(function(e,t){h(e,t),function(e){l.push(e),a&&(g?g.then(b):c?c(b):(m=-m,v.data=m))}(t)})),n.on("open-xhr-start",h),a){var g=s&&s.resolve();if(!c&&!s){var m=1,v=document.createTextNode(m);new a(b).observe(v,{characterData:!0})}}else r.on("fn-end",(function(e){e[0]&&e[0].type===u||b()}));function b(){for(var e=0;e<l.length;e++)h(0,l[e]);l.length&&(l=[])}function y(e,t){return t}return n}var Y="fetch-",J=Y+"body-",X=["arrayBuffer","blob","json","text","formData"],Q=p.gm.Request,ee=p.gm.Response,te="prototype";const re={};function ne(e){const t=function(e){return(e||B.ee).get("fetch")}(e);if(!(Q&&ee&&p.gm.fetch))return t;if(re[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[B.P]&&o[B.P].dt&&(e=o[B.P].dt);var a=i.apply(this,r);return t.emit(n+"start",[r,e],a),a.then((function(e){return t.emit(n+"end",[null,e],a),e}),(function(e){throw t.emit(n+"end",[e],a),e}))})}return re[t.debugId]=1,X.forEach((e=>{r(Q[te],e,J),r(ee[te],e,J)})),r(p.gm,"fetch",Y),t.on(Y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(Y+"done",[null,r],n)}else t.emit(Y+"done",[e],n)})),t}var ie=i(7485),oe=i(5603);class ae{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,oe.o)(this.agentIdentifier);if(!t)return null;var n=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,o=(t.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,r.ZF)(),s=(0,r.el)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof p.gm?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,P.A)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,s.gD)(this.agentIdentifier,"distributed_tracing")&&(r=(0,s.D0)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ie.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}isDtEnabled(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.enabled}excludeNewrelicHeader(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.cors_use_tracecontext_headers}}var se=i(9300),ce=i(7295),ue=["load","error","abort","timeout"],de=ue.length,le=(0,R.dV)().o.REQ,fe=(0,R.dV)().o.XHR;const he="X-NewRelic-App-Data";class pe extends b{static featureName=se.T;constructor(e,t=!0){super(e,se.T,t),this.dt=new ae(e.agentIdentifier),this.handler=(e,t,r,n)=>(0,x.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};p.gm?.performance?.getEntriesByType("resource").forEach((t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},n={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};ge(r,t.name),this.handler("xhr",[r,n,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,a.K7.ajax)}}))}catch(e){}ne(this.ee),Z(this.ee),function(e,t,r,n){function i(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=R,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){E(t,e)}),(0,A.jT)(!1)),p.lR||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,A.jT)(!1))}function o(e){this.params={method:e[0]},ge(this,e[1]),this.metrics={}}function s(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var i=n.generateTracePayload(this.parsedOrigin);if(i){var o=!1;i.newrelicHeader&&(r.setRequestHeader("newrelic",i.newrelicHeader),o=!0),i.traceContextParentHeader&&(r.setRequestHeader("traceparent",i.traceContextParentHeader),i.traceContextStateHeader&&r.setRequestHeader("tracestate",i.traceContextStateHeader),o=!0),o&&(this.dt=i)}}function c(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var a=G(i);a&&(n.txSize=a)}this.startTime=(0,S.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s<de;s++)r.addEventListener(ue[s],this.listener,(0,A.jT)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function d(e,t){var r=""+V(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function l(e,t){var r=""+V(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function f(){this.endTime=(0,S.t)()}function h(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function g(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function m(e,t,r){t instanceof fe&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,S.t)()))}function v(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,S.t)()-this.xhrCbStart,this.onload,r],r)}function b(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&p.RI&&(t=""+p.gm.location.href):e[0]&&e[0].url?t=e[0].url:p.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ie.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var i=n.generateTracePayload(this.parsedOrigin);if(i&&(i.newrelicHeader||i.traceContextParentHeader))if(e[0]&&e[0].headers)s(e[0].headers,i)&&(this.dt=i);else{var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),s(o.headers,i)&&(this.dt=i),e.length>1?e[1]=o:e.push(o)}}function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function y(e,t){this.params={},this.metrics={},this.startTime=(0,S.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof le?r=i.url:p.gm?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),ge(this,r);var o=(""+(i&&i instanceof le&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.body=n.body,this.txSize=G(n.body)||0}function w(e,t){if(this.endTime=(0,S.t)(),this.params||(this.params={}),(0,ce.iW)(this.params))return;let n;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);const i={txSize:this.txSize,rxSize:n,duration:(0,S.t)()-this.startTime};r("xhr",[this.params,i,this.startTime,this.endTime,"fetch"],this,a.K7.ajax)}function R(e){const t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<de;t++)e.removeEventListener(ue[t],this.listener,!1);t.aborted||(0,ce.iW)(t)||(n.duration=(0,S.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):E(this,e),n.cbTime=this.cbTime,r("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,a.K7.ajax))}}function E(e,r){e.params.status=r.status;var n=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?G(e.response):"text"===r||""===r||void 0===r?G(e.responseText):void 0}(r,e.lastSize);if(n&&(e.metrics.rxSize=n),e.sameOrigin&&r.getAllResponseHeaders().indexOf(he)>=0){var i=r.getResponseHeader(he);i&&((0,x.p)(_.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,a.K7.metrics,t),e.params.cat=i.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",i),t.on("open-xhr-start",o),t.on("open-xhr-end",s),t.on("send-xhr-start",c),t.on("xhr-cb-time",u),t.on("xhr-load-added",d),t.on("xhr-load-removed",l),t.on("xhr-resolved",f),t.on("addEventListener-end",h),t.on("removeEventListener-end",g),t.on("fn-end",v),t.on("fetch-before-start",b),t.on("fetch-start",y),t.on("fn-start",m),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator(e)}}function ge(e,t){var r=(0,ie.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const me={},ve=["pushState","replaceState"];function be(e){const t=function(e){return(e||B.ee).get("history")}(e);return!p.RI||me[t.debugId]++||(me[t.debugId]=1,(0,W.YM)(t).inPlace(window.history,ve,"-")),t}var ye=i(3738);const{He:we,bD:Re,d3:xe,Kp:Ee,TZ:Ae,Lc:Te,uP:Se,Rz:Ne}=ye;class _e extends b{static featureName=Ae;constructor(e,t=!0){super(e,Ae,t);if(!(0,m.V)(this.agentIdentifier))return void this.deregisterDrain();const r=this.ee;let n;be(r),this.eventsEE=(0,F.u)(r),this.eventsEE.on(Se,(function(e,t){this.bstStart=(0,S.t)()})),this.eventsEE.on(Te,(function(e,t){(0,x.p)("bst",[e[0],t,this.bstStart,(0,S.t)()],void 0,a.K7.sessionTrace,r)})),r.on(Ne+xe,(function(e){this.time=(0,S.t)(),this.startPath=location.pathname+location.hash})),r.on(Ne+Ee,(function(e){(0,x.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,a.K7.sessionTrace,r)}));try{n=new PerformanceObserver((e=>{const t=e.getEntries();(0,x.p)(we,[t],void 0,a.K7.sessionTrace,r)})),n.observe({type:Re,buffered:!0})}catch(e){}this.importAggregator(e,{resourceObserver:n})}}var Oe=i(2614);class Ie extends b{static featureName=t.TZ;#i;#o;constructor(e,r=!0){let n;super(e,t.TZ,r),this.replayRunning=!1,this.#o=e;try{n=JSON.parse(localStorage.getItem("".concat(Oe.H3,"_").concat(Oe.uh)))}catch(e){}(0,g.SR)(e.agentIdentifier)&&this.ee.on(t.G4.RECORD,(()=>this.#a())),this.#s(n)?(this.#i=n?.sessionReplayMode,this.#c()):this.importAggregator(e),this.ee.on("err",(e=>{this.replayRunning&&(this.errorNoticed=!0,(0,x.p)(t.G4.ERROR_DURING_REPLAY,[e],void 0,this.featureName,this.ee))})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.replayRunning=e}))}#s(e){return e&&(e.sessionReplayMode===Oe.g.FULL||e.sessionReplayMode===Oe.g.ERROR)||(0,g.Aw)(this.agentIdentifier)}#u=!1;async#c(e){if(!this.#u){this.#u=!0;try{const{Recorder:t}=await Promise.all([i.e(478),i.e(249)]).then(i.bind(i,8589));this.recorder??=new t({mode:this.#i,agentIdentifier:this.agentIdentifier,trigger:e,ee:this.ee,agentRef:this.#o}),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording}catch(e){}this.importAggregator(this.#o,{recorder:this.recorder,errorNoticed:this.errorNoticed})}}#a(){this.featAggregate?this.featAggregate.mode!==Oe.g.FULL&&this.featAggregate.initializeRecording(Oe.g.FULL,!0):(this.#i=Oe.g.FULL,this.#c(t.Qb.API),this.recorder&&this.recorder.parent.mode!==Oe.g.FULL&&(this.recorder.parent.mode=Oe.g.FULL,this.recorder.stopRecording(),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording))}}var Pe=i(3962);class je extends b{static featureName=Pe.TZ;constructor(e,t=!0){if(super(e,Pe.TZ,t),!p.RI||!(0,R.dV)().o.MO)return;const r=be(this.ee);Pe.tC.forEach((e=>{(0,A.sp)(e,(e=>{a(e)}),!0)}));const n=()=>(0,x.p)("newURL",[(0,S.t)(),""+window.location],void 0,this.featureName,this.ee);r.on("pushState-end",n),r.on("replaceState-end",n);try{this.removeOnAbort=new AbortController}catch(e){}(0,A.sp)("popstate",(e=>(0,x.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)),!0,this.removeOnAbort?.signal);let i=!1;const o=new((0,R.dV)().o.MO)(((e,t)=>{i||(i=!0,requestAnimationFrame((()=>{(0,x.p)("newDom",[(0,S.t)()],void 0,this.featureName,this.ee),i=!1})))})),a=(0,v.s)((e=>{(0,x.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})}),100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,{domObserver:o})}}var Ce=i(7378);const ke={},Le=["appendChild","insertBefore","replaceChild"];function He(e){const t=function(e){return(e||B.ee).get("jsonp")}(e);if(!p.RI||ke[t.debugId])return t;ke[t.debugId]=!0;var r=(0,W.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function a(e,t){if(!e)return t;const r=e.match(o),n=r[1];return a(r[3],t[n])}return r.inPlace(Node.prototype,Le,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(s=e.src,c=s.match(n),c?c[1]:null);var s,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:a(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,A.jT)(!1)),e.addEventListener("error",f,(0,A.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}const Me={};function De(e){const t=function(e){return(e||B.ee).get("promise")}(e);if(Me[t.debugId])return t;Me[t.debugId]=!0;var r=t.context,n=(0,W.YM)(t),i=p.gm.Promise;return i&&function(){function e(r){var o=t.context(),a=n(r,"executor-",o,null,!1);const s=Reflect.construct(i,[a],e);return t.context(s).getCtx=function(){return o},s}p.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach((function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,a=r(i);a.promise=i,e[0]=n(e[0],"cb-",a,null,!1),e[1]=n(e[1],"cb-",a,null,!1);const s=o.apply(this,e);return a.nextPromise=s,t.emit("propagate",[i,!0],s,!1,!1),s},i.prototype.then[W.Jt]=o,t.on("executor-start",(function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)})),t.on("executor-err",(function(e,t,r){e[1](r)})),t.on("cb-end",(function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)})),t.on("propagate",(function(e,r,n){this.getCtx&&!r||(this.getCtx=function(){if(e instanceof Promise)var r=t.context(e);return r&&r.getCtx?r.getCtx():this})}))}(),t}const Ke={},Ue="setTimeout",Ve="setInterval",Ge="clearTimeout",Fe="-start",Be=[Ue,"setImmediate",Ve,Ge,"clearImmediate"];function We(e){const t=function(e){return(e||B.ee).get("timer")}(e);if(Ke[t.debugId]++)return t;Ke[t.debugId]=1;var r=(0,W.YM)(t);return r.inPlace(p.gm,Be.slice(0,2),Ue+"-"),r.inPlace(p.gm,Be.slice(2,3),Ve+"-"),r.inPlace(p.gm,Be.slice(3),Ge+"-"),t.on(Ve+Fe,(function(e,t,n){e[0]=r(e[0],"fn-",null,n)})),t.on(Ue+Fe,(function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)})),t}const ze={};function qe(e){const t=function(e){return(e||B.ee).get("mutation")}(e);if(!p.RI||ze[t.debugId])return t;ze[t.debugId]=!0;var r=(0,W.YM)(t),n=p.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:Ze,d3:Ye,Kp:Je,$p:Xe,wW:$e,e5:Qe,tH:et,uP:tt,rw:rt,Lc:nt}=Ce;class it extends b{static featureName=Ze;constructor(e,t=!0){if(super(e,Ze,t),!p.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let r,n=0;const i=this.ee.get("tracer"),o=He(this.ee),a=De(this.ee),s=We(this.ee),c=Z(this.ee),u=this.ee.get("events"),d=ne(this.ee),l=be(this.ee),f=qe(this.ee);function h(e,t){l.emit("newURL",[""+window.location,t])}function g(){n++,r=window.location.hash,this[tt]=(0,S.t)()}function m(){n--,window.location.hash!==r&&h(0,!0);var e=(0,S.t)();this[Qe]=~~this[Qe]+e-this[tt],this[nt]=e}function v(e,t){e.on(t,(function(){this[t]=(0,S.t)()}))}this.ee.on(tt,g),a.on(rt,g),o.on(rt,g),this.ee.on(nt,m),a.on($e,m),o.on($e,m),this.ee.on("fn-err",((...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,x.p)("function-err",[...t],void 0,this.featureName,this.ee)})),this.ee.buffer([tt,nt,"xhr-resolved"],this.featureName),u.buffer([tt],this.featureName),s.buffer(["setTimeout"+Je,"clearTimeout"+Ye,tt],this.featureName),c.buffer([tt,"new-xhr","send-xhr"+Ye],this.featureName),d.buffer([et+Ye,et+"-done",et+Xe+Ye,et+Xe+Je],this.featureName),l.buffer(["newURL"],this.featureName),f.buffer([tt],this.featureName),a.buffer(["propagate",rt,$e,"executor-err","resolve"+Ye],this.featureName),i.buffer([tt,"no-"+tt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),v(d,et+Ye),v(d,et+"-done"),v(o,"new-jsonp"),v(o,"jsonp-end"),v(o,"cb-start"),l.on("pushState-end",h),l.on("replaceState-end",h),window.addEventListener("hashchange",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){h(0,n>1)}),(0,A.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var ot=i(3333);class at extends b{static featureName=ot.TZ;constructor(e,t=!0){super(e,ot.TZ,t);const r=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];if(p.RI&&(e.init.user_actions.enabled&&(ot.Zp.forEach((e=>(0,A.sp)(e,(e=>(0,x.p)("ua",[e],void 0,this.featureName,this.ee)),!0))),ot.qN.forEach((e=>{const t=(0,v.s)((e=>{(0,x.p)("ua",[e],void 0,this.featureName,this.ee)}),500,{leading:!0});(0,A.sp)(e,t)}))),e.init.performance.resources.enabled&&p.gm.PerformanceObserver?.supportedEntryTypes.includes("resource"))){new PerformanceObserver((e=>{e.getEntries().forEach((e=>{(0,x.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)}))})).observe({type:"resource",buffered:!0})}r.some((e=>e))?this.importAggregator(e):this.deregisterDrain()}}var st=i(993),ct=i(3785),ut=i(9414);class dt extends b{static featureName=st.TZ;constructor(e,t=!0){super(e,st.TZ,t);const r=this.ee;(0,ut.J)(r,p.gm.console,"log",{level:"info"}),(0,ut.J)(r,p.gm.console,"error",{level:"error"}),(0,ut.J)(r,p.gm.console,"warn",{level:"warn"}),(0,ut.J)(r,p.gm.console,"info",{level:"info"}),(0,ut.J)(r,p.gm.console,"debug",{level:"debug"}),(0,ut.J)(r,p.gm.console,"trace",{level:"trace"}),this.ee.on("wrap-logger-end",(function([e]){const{level:t,customAttributes:n}=this;(0,ct.R)(r,e,n,t)})),this.importAggregator(e)}}new class extends o{constructor(t){super(),p.gm?(this.features={},(0,R.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(w),this.runSoftNavOverSpa=[...this.desiredFeatures].some((e=>e.featureName===a.K7.softNav)),(0,d.j)(this,t,t.loaderType||"agent"),this.run()):(0,e.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}run(){try{const t=u(this.agentIdentifier),r=[...this.desiredFeatures];r.sort(((e,t)=>a.P3[e.featureName]-a.P3[t.featureName])),r.forEach((r=>{if(!t[r.featureName]&&r.featureName!==a.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&r.featureName===a.K7.spa)return;if(!this.runSoftNavOverSpa&&r.featureName===a.K7.softNav)return;const n=function(e){switch(e){case a.K7.ajax:return[a.K7.jserrors];case a.K7.sessionTrace:return[a.K7.ajax,a.K7.pageViewEvent];case a.K7.sessionReplay:return[a.K7.sessionTrace];case a.K7.pageViewTiming:return[a.K7.pageViewEvent];default:return[]}}(r.featureName).filter((e=>!(e in this.features)));n.length>0&&(0,e.R)(36,{targetFeature:r.featureName,missingDependencies:n}),this.features[r.featureName]=new r(this)}))}catch(t){(0,e.R)(22,t);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,R.Zm)();delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return r.ee.get(this.agentIdentifier).abort(),!1}}}({features:[pe,w,N,_e,Ie,O,M,at,dt,je,it],loaderType:"spa"})})()})();</script><meta charset="utf-8" /><meta name="viewport" content="width=device-width, initial-scale=1" /><meta http-equiv="Expires" content="0" /><meta name="DCSext.FullHTMLview" content="1" /><meta name="WT.cg_n" content="hep" /><meta name="WT.cg_s" content="Articles" /><meta name="wkhealth_journal_title" content="Hepatology" /><meta name="wkhealth_journal_title_legacy" content="Hepatology" /><meta name="wkhealth_issue" content="3" /><meta name="wkhealth_article_publication_date" content="August 04, 2015" /><meta name="wkhealth_volume" content="62" /><meta name="wkhealth_ovid_accession_number" content="01515467-201509000-00029" /><meta name="wkhealth_issn" content="0270-9139" /><meta name="wkhealth_title" content="Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus" /><meta name="wkhealth_authors" content="AASLD/IDSA HCV Guidance Panel" /><meta name="wkhealth_doi" content="10.1002/hep.27950" /><meta name="wkhealth_abstract_html_url" content="https://journals.lww.com/hep/abstract/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx" /><meta name="wkhealth_fulltext_html_url" content="https://journals.lww.com/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx" /><meta name="wkhealth_toc_section" content="Practice Guidance" /><meta name="wkhealth_toc_sub_section" /><meta name="wkhealth_eJpId" content="hep:2015:09000:00029" /><meta name="wkhealth_firstpage" content="932" /><meta name="wkhealth_date" content="September 2015" /><meta name="wkhealth_pdf_url" content="https://journals.lww.com/hep/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=Other&an=01515467-201509000-00029" /><meta property="og:site_name" content="LWW" /><meta property="og:type" content="article" /><meta property="og:title" content="Hepatitis C guidance: AASLD‐IDSA recommendations for... : Hepatology" /><meta property="og:description" content="An abstract is unavailable." /><meta property="og:image" content="https://images.journals.lww.com/hep/SocialThumb.01515467-201509000-00029.hep27950-tbl-0001.jpeg" /><meta property="og:image:width" content="1212" /><meta property="og:image:height" content="487" /><meta property="og:url" content="https://journals.lww.com/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx" /><meta property="twitter:card" content="summary" /><meta name="robots" content="index, follow, noarchive" /><meta name="WT.sv" content="ZUSE1PEJPWEB03" /><meta name="Title" content="Hepatology" /><style id="SPThemeHideForms" type="text/css">body {opacity:0 !important}</style>  <link href="https://fonts.googleapis.com/css?family=Arvo:400,400i,700|Fira+Sans:300,300i,400,400i,500,500i,600,600i,700,700i&display=swap" rel="stylesheet" /> <script> // temporary workaround for Bug 316328:[Stage][Registration][Regression 05.04] - Omniture events are not displayed for article viewer page // prevents JS exception in Adobe launch.js caused by situation when wkhealth_institution_type meta tag is present while wkhealth_institution_name tag is not in the page head // see this check in Adobe launch.js: null != document.querySelector("meta[name='wkhealth_institution_name']") ... // TODO: implement proper code fix after release 05.04.00 deployment var wkhealth_institution_type = document.querySelector("meta[name='wkhealth_institution_type']"); var wkhealth_institution_name = document.querySelector("meta[name='wkhealth_institution_name']"); console.warn(wkhealth_institution_type); console.warn(wkhealth_institution_name); if (wkhealth_institution_type && !wkhealth_institution_name) { console.warn('Workaround in release 05.04.00 - removing wkhealth_institution_type meta tag if wkhealth_institution_name is not present'); wkhealth_institution_type.remove(); } </script> <link rel="shortcut icon" href="https://cdn.wolterskluwer.io/wk-logos/1.0.x/favicon.png" type="image/vnd.microsoft.icon" id="favicon" /> <link id="ctl00_ctl14_wkfavicon_linkFavIcon" rel="shortcut icon" href="/hep/PublishingImages/WKfavicon.ico" type="image/x-icon"></link> <meta name="msapplication-TileImage" content="/_layouts/15/images/SharePointMetroAppTile.png" /><meta name="msapplication-TileColor" content="#0072C6" /> <link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/1033/styles/Themable/corev15.css?v=05.24.00.023" media="screen" /> <link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/oaks.journals/core/bootstrap.min.css?v=05.24.00.023" media="screen" /> <link id="ctl00_ctl14_FontAwesomeStylesheet" rel="stylesheet" type="text/css" href="https://unpkg.com/font-awesome@4.4.0/css/font-awesome.min.css"></link> <link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/1033/styles/oaks.journals/bootstrap-overwrites.css?v=05.24.00.023" media="screen" /><link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/1033/styles/oaks.journals/tachyons.css?v=05.24.00.023" media="screen" /><link rel="stylesheet" type="text/css" href="/hep/_layouts/15/1033/styles/oaks.journals/base-main-header.css?v=05.24.00.023" media="screen" /><link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/oaks.journals/core/lww-core.css?v=05.24.00.023" media="screen" /><link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/oaks.journals/core/ejp.css?v=05.24.00.023" media="screen" /><link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/oaks.journals/core/ejp-print.css?v=05.24.00.023" media="print" /><link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/15/oaks.journals/core/jqueryui.css?v=05.24.00.023" media="screen" /> <link rel="stylesheet" type="text/css" href="/hep/Style%20Library/journal.css?v=05.24.00.023" media="screen" /> <link rel="stylesheet" type="text/css" href="/hep/Style%20Library/custom.journal.css?v=05.24.00.023" media="screen" /> <script>var WebContext = {"EndPoints":{"ArticleMetricsEndpoint":"//services.journals.lww.com/IntegrationServices/ArticleMetricsService.svc","ThirdPartyRSSFeedServiceEndPoint":"https://services.journals.lww.com/IntegrationServices/ThirdPartyRSSFeedService.svc","JwtTokenServiceEndpoint":"https://journals.lww.com/hep/_layouts/15/OAKS.Journals/JsonWebToken.svc"}}</script> <script type="text/javascript">// <![CDATA[ var g_SPOffSwitches={}; // ]]> </script> <script type="text/javascript" src="/_layouts/15/1033/initstrings.js?rev=nDf18IVeB%2B72%2BM6Jhf9Utg%3D%3DTAG0"></script> <script type="text/javascript" src="/_layouts/15/init.js?rev=9ktdD%2FCJq19EDntIfWJSag%3D%3DTAG0"></script> <script type="text/javascript" src="/_layouts/15/1033/strings.js?rev=ZpwERQVJtz0nJ0TWzlZWYw%3D%3DTAG0"></script> <script type="text/javascript" src="/_layouts/15/theming.js?rev=SuLUbbwTXcxFWOWLFUsOkw%3D%3DTAG0"></script> <script type="text/javascript" src="/_layouts/15/ie55up.js?rev=nEbMZCb7SAfwcNHpfjlQ9g%3D%3DTAG0"></script> <script type="text/javascript" src="/ScriptResource.axd?d=F7rjznvAP1ZvjwmSYaDR9a3zqrnKFnNGXs7A_cRIg2rplizpOOjwg9eBfW_KxBMLRVN3lzATjzWkisQusj_Iaw7I7xHhM2EsA2p1WTk5lIh-1_uEIMq1sktVYKM3D6Gp5VSqOtDTEnrScqHWTHOzdCPnKDjm2mtJH72pNbP0u4uI_zDnfi9spPAqI_kz3qnF0&t=ffffffffaa493ab8"></script> <script type="text/javascript" src="/_layouts/15/blank.js?rev=bSwUuDrVd4rvOQePvjjhaw%3D%3DTAG0"></script> <script type="text/javascript" src="/ScriptResource.axd?d=yatK8ruofouVZAe4qMCnoohEpb3HRGGjDeZZjZ7kMmC722OeAMhxqxkQCI5Rxx8YROZ4ohEXEd-BY-UzqqqylduXIs6jc38C73kN3lT2QdlwTljpny1fYEjcvvbYSMHNq1-TT-bDa0cFUDuAr5ywhChhEELpPbB_In_xfOO6OlgjpjP86LmsgZzKkXo8aCS90&t=ffffffffaa493ab8"></script> <script type="text/javascript" src="/ScriptResource.axd?d=Fr5k7XDliwj7SPEiKSqb-V3uT_yv_Vc0LBq3yd_m1_Ea8vkvI41fPqtWB8rH7kW9D2--SObxiXOCEDDg2Tv5yxNEAylK5ZpV5j9rD03yPUcCPh8w-y9A8MWLSg0jrQ-0kisGzu4Hba8Ct3e6oiiAj5nLa8lUDGLzNSKFrT8wEzRvrGDuqa6AKloxdLDyhLNb6sYlIjtGIn7oUTXlG_HGsg2&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=LXNyktQiaIpbp533FW-c46OHB30ylIqDlrzk7r3HlWeMLy05SwQ7ZZDsPGq7NzzDRSU0tvewepiuVrszZuoio7QLmOYibhCj6dQNfSL2hGpxpyP-E7et27fbWMHpoIuHecopwN8d_b-WR8rimwUGdbN6akitIdX32lXMez7LH7qkG1jVMDvXf2M0_6gdMpGjpPKlEhmMrNGzYuo05_KLRO4TeTkKykcR_5pPB2fyzgk1&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=UozfgYfgcP8g118ZMoKEWz_x5V51ZaIWOeFUe49mdZ8Yy8frQahBfRlFRNNeizXxYfmbtpE1uZMOMW2QeF7QCWjREvRvpNDSCGO5YICh1GalcUtEGJaGvVObluwmGza6-lV8S-wgb9vDF6UYZlWbyLOo-d94ckB8BN1hUlnIdqL9auDE1qR-ddFC7rw_89VZWQ6uTxR6vOlq2jE0iTr3J_6_Q3a7SLOduMua_ZXDgk7k01lBMUodCwi6dm-oTxLE0&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=ZWgxL8bxzPcm3sf7nBtjnXIE2wsAF-izuHnFdkP9YIwhY40NTQZWAMXXd5_I4JNrdCjHASB5kHO0Yp663zuk5AhL_jRl1k_SY5vnpUrSCkFxyolVdXM4FQlXIKn4Vvw31N76GuK5LU06Z_W9PLwfY2Syw-289UtPxVzBx9gVTRruCab2sQxw8wsPzWwQuzodrorJnIINUBwKL_vl4JpUyg2&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=EBaCwkyF6v0hRUf3ae-93ssVmxQ7oIMqv_PPxkqrb9oreHGbb2-nfpYVrHcdp3m-zVM-7IejfExLCflpv83MelmvDxCP_bfWTqE6qeqNKtnJrC6U7f-VSqzDeiqxeFeQcr2gdWPsj6xuQIL9yofEjL-H9aGyCIOqWIpEBJ7whIjP5cINMF1LSl9sjJQ7m8EzvCkRy97Lv87xdtMaOwsPZQua3oe2eRAfQMy5DfH1rBU1&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=wD8VqdUYdbEDwBKpnhKPdzJbzZckynHSZAFSwtw0pb9xBjjkE5QcyWugHeKYmmlr5VSa3nfGB1Xz7jafz_E7BWSKiwSgokhW7jiO928L_QrPFxF6EUuMyF_R_k74O2ZH3Z2j_4YTihok5YYe4jIHNbXew2ICIYicdQ6t5hTNp6rgynp1DalRocxe5znBs87HZLCu8p1QfDK38eKJRZE968HV31IWzfYmG-OLm0YY--COCDBd2W06gq-Q4GGHyVyR0&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=-7EYqBUD5SBnN9GXen_j6q1vUCHCiGsBm9LG-6jUM7Rd46ySBRRKNEzamKwU97Ev4GNWdvuZGqjKPpTco_vaUnZotagIyWjSOr8Y_YpPpCBN41u1qvqUa_Z3KhaMpFpLnBCVAOGXsZBX0gnLdrWl7SPrwgrfSJovgJOyKQNohnCagrVGRS7D0SajjiwZiBwbRFFXzQUODi-UXS4-R3OUE9NEoYmrfX_DvTq3geTEsrQ1&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=1Bz5XD8diaSe1jTYew43lskkqvoOQ7xUk9zYBR9yPfNI5dG64NIPCYkFSKOHNDL_QVi-dGp62xDY0jGHiOTaybK9bApxYHqJLIbzEwEQB4irPiQPiKBzzY5p7N4f-D0FpCNtiMYBBQwavF6nxBbyIVOMdRyTBQ10Hm9Zmj9z2NOmhfNxDVkOcXNQDwO54qpnA74wIl4P7kqB5Ngz9hx4kY3xEadtMKXSX7uqRVTMzso1&t=596f116c"></script> <script type="text/javascript" src="/ScriptResource.axd?d=2jUlVNSVbehJJ-Lt4PSuX3imkArDDoAUwrw500StXDnRKdoHS2np91egmJiBUG7feIOax9x-3d3eG4JYvatg-8X9LQmJU49eWww19gWY7vSdphyQrCWf_QI352TwlgZkOjBO9SLzCdnP0Rkx2chN2q3GkIbDzjCD2z0q_V19F4FLoBgT9FcKUizcWUqIzBoXhgYN9ZOMKI0YCb0cjcqnIG9l7yUe6eYzolUqVyyoo5k1&t=596f116c"></script> <script type="text/javascript">RegisterSod("require.js", "\u002f_layouts\u002f15\u002frequire.js?rev=bv3fWJhk0uFGpVwBxnZKNQ\u00253D\u00253DTAG0");</script> <script type="text/javascript">RegisterSod("core.js", "\u002f_layouts\u002f15\u002fcore.js?rev=g9HqQVNT6hcLiEteDP6VMg\u00253D\u00253DTAG0");</script> <script type="text/javascript">RegisterSod("menu.js", "\u002f_layouts\u002f15\u002fmenu.js?rev=6dnih6LFrDf0hiSAR8r07Q\u00253D\u00253DTAG0");</script> <script type="text/javascript">RegisterSod("mQuery.js", "\u002f_layouts\u002f15\u002fmquery.js?rev=BEyC5TBPjHrLE6naIsb\u00252B9w\u00253D\u00253DTAG0");</script> <script type="text/javascript">RegisterSod("callout.js", "\u002f_layouts\u002f15\u002fcallout.js?rev=PLncbR7kHsk4oUK8vdAhcQ\u00253D\u00253DTAG0");RegisterSodDep("callout.js", "mQuery.js");RegisterSodDep("callout.js", "core.js");</script> <script type="text/javascript">RegisterSod("clienttemplates.js", "\u002f_layouts\u002f15\u002fclienttemplates.js?rev=a5u\u00252Bo\u00252BV0203wesJh2YZbGg\u00253D\u00253DTAG0");</script> <script type="text/javascript">RegisterSod("sharing.js", "\u002f_layouts\u002f15\u002fsharing.js?rev=PjtFjtv583IcaWp62rfCtQ\u00253D\u00253DTAG0");RegisterSodDep("sharing.js", "mQuery.js");RegisterSodDep("sharing.js", "clienttemplates.js");RegisterSodDep("sharing.js", "core.js");</script> <script type="text/javascript">RegisterSod("suitelinks.js", "\u002f_layouts\u002f15\u002fsuitelinks.js?rev=N\u00252FGVXPUEi4baLK9zU4xPWQ\u00253D\u00253DTAG0");RegisterSodDep("suitelinks.js", "core.js");</script> <script type="text/javascript">RegisterSod("followingcommon.js", "\u002f_layouts\u002f15\u002ffollowingcommon.js?rev=i\u00252BsPiVphgLOXyrYYvFW6Yg\u00253D\u00253DTAG0");RegisterSodDep("followingcommon.js", "sp.js");RegisterSodDep("followingcommon.js", "userprofile");RegisterSodDep("followingcommon.js", "core.js");RegisterSodDep("followingcommon.js", "mQuery.js");</script> <script type="text/javascript">RegisterSod("profilebrowserscriptres.resx", "\u002f_layouts\u002f15\u002f1033\u002fprofilebrowserscriptres.js?rev=qwf69WaVc1mYlJLXqmZmVA\u00253D\u00253DTAG0");</script> <script type="text/javascript">RegisterSod("inplview", "\u002f_layouts\u002f15\u002finplview.js?rev=rrVJKHzFwnUJ0WDOINoX7A\u00253D\u00253DTAG0");RegisterSodDep("inplview", "core.js");RegisterSodDep("inplview", "clienttemplates.js");RegisterSodDep("inplview", "sp.js");</script> <script type="text/javascript">RegisterSod("dragdrop.js", "\u002f_layouts\u002f15\u002fdragdrop.js?rev=o1DmLzVvr8fHXlmK8I5Y0g\u00253D\u00253DTAG0");</script> <script type="text/javascript">RegisterSod("quicklaunch.js", "\u002f_layouts\u002f15\u002fquicklaunch.js?rev=I4YOskvft8dvplFH5iVlMg\u00253D\u00253DTAG0");RegisterSodDep("quicklaunch.js", "dragdrop.js");</script> <script type="text/javascript">RegisterSod("WPAdderClass", "\u002f_layouts\u002f15\u002fwpadder.js?rev=0XmW5VvSze747dmFn49Kiw\u00253D\u00253DTAG0");</script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/jquery.js?v=05.24.00.023"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/bootstrap.bundle.min.js?v=05.24.00.023" defer="true"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/jqueryui.js?v=05.24.00.023"> </script> <link type="text/xml" rel="alternate" href="/hep/_vti_bin/spsdisco.aspx" /> <link rel="canonical" href="https://journals.lww.com/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx" /> <noscript> <meta http-equiv="Refresh" content="3;url=/_layouts/1033/OAKS.Journals/Error/JavaScript.html" /> </noscript> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/lww-core.js?v=05.24.00.023"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/journal-navigation.min.js?v=05.24.00.023" defer="true"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/journals_master.min.js?v=05.24.00.023"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/manifest.js?v=05.24.00.023" defer="true"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/ejp.js?v=05.24.00.023" defer="true"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/react-redux-vendors.js?v=05.24.00.023" defer="true"> </script> <script type="text/javascript"> var scpl_time = new Date(); scpl_time = scpl_time.getTime(); window.A8AJQ = jQuery.noConflict(); window.$ = jQuery.noConflict(); </script> <script async type="text/plain" src="https://aim-tag.hcn.health/js/client.js?dl=aimDataLayer&target=ie11" class="optanon-category-C0004"></script> <script> window.aimDataLayer = window.aimDataLayer || []; function aimTag() { aimDataLayer.push(arguments); } aimTag('2429bf11-c05b-409f-b998-8acef505546e', 'pageview'); aimTag('2429bf11-c05b-409f-b998-8acef505546e', 'signal', function (err, success) { if (err) { console.log(err); } else { console.log(success); if (success.identity_type === "AUT") { } } }); </script> <meta name="citation_doi" content="10.1002/hep.27950"><meta name="citation_fulltext_world_readable" content="" /></head> <body id="ctl00_BodyTag" class="lww-body lww-article-view"> <span class="js-custom-event" data-config="{"name":"omni:page:view","detail":{"uid":"","uid_src":"None","page_loc":"https://journals.lww.com/hep/pages/articleviewer.aspx?year=2015&issue=09000&article=00029&type=Fulltext","page_ttl":"Hepatology"},"order":2147483647,"config":{"bubbles":true,"cancelable":true,"composed":false}}"></span>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NLR6H6W"height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div id="imgPrefetch" style="display:none"> <img src="https://cdn.wolterskluwer.io/wk-logos/1.0.x/favicon.png?rev=43" /> <img src="/_layouts/15/images/spcommon.png?rev=43" /> </div> <noscript><div class='noindex'>You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.</div></noscript> <form method="post" action="/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx" onsubmit="javascript:return WebForm_OnSubmit();" id="aspnetForm"> <div class="aspNetHidden"> <input type="hidden" name="_wpcmWpid" id="_wpcmWpid" value="" /> <input type="hidden" name="wpcmVal" id="wpcmVal" value="" /> <input type="hidden" name="MSOWebPartPage_PostbackSource" id="MSOWebPartPage_PostbackSource" value="" /> <input type="hidden" name="MSOTlPn_SelectedWpId" id="MSOTlPn_SelectedWpId" value="" /> <input type="hidden" name="MSOTlPn_View" id="MSOTlPn_View" value="0" /> <input type="hidden" name="MSOTlPn_ShowSettings" id="MSOTlPn_ShowSettings" value="False" /> <input type="hidden" name="MSOGallery_SelectedLibrary" id="MSOGallery_SelectedLibrary" value="" /> <input type="hidden" name="MSOGallery_FilterString" id="MSOGallery_FilterString" value="" /> <input type="hidden" name="MSOTlPn_Button" id="MSOTlPn_Button" value="none" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__REQUESTDIGEST" id="__REQUESTDIGEST" value="noDigest" /> <input type="hidden" name="MSOSPWebPartManager_DisplayModeName" id="MSOSPWebPartManager_DisplayModeName" value="Browse" /> <input type="hidden" name="MSOSPWebPartManager_ExitingDesignMode" id="MSOSPWebPartManager_ExitingDesignMode" value="false" /> <input type="hidden" name="MSOWebPartPage_Shared" id="MSOWebPartPage_Shared" value="" /> <input type="hidden" name="MSOLayout_LayoutChanges" id="MSOLayout_LayoutChanges" value="" /> <input type="hidden" name="MSOLayout_InDesignMode" id="MSOLayout_InDesignMode" value="" /> <input type="hidden" name="_wpSelected" id="_wpSelected" value="" /> <input type="hidden" name="_wzSelected" id="_wzSelected" value="" /> <input type="hidden" name="MSOSPWebPartManager_OldDisplayModeName" id="MSOSPWebPartManager_OldDisplayModeName" value="Browse" /> <input type="hidden" name="MSOSPWebPartManager_StartWebPartEditingName" id="MSOSPWebPartManager_StartWebPartEditingName" value="false" /> <input type="hidden" name="MSOSPWebPartManager_EndWebPartEditing" id="MSOSPWebPartManager_EndWebPartEditing" value="false" /> <input type="hidden" name="listContainerControlstate" id="listContainerControlstate" value="AAEAAAD/////AQAAAAAAAAAEAQAAAA5TeXN0ZW0uQm9vbGVhbgEAAAAHbV92YWx1ZQABAAs=" /> <input type="hidden" name="hiddenDisplayItemView" id="hiddenDisplayItemView" value="Citation" /> <input type="hidden" name="hiddenSortBy" id="hiddenSortBy" value="" /> <input type="hidden" name="__LASTFOCUS" id="__LASTFOCUS" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=dnaDAFNiQGyAS-8AAnEusSAvRcEvxsZnbowJJdr_Pi9Oz7lzs5k45FStkRo1xlEHk9NeovbY1Hwq_CwXR_md87LXDXM1L2hMpaL8ksMyAA01&t=637811513229275428" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var MSOWebPartPageFormName = 'aspnetForm'; var g_presenceEnabled = true; var g_wsaEnabled = false; var g_correlationId = '44e38ea1-d20e-f0c3-6507-57a5a06effc4'; var g_wsaQoSEnabled = false; var g_wsaQoSDataPoints = []; var g_wsaRUMEnabled = false; var g_wsaLCID = 1033; var g_wsaListTemplateId = 850; var g_wsaSiteTemplateId = 'EJOURNALS#7'; var _spPageContextInfo={"webServerRelativeUrl":"/hep","webAbsoluteUrl":"https://journals.lww.com/hep","viewId":"","listId":"{b807cb8a-3cdf-4126-b475-cf89c1612eb3}","listPermsMask":{"High":0,"Low":200769},"listUrl":"/hep/Pages","listTitle":"Pages","listBaseTemplate":850,"viewOnlyExperienceEnabled":false,"blockDownloadsExperienceEnabled":false,"idleSessionSignOutEnabled":false,"cdnPrefix":"","siteAbsoluteUrl":"https://journals.lww.com/hep","siteId":"{2c6587f4-72ed-421d-b7cf-8bc89dbb8af8}","showNGSCDialogForSyncOnTS":false,"supportPoundStorePath":true,"supportPercentStorePath":true,"siteSubscriptionId":null,"CustomMarkupInCalculatedFieldDisabled":true,"AllowCustomMarkupInCalculatedField":false,"isSPO":false,"farmLabel":null,"serverRequestPath":"/hep/pages/articleviewer.aspx","layoutsUrl":"_layouts/15","webId":"{fad62b21-61f6-402d-b613-d5e24dd4ad5b}","webTitle":"Hepatology","webTemplate":"20200","webTemplateConfiguration":"EJOURNALS#7","webDescription":"","tenantAppVersion":"0","isAppWeb":false,"webLogoUrl":"_layouts/15/images/siteicon.png","webLanguage":1033,"currentLanguage":1033,"currentUICultureName":"en-US","currentCultureName":"en-US","currentCultureLCID":1033,"env":null,"nid":0,"fid":0,"serverTime":"2025-03-28T09:13:48.2102931Z","siteClientTag":"0$$16.0.10416.20041","crossDomainPhotosEnabled":false,"openInClient":false,"Has2019Era":true,"webUIVersion":15,"webPermMasks":{"High":0,"Low":196609},"pageListId":"{b807cb8a-3cdf-4126-b475-cf89c1612eb3}","pageItemId":77,"pagePermsMask":{"High":0,"Low":200769},"pagePersonalizationScope":1,"userEmail":"","userId":0,"userLoginName":null,"userDisplayName":null,"isAnonymousUser":true,"isAnonymousGuestUser":false,"isEmailAuthenticationGuestUser":false,"isExternalGuestUser":false,"systemUserKey":null,"alertsEnabled":true,"siteServerRelativeUrl":"/hep","allowSilverlightPrompt":"True","themeCacheToken":"/hep::1:","themedCssFolderUrl":null,"themedImageFileNames":null,"modernThemingEnabled":true,"isSiteAdmin":false,"ExpFeatures":[480216468,1884350801,1158731092,62197791,538521105,335811073,4194306,34614301,268500996,-1946025984,28445328,-2147475455,134291456,65536,288,950272,1282,808326148,134217873,0,0,-1073217536,545285252,18350656,-467402752,6291457,-2147483644,1074794496,-1728053184,1845537108,622628,4102,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"killSwitches":{},"InternalValidAuthorities":["journals.na.lww.com","journals.lww.com","journals.na.lww.com","journals.lww.com","cloud-journals.lww.com","cloud-journals.lww.com"],"CorrelationId":"44e38ea1-d20e-f0c3-6507-57a5a06effc4","hasManageWebPermissions":false,"isNoScriptEnabled":false,"groupId":null,"groupHasHomepage":true,"groupHasQuickLaunchConversationsLink":false,"departmentId":null,"hubSiteId":null,"hasPendingWebTemplateExtension":false,"isHubSite":false,"isWebWelcomePage":false,"siteClassification":"","hideSyncButtonOnODB":false,"showNGSCDialogForSyncOnODB":false,"sitePagesEnabled":false,"sitePagesFeatureVersion":0,"DesignPackageId":"00000000-0000-0000-0000-000000000000","groupType":null,"groupColor":"#757575","siteColor":"#757575","headerEmphasis":0,"navigationInfo":null,"guestsEnabled":false,"MenuData":{"SignInUrl":"/hep/_layouts/15/Authenticate.aspx?Source=%2Fhep%2Ffulltext%2F2015%2F09000%2Fhepatitis%5Fc%5Fguidance%5F%5Faasld%5Fidsa%5Frecommendations%2E29%2Easpx"},"RecycleBinItemCount":-1,"PublishingFeatureOn":true,"PreviewFeaturesEnabled":false,"disableAppViews":false,"disableFlows":false,"serverRedirectedUrl":null,"formDigestValue":"0x76CA10295F4D5707D43E4BB7145BC3574B8DE098AB5892EE747E18A287ED8E71D2459A52660F70B3F34094751D55E5C2F02E1790E9A5B8C69BB31E8A5E0628FC,28 Mar 2025 09:13:48 -0000","maximumFileSize":10240,"formDigestTimeoutSeconds":1800,"canUserCreateMicrosoftForm":false,"canUserCreateVisioDrawing":true,"readOnlyState":null,"isTenantDevSite":false,"preferUserTimeZone":false,"userTimeZoneData":null,"userTime24":false,"userFirstDayOfWeek":null,"webTimeZoneData":null,"webTime24":false,"webFirstDayOfWeek":null,"isSelfServiceSiteCreationEnabled":null,"alternateWebAppHost":"","aadTenantId":"","aadUserId":"","aadInstanceUrl":"","msGraphEndpointUrl":"https://","allowInfectedDownload":true};_spPageContextInfo.updateFormDigestPageLoaded=new Date();_spPageContextInfo.clientServerTimeDelta=new Date(_spPageContextInfo.serverTime)-new Date();if(typeof(define)=='function'){define('SPPageContextInfo',[],function(){return _spPageContextInfo;});}var L_Menu_BaseUrl="/hep"; var L_Menu_LCID="1033"; var L_Menu_SiteTheme="null"; document.onreadystatechange=fnRemoveAllStatus; function fnRemoveAllStatus(){removeAllStatus(true)};//]]> </script> <script src="https://lww.com/_layouts/15/1033/Scripts/wk/alerts-subscription.min.js?v=05.24.00.023" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ Flighting.ExpFeatures = [480216468,1884350801,1158731092,62197791,538521105,335811073,4194306,34614301,268500996,-1946025984,28445328,-2147475455,134291456,65536,288,950272,1282,808326148,134217873,0,0,-1073217536,545285252,18350656,-467402752,6291457,-2147483644,1074794496,-1728053184,1845537108,622628,4102,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0]; (function() { if(typeof(window.SP) == "undefined") window.SP = {}; if(typeof(window.SP.YammerSwitch) == "undefined") window.SP.YammerSwitch = {}; var ysObj = window.SP.YammerSwitch; ysObj.IsEnabled = false; ysObj.TargetYammerHostName = "www.yammer.com"; } )(); var _spWebPartComponents = new Object();function openEmtcIfAuthenticated(resourceId){logCounterDataEmailToColleagueByAN('01515467-201509000-00029', false); window.location.assign('https://journals.lww.com/hep/pages/login.aspx?ReturnUrl=%2fhep%2ffulltext%2f2015%2f09000%2fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx');}function slideShow_NavigateToUrl(urlToNavigate) { $('#ArticleImageModal').modal('hide'); logCounterDataImageGalleryByAN('01515467-201509000-00029'); window.location = urlToNavigate; }function HideSlideShow() { $('#ArticleImageModal').modal('hide'); }//]]> </script> <script src="https://lww.com/_layouts/15/1033/Scripts/wk/ListContainerControlBase.js?v=05.24.00.023" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ function getSelectedItemsField() { return $get("selectedItems"); }function getCheckBoxListContainer() { return $get("checkBoxListContainer"); }function getListActionsContainerTop() { return $get("listActionsContainerTop"); }function getListActionsContainerBottom() { return $get("listActionsContainerBottom"); }function getSelectedItemsCount() {{ return getSelectedItemsField().value.split(';').length - 1; }}function article_AddSelectedItem(){ addToMyCollectionsLinkClicked('00029'); }function getEmailRegularExpression() { return /^(([a-zA-Z0-9_\-\.]+)@([a-zA-Z0-9_\-\.]+)\.([a-zA-Z]{2,5}){1,25})$/; }function getMultipleEmailsRegularExpression() { return /^(([a-zA-Z0-9_\-\.]+)@([a-zA-Z0-9_\-\.]+)\.([a-zA-Z]{2,5}){1,25})+([;.](([a-zA-Z0-9_\-\.]+)@([a-zA-Z0-9_\-\.]+)\.([a-zA-Z]{2,5}){1,25})+)*$/; }function getMailMessage() { return 'Thought you might appreciate this item(s) I saw in Hepatology.'; }function getImageCountStatus() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_imageCountStatus"); }function getCallshowImage() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_callShowImage"); }function getImageUrl() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_url"); }function getDescription() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_description"); }function getImageSourceTitle() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceTitle"); }function getImageSourceUrl() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceUrl"); }function getImageSourceInfo() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceInfo"); }function getImageKey() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_key"); }function getImageFullSizeUrl() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_fullSizeUrl"); }function getImageGalleryUrl() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_imageGalleryUrl"); }function getEmailTOColleaguePopupID() { return "ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague"; }function image(id, nextImageId, previousImageId, title, description, rolloverUrl, popupUrl, fullSizeUrl, originalUrl, imageGalleryUrl, windowId){this.id = id;this.title = title;this.description = description;this.rolloverUrl = rolloverUrl;this.popupUrl = popupUrl;this.nextImageId = nextImageId;this.previousImageId = previousImageId; this.fullsizeUrl = fullSizeUrl; this.originalUrl = originalUrl;this.imageGalleryUrl = imageGalleryUrl; this.windowId=windowId}function getPopupImageId() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_popupImageId"); }function getIsExportToPPT() { return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_IsExportToPPT"); }//]]> </script> <script src="/ScriptResource.axd?d=11ySqNT2t8wJXf-5ynqkHTYVaR0CZPUQDLhFk5-B61-yY4pHK9T4A-OmNoLERHX1OU2F3io32lKHXeNlvH0kpnJP6-ZQm2Ado5OlvNqUwB9TpwuIgMVQBgIz-DSVpHWqDoVFHrt69C9fSrbhF6t9QBuuAcSpa-p9_2de4EnR0aU1&t=2265eaa7" type="text/javascript"></script> <script src="/_layouts/15/blank.js?rev=bSwUuDrVd4rvOQePvjjhaw%3D%3DTAG0" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ window.SPThemeUtils && SPThemeUtils.RegisterCssReferences([]); (function(){ if (typeof(_spBodyOnLoadFunctions) === 'undefined' || _spBodyOnLoadFunctions === null) { return; } _spBodyOnLoadFunctions.push(function() { SP.SOD.executeFunc('core.js', 'FollowingDocument', function() { FollowingDocument(); }); }); })();(function(){ if (typeof(_spBodyOnLoadFunctions) === 'undefined' || _spBodyOnLoadFunctions === null) { return; } _spBodyOnLoadFunctions.push(function() { SP.SOD.executeFunc('core.js', 'FollowingCallout', function() { FollowingCallout(); }); }); })();if (typeof(DeferWebFormInitCallback) == 'function') DeferWebFormInitCallback();//]]> </script> <script src="/WebResource.axd?d=ujR-dJ4zUHGN6jELxLVetl199sJpE_qZiBmEfUoaRM4DCmEfpBr9GGhTGo9ZJcfF6mQ45yf4Ik1RnQ9yqZG9_5EcA9R0xynU6JEfYiEh3vA1&t=637811513229275428" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ function WebForm_OnSubmit() { UpdateFormDigest('\u002fhep', 1440000);if (typeof(ValidatorOnSubmit) == "function" && ValidatorOnSubmit() == false) return false;if (typeof(_spFormOnSubmitWrapper) != 'undefined') {return _spFormOnSubmitWrapper();} else {return true;}; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="E50BF36A" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="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" /> </div> <script type="text/javascript"> var submitHook = function () { return false; }; theForm._spOldSubmit = theForm.submit; theForm.submit = function () { if (!submitHook()) { this._spOldSubmit(); } }; </script> <span id="DeltaSPWebPartManager"> </span> <script type="text/javascript">$.getJSON("https://login.journals.lww.com/AuthCheck.aspx?Callback=?", null, function (data) { if(data.IsAuthenticated.toLowerCase() == "true") {window.location.replace("https://login.journals.lww.com/?wa=wsignin1.0&wtrealm=urn%3ajournals&wctx=https%3a%2f%2fjournals.lww.com%2fhep%2f_layouts%2f15%2fAuthenticate.aspx%3fSource%3d%252fhep%252ffulltext%252f2015%252f09000%252fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx"); } }) </script> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$ScriptManager', 'aspnetForm', ['fctl00$WebPartAdderUpdatePanel',''], [], ['ctl00$WebPartAdder','','ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnOpenExportDialog',''], 90, 'ctl00'); //]]> </script> <span id="DeltaDelegateControls"> </span>   <div id="ctl00_MicrobarContainer" class="top-microbar-container"> <script> ; (function ($) { $.fn.responsiveMenu = function (options) { var settings = $.extend({ breakWidth: 600, label: 'Visit our other sites', position: 'left' }, options); var menu = $(this); var clone = menu.clone().insertBefore(menu).removeAttr('class').removeAttr('id'); var wrapper = $('<div class="responsive-menu rm-' + settings.position + '"></div>'); var button = $('<button onclick="return false;" class="rm-toggle">' + (settings.label ? '<span class="caret"></span><span class="rm-label">' + settings.label + '</span>' : '') + '</button>'); wrapper.insertBefore(menu); wrapper.prepend(clone); wrapper.prepend(button); var switchMenu = function () { if ($(window).width() <= settings.breakWidth) { wrapper.show(); menu.hide(); } else { wrapper.hide(); menu.hide(); } }; switchMenu(); button.click(function () { clone.toggle(); }); $(window).resize(switchMenu); }; })(window.Zepto || window.jQuery); </script> <script> $(function () { $('#menu').responsiveMenu({ breakWidth: 1000, // label: false, position: 'right' }); }); </script> <div id="ctl00__ff7d6dbe7f74c4f9_headerLinks"><script type="text/javascript"> window._mfq = window._mfq || []; (function() { var mf = document.createElement("script"); mf.type = "text/javascript"; mf.async = true; mf.src = "//cdn.mouseflow.com/projects/d007e6ad-c565-44cd-bbf8-fdebe41c0fca.js"; document.getElementsByTagName("head")[0].appendChild(mf); })(); </script> <div class="headerNav"> <div class="headerNavContent"> <ul class="headerNavTabs"> <li class="headerNavTab firstNavTab"><a href="/aasldpubs/Pages/default.aspx" target="_blank">AASLD Publications</a></li> <li class="headerNavTab navTab on"><a href="/hep/Pages/default.aspx" target="_blank">Hepatology</a></li> <li class="headerNavTab lastTab"><a href="/lt/Pages/default.aspx">Liver Transplantation</a></li> <li class="headerNavTab navTab"><a href="/hepcomm/Pages/default.aspx" target="_blank">Hepatology Communications</a></li> <li class="headerNavTab lastTab"><a href="/cld/Pages/default.aspx" target="_blank">Clinical Liver Disease</a></li> </ul> </div> </div> <ul id="menu" class="navbar dummyhidden" style="display:none;"> <li><a href="/aasldpubs/Pages/default.aspx" target="_blank">AASLD Publications</a></li> <li class="on"><a href="/hep/Pages/default.aspx" target="_blank">Hepatology</a></li> <li><a href="/lt/Pages/default.aspx" target="_blank">Liver Transplantation</a></li> <li><a href="/hepcomm/Pages/default.aspx" target="_blank">Hepatology Communications</a></li> <li><a href="/cld/Pages/default.aspx" target="_blank">Clinical Liver Disease</a></li> </ul> <style type="text/css"> div.headerNav{ background-color: #EFEFEF; height: 30px; width: 100%; word-spacing: 1.5px; } div.headerNavContent{ margin: 0 auto; min-height: 30px; padding-right: 2.7%px; width: 90%; } ul.headerNavTabs{ clear: both; display: block; left: auto; margin: 0 auto; position: relative; width: 95%; } li.navTab{ width:20%; } li.firstNavTab{ width: 20%; } li.lastTab{ width:20%; } li.on{ background: none repeat scroll 0 0 #006421 !important; color:#ffffff; } /****** Highlight JBJS Link ******/ li.org{ background: none repeat scroll 0 0 #006421 !important; } .org a{ background-color:#003F7B !important; color: #ffffff !important; } .org a:hover{ background-color:#003262 !important; } li.headerNavTab{ background: none repeat scroll 0 0 #EFEFEF; display: inline; float: left; height: 30px; margin: 0; padding: 0; } ul.headerNavTabs li{ display: inline; float: left; text-align: center; } ul.headerNavTabs li a:link, ul.headerNavTabs li a:active, ul.headerNavTabs li a:hover, ul.headerNavTabs li a:visited{ color: #000; font-size: 12px; font-style: normal; font-weight: bold; outline: 0 none; position: relative; text-decoration: none; } li.lastNavTab { float: left; width: 123px; } li.lastNavTab, li.lastMainNavTab { float: right; } span.headerNavTab { color: #FFFFFF; font-size: 12px; font-style: normal; font-weight: bold; outline: 0 none; position: relative; text-decoration: none; top: 10px; } li.on a { color: #fff !important; } @-moz-document url-prefix() { ul.headerNavTabs li a:link, ul.headerNavTabs li a:active, ul.headerNavTabs li a:hover, ul.headerNavTabs li a:visited { top: 6px; } span.headerNavTab { top: 6px; } } </style> <script type="text/javascript" language="javascript"> $(document).ready(function () { setHeaderLinks(); }); function setHeaderLinks() { $('li.headerNavTab').click(function (event) { }).mouseenter(function () { if ($(this).children('ul').length > 0) { $(this).children('ul').show(); $(this).css('background-color', '#194F3D'); } }).mouseleave(function () { if ($(this).children('ul').length > 0) { $(this).children('ul').hide(); $(this).css('background-color', '#323232'); } }); } </script></div> </div>  <a id="HiddenAnchor" href="javascript:;" style="display: none;"></a>  <div id="ctl00_TopAdvertisementContainer" class="advertisement-content_top top-banner"> <div class="top-banner__content--centered top-banner--low-opacity"> <div id="ctl00_ctl49_adContainer" class="ej-advertisement ej-advertisement-topcombo"> <div class="ej-advertisement-content"> <div> <div id="ga_3cd1c9c9-5fe6-4531-a86a-699f99879795" class="ad-slot-container ad-slot-container-ga_3cd1c9c9-5fe6-4531-a86a-699f99879795" data-sizemap="[[[730, 500], [[728, 90]]], [[0, 0], [[300, 50]]]]" data-adpath="/15726702761/Desktop/hep/Article/Top" data-autoload="yes" data-outofpage="no" data-sticky="no" data-slottargeting='' data-displayslug="yes" data-sticky-duration="5" data-name="Top"></div> </div> </div> </div> </div> </div> <div class="main-wrapper"> <div id="main-container">  <header class="header"> <div class="header__holder"> <div class="header__layout-top society wk-grid-page-container"> <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/UserToolbarDropdown.js?v=05.24.00.023" defer="true"> </script> <section class="user-action-toolbar"> <ul class="user-menu user-info" role="tablist"> <li id="ctl00_ctl51_Header_UserActionTools_liLogin" class="user-menu__item user-menu__item--popup-container user-menu__item--login-popup-container dib"> <button class="user-menu__link user-menu__link--login js-ejp-login-btn" type="button" data-config="{"eventName":"login","eventDetail":{"source":"Masthead Dropdown"},"isNull":false}"> <i class="fa fa-sign-in"></i> <span>Log in</span> </button> </li> <li id="ctl00_ctl51_Header_UserActionTools_liOr" class="dib or-spacing"><span>or</span></li> <li id="ctl00_ctl51_Header_UserActionTools_liRegister2" class="user-menu__item dib"> <a id="ctl00_ctl51_Header_UserActionTools_RegisterUserPopupLnk" class="user-menu__link js-register-link" data-config="{"eventName":"Register","eventDetail":{"source":"Masthead Dropdown"},"isNull":false}" href="https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2015%2f09000%2fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx">Register</a> </li> <li id="ctl00_ctl51_Header_UserActionTools_liSubscribe" role="presentation" class="user-menu__item dib"> <a id="ctl00_ctl51_Header_UserActionTools_lnkSubscribe" class="user-menu__link" href="https://shop.lww.com/p/0270-9139" target="_blank"><i class="fa fa-bars"></i> <span class="hideOnFixed">Subscribe to journal</span><span class="showOnFixed">Subscribe</span></a> </li> <li id="ctl00_ctl51_Header_UserActionTools_liIssueAlerts" class="user-menu__item dib"> <i class="fa fa-envelope"></i> <a rel="nofollow" title href="javascript:javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');;" onclick="javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');" class="user-menu__link"><span id="ctl00_ctl51_Header_UserActionTools_SubscribeToAlertsActionToolLink_defaultText" class="hideOnFixed">Get new issue alerts</span><span id="ctl00_ctl51_Header_UserActionTools_SubscribeToAlertsActionToolLink_stickyText" class="showOnFixed">Get alerts</span></a> </li> <li id="ctl00_ctl51_Header_UserActionTools_liDynamicItem" class="user-menu__item dib"> <i class="fa fa-stop user-menu__dynamic-item-icon"></i> <a id="ctl00_ctl51_Header_UserActionTools_lnkDynamicItem" class="user-menu__link" href="https://login.journals.lww.com/OneID/Login.aspx?PartnerIdpId=https://my.aasld.org&Login_type=SocietySso&returnUrl=https%3a%2f%2fjournals.lww.com%2flt%2fpages%2fdefault.aspx">AASLD Member? Login here</a> </li> </ul> </section> <span id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_dummyTargetControl"></span> <div id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pnlunSubscribeToAlerts" style="display: none;"> <div tabindex="-1" role="dialog" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal"> <div id="ej-box-modal-style-1"> <div id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pnlMain"> <div id="tocUnsubscribeModal" > <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"></div> <button aria-label="close dialog" class="js-close primary-button wk-button-icon wk-modal-close ejp-modal-close "><i class="fa fa-times"></i></button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <p> <span id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage"></span> </p> <div class="wk-button-bar"> <div class="wk-button-group-left"> <p id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons" Style="display: none;"> <input type="submit" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$btnContinue" value="Yes" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$btnContinue", "", true, "", "", false, false))" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_btnContinue" class="primary-button" /> <input type="button" value="No" id="btnCancel" aria-label="close dialog" class="js-close secondary-button" /> </p> </div> </div> </div> </div> </section> </div> </div> </div> </div> </div> <div id="ej-clear-float"> </div> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenUnSubscribeAlertType" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenUnsubscribeJournalId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenUnsubscribeMessage" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenTopicalCollectionId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenTopicalCollectionId" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenOvidId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenOvidId" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenJournalId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId" /> <script type="text/javascript"> function alerts_ShowUnSubscribeeTOCPopup(title, alertType, journalId) { var unSubscribeeTocPopup = $find('unSubscribeToAlerts'); var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage'); lblUnsubscribeMessage.innerHTML = title; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = alertType; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title; $('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show(); if (document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == null || document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == '') { document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value = journalId; } if (unSubscribeeTocPopup != null) { unSubscribeeTocPopup.show(); } } function alerts_ShowUnSubscribeeTOCPopup_Root(title, journalId, alertType) { var unSubscribeeTocPopup = $find('unSubscribeToAlerts'); var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage'); lblUnsubscribeMessage.innerHTML = title; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = alertType; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId').value = journalId; $('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show(); if (unSubscribeeTocPopup != null) { unSubscribeeTocPopup.show(); } } function alerts_ShowUnSubscribeeTOCPopup_Citation(title, journalId, ovidId) { var unSubscribeeTocPopup = $find('unSubscribeToAlerts'); var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage'); lblUnsubscribeMessage.innerHTML = title; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = 'Citation'; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId').value = journalId; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenOvidId').value = ovidId; $('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show(); if (unSubscribeeTocPopup != null) { unSubscribeeTocPopup.show(); } } function alerts_ShowUnSubscribeeTOCPopup_Topical(title, journalId, topicalCollectionId) { var unSubscribeeTocPopup = $find('unSubscribeToAlerts'); var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage'); lblUnsubscribeMessage.innerHTML = title; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = 'Topical'; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId').value = journalId; document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenTopicalCollectionId').value = topicalCollectionId; $('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show(); if (document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == null || document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == '') { document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value = journalId; } if (unSubscribeeTocPopup != null) { unSubscribeeTocPopup.show(); } } function alerts_ShowUnSubscribeeTOCSuccessPopup() { var unSubscribeeTocPopup = $find('unSubscribeToAlerts'); if (unSubscribeeTocPopup != null) { unSubscribeeTocPopup.show(); } } $('.js-close').on('click', function() { var unSubscribeeTocPopup = $find('unSubscribeToAlerts'); if (unSubscribeeTocPopup != null) { unSubscribeeTocPopup.hide(); } return false; }); </script> <span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_dummyTargetControl"></span> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenSubscribeToEtocPopupState" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscribeToEtocPopupState" value="showemail" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenConfirmSubscriptionPageUrl" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenConfirmSubscriptionPageUrl" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenJournalId" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenJournalId" /> <input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenSubscriptionType" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscriptionType" /> <div id="divPopupOverLay" class="Popup-Overlay" style="display: none; position: fixed; left: 0; top: 0; z-index: 3800; width: 1920px; height: 4517px;"></div> <div id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlSubscribeToEtoc" class="etoc-popup ej-box-modal-drop-shadow" style="display: none;"> <div tabindex="-1" role="dialog" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal"> <div id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlMain" onkeypress="javascript:return WebForm_FireDefaultButton(event, 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_btnContinue')"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"> <span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblTitle"></span> </div> <button aria-label="close dialog" class="js-close primary-button wk-button-icon wk-modal-close ejp-modal-close "> <i class="fa fa-times"></i> </button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <div class="wk-field-body"> <strong> <span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblThankYouMessage"></span></strong> </div> <div class="wk-field-body"> <span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError" style="color:Black;display:none;"> <div class="ej-error-message"> <p class="ej-error-message-icon error-red"> </p> </div> </span> <label for="Email input">Enter your Email address:</label> <div class="wk-field-body"> <input name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$txtEmailAddress" type="text" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_txtEmailAddress" class="ej-box-modal-style-1-input" /> </div> </div> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="submit" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$btnContinue" value="Continue" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$btnContinue", "", true, "", "", false, false))" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_btnContinue" class="primary-button" /> <input type="button" value="Cancel" id="btnCancel" class="js-close secondary-button" /> </div> </div> </div> <div class="wk-field-item"> <div class="wk-field-body"> <a id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hypPrivacy" href="https://journals.lww.com/hep/_layouts/oaks.journals/privacy.aspx" target="_blank">Privacy Policy</a> </div> </div> </div> </section> </div> <div id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlAuthenticatedUser" style="display: none;"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"></div> <button aria-label="close dialog" class="js-close primary-button wk-button-icon wk-modal-close ejp-modal-close "><i class="fa fa-times"></i></button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <p> <strong> <span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblAuthenticatedUserTitle"></span> </strong> </p> </div> <p id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pAuthenticatedUserMessage"> </p> </div> </section> </div> </div> </div> <div id="ej-clear-float"> </div> <script type="text/javascript"> function alerts_SaveSubscriptionTypeInHiddenField(url, subscriptionType, journalId, yearId, issueId, articleId) { if (journalId && yearId && issueId && articleId) { logCounterDataAlertWhenCitedSynchronously(journalId, yearId, issueId, articleId); } $('#' + 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscriptionType').val(subscriptionType); $('#' + 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenJournalId').val(journalId); if (url) window.location = url; else __doPostBack('hypSubscribeToAlerts'); return false; } function alerts_ShowSubscribeeTOCPopup(journalTitle, journalId, subscriptionType, displaySubscriptionType) { $('#' + 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscriptionType').val(subscriptionType); var subscribeToEtocPopup = $find('subscribeToEtoc'); subscribeToEtocPopup.show(); document.getElementsByTagName( 'html' )[0].classList.add('no-scroll'); var modelPopupState = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscribeToEtocPopupState'); var emailTextBox = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_txtEmailAddress'); var thanksPanel = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlAuthenticatedUser'); var mainPanel = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlMain'); var thankYouMessageUnAuthenticated = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblThankYouMessage'); var thankYouMessageAuthenticated = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblAuthenticatedUserTitle'); if (!displaySubscriptionType) { displaySubscriptionType = subscriptionType; } if (modelPopupState.value == 'showthanksmessage') { thanksPanel.style.display = "block"; mainPanel.style.display = "none"; thankYouMessageAuthenticated.innerHTML = "Thank you for subscribing to the " + displaySubscriptionType + " for " + journalTitle + "."; } if (modelPopupState.value == 'showemail') { thanksPanel.style.display = "none"; mainPanel.style.display = "block"; thankYouMessageUnAuthenticated.innerHTML = "Thank you for choosing to subscribe to the " + displaySubscriptionType + " for " + journalTitle + "."; } if ($('.etoc-popup') != null) { document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenJournalId').value = journalId; if (modelPopupState.value == 'showemail') emailTextBox.focus(); } } $('.js-close').on('click', function () { document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_txtEmailAddress').value = ""; document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError').style.display = "none"; var pageUrl = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenConfirmSubscriptionPageUrl'); var subscribeeTocPopup = $find('subscribeToEtoc'); if (subscribeeTocPopup != null) { subscribeeTocPopup.hide(); document.getElementsByTagName( 'html' )[0].classList.remove('no-scroll'); if (pageUrl.value !== '' && pageUrl.value !== window.location.pathname) window.location = pageUrl.value; } return false; }); </script> <div id="ctl00_ctl51_Header_UserActionTools_eTocTopContainer"> <div id="eTocTop" style="display: none;"> <a rel="nofollow" title href="javascript:javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');;" onclick="javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');"><span id="ctl00_ctl51_Header_UserActionTools_alertLinkControlTop_defaultText" class="hideOnFixed">Subscribe to eTOC</span></a> </div> </div> <script> $(function () { //find recent searches link and move container var recentSearchesControl = $("a[id$='RecentSearches']"); if (recentSearchesControl.length) { recentSearchesControl.click(function (e) { e.stopPropagation(); if ($("#ResentSearchContainer").is(":hidden")) { $("#ResentSearchContainer").slideDown("slow"); recentSearchesControl.addClass('open'); } else { $("#ResentSearchContainer").hide(); recentSearchesControl.removeClass('open'); } }); } var eTocAccountLink = $("ul.js-user-action-toolbar__dropdown>li>a[id='SubscribeToEToc']"); if (eTocAccountLink.length) { eTocAccountLink.parent().html($("#eTocTop>a")); } }); </script> <a class="logo-secondary black" href="https://www.aasld.org/" target="_blank"> <h3 class="logo-secondary-text">Secondary Logo</h3> </a> <a href="#" class="sticky-search"><i class="fa fa-search"></i></a> </div> <div class="header__layout-bottom wk-grid-page-container"> <a id="hypJournals" class="logo-main" href="https://journals.lww.com/hep/pages/default.aspx"> <h3 class="logo-main-text">Journal Logo </h3> </a> <div class="search-v2"> <div class="search-wrapper"> <select name="ctl00$ctl51$Header$SearchTopBoxControl$ddlContentScope" id="ctl00_ctl51_Header_SearchTopBoxControl_ddlContentScope"> <option value="All">All</option> <option selected="selected" value="Articles">Articles</option> <option value="Images">Images</option> <option value="Videos">Videos</option> <option value="Podcasts">Podcasts</option> <option value="Blogs">Blogs</option> </select> <div class="input-group" id="globalSearch"> <input name="ctl00$ctl51$Header$SearchTopBoxControl$txtKeywords" type="text" value="Search" id="ctl00_ctl51_Header_SearchTopBoxControl_txtKeywords" class="form-control searchText" /> <span class="input-group-btn"> <button id="ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearchMagnifier" type="submit" class="btn btn-default"><i class="fa fa-search"></i></button> </span> <input type="hidden" name="ctl00$ctl51$Header$SearchTopBoxControl$IsAutoCompleteEnabled" id="ctl00_ctl51_Header_SearchTopBoxControl_IsAutoCompleteEnabled" value="false" /> <input type="hidden" name="ctl00$ctl51$Header$SearchTopBoxControl$AutocompleteApiUrl" id="ctl00_ctl51_Header_SearchTopBoxControl_AutocompleteApiUrl" value="https://platformservices.wolterskluwerhealth.com/autocomplete/HEPA/shingle/" /> </div> </div> <div class="advance-search" style=""> <a id="ctl00_ctl51_Header_SearchTopBoxControl_lnkAdvanceSearch" href="https://journals.lww.com/hep/pages/advancedsearch.aspx">Advanced Search</a> <input type="submit" name="ctl00$ctl51$Header$SearchTopBoxControl$btnGlobalSearch" value="" id="ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearch" disabled="disabled" class="aspNetDisabled btnGlobalSearch" style="display: none;" /> <input name="ctl00$ctl51$Header$SearchTopBoxControl$hfldKeywords" type="hidden" id="ctl00_ctl51_Header_SearchTopBoxControl_hfldKeywords" class="hfldKeywords" value="disableButton" /> </div> </div> <script> $(function() { try { var objSearchBox = { btnGlobalSearchMagnifierId: 'ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearchMagnifier', searchButtonId: 'ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearch', txtKeywordsId: 'ctl00_ctl51_Header_SearchTopBoxControl_txtKeywords', hfldKeywordsHiddenId: 'ctl00_ctl51_Header_SearchTopBoxControl_hfldKeywords', defaultSearchText: 'Search' }; new Searchbox(objSearchBox).Init(); } catch (e) { console.error(e); } }); //autocomplete functionality for basic search //this functionality will call the SBA url and start suggesting after typing 3rd character var textKeywords = null; var hiddenAutocompleteApiUrl = null; var buttonGlobalSearch = null; $(function () { try { var objAutocomplete = { hiddenIsAutoCompleteEnabled: $('#ctl00_ctl51_Header_SearchTopBoxControl_IsAutoCompleteEnabled'), textKeywords: $('#ctl00_ctl51_Header_SearchTopBoxControl_txtKeywords'), hiddenAutocompleteApiUrl: $('#ctl00_ctl51_Header_SearchTopBoxControl_AutocompleteApiUrl'), buttonGlobalSearch: $('#ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearch'), enableNewAutoComplete: true, newAutoCompleteUrl: 'https://dxg-search-na-prd.wkgposvc.cloud/Query.svc/Query_Expand', newAutoCompleteMaxSuggestions: '10', newAutoCompleteDictionaryIds: 'ovid_sted28_mesh22' }; autoComplete(objAutocomplete); } catch (e) { console.error(e); } }); $(function () { let searchSelect = $('select[id$="ddlContentScope"]');; if (searchSelect.length){ searchSelect.selectize(); } }); </script> </div> <div id="main-nav-container-v2"> <nav id="main-nav" class="navbar navbar-default yamm wk-grid-page-container"> <div class="navbar-header"> <button id="fatJuicy" type="button" class="navbar-hamburger-button navbar-toggle collapsed pull-left" data-bs-toggle="collapse" data-bs-target="#zz1_TopNavigationMenu" aria-expanded="false" aria-controls="navbar"> <span class="visually-hidden">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="navbar-hamburger-button__text"></span> </button> </div> <div id="navActionButtons" class="btn-group navbar-hover-color" role="group" aria-label="..."> <a id="ctl00_ctl51_lnkSubscribe" class="btn btn-default navbar-button" href="https://shop.lww.com/p/0270-9139" target="_blank">Subscribe</a> <a id="ctl00_ctl51_lnkRegister" class="btn btn-default navbar-button" href="https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2015%2f09000%2fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx">Register</a> <button class="user-menu__link user-menu__link--login js-ejp-login-btn btn btn-default navbar-button" type="button" data-config="{"eventName":"login","eventDetail":{},"isNull":false}"> <span>Login</span> </button> </div> <div id="ctl00_ctl51_TopNavigationMenuConfiguration" style="display:none" class="js-top-navigation-menu-configuration" data-config="{"browsingHistory":{"isEnabled":true,"serviceUrl":"https://apim-hlrp-ejp-prod.azure-api.net/ee","pdfDownloadUrl":"/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=HistoryTab"}}"></div> <div id="zz1_TopNavigationMenu" class="navbar-collapse collapse js-top-navigation-menu noindex ms-core-listMenu-horizontalBox"> <ul id="zz2_RootAspMenu" class="root ms-core-listMenu-root static"> <li class="static selected"><a class="static selected menu-item ms-core-listMenu-item ms-displayInline ms-core-listMenu-selected ms-navedit-linkNode" href="/hep/pages/default.aspx" accesskey="1"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Home</span><span class="ms-hidden">Currently selected</span></span></a></li><li class="static dynamic-children"><span class="static dynamic-children menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode"><span aria-haspopup="true" class="additional-background ms-navedit-flyoutArrow dynamic-children"><span class="menu-item-text">Browse</span></span></span><ul aria-hidden="true" class="dynamic"> <li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/toc/publishahead"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Articles in Press</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/currenttoc.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Current Issue</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/issuelist.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">All Issues</span></span></a></li> </ul></li><li class="static dynamic-children"><a class="static dynamic-children menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/collections.aspx?Collection=Topical"><span aria-haspopup="true" class="additional-background ms-navedit-flyoutArrow dynamic-children"><span class="menu-item-text">Collections</span></span></a><ul aria-hidden="true" class="dynamic"> <li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/collectiondetails.aspx?TopicalCollectionId=5"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Review Articles</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/collectiondetails.aspx?TopicalCollectionId=6"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Graphical Abstracts</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/collectiondetails.aspx?TopicalCollectionId=9"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Top Cited Articles</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/collectiondetails.aspx?TopicalCollectionId=10"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Top Altmetric Articles</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://journals.lww.com/aasldpubs/pages/collections.aspx?Collection=Topical"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Multi-journal Article Collections</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/collectiondetails.aspx?TopicalCollectionId=11"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">The Future of Hepatology</span></span></a></li> </ul></li><li class="static dynamic-children"><span class="static dynamic-children menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode"><span aria-haspopup="true" class="additional-background ms-navedit-flyoutArrow dynamic-children"><span class="menu-item-text">About</span></span></span><ul aria-hidden="true" class="dynamic"> <li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/aboutthejournal.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">About the Journal</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/Pages/About-the-Association.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">About AASLD</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/pages/editorialboard.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Editorial Board</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://edmgr.ovid.com/hep/accounts/ifauth.htm"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Instructions for Authors</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/Pages/Advertising.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Advertising</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/Pages/Permissions.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Permissions</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Open Access</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/Pages/Reprints.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Reprints</span></span></a></li> </ul></li><li class="static dynamic-children"><span class="static dynamic-children menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode"><span aria-haspopup="true" class="additional-background ms-navedit-flyoutArrow dynamic-children"><span class="menu-item-text">For Authors</span></span></span><ul aria-hidden="true" class="dynamic"> <li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://edmgr.ovid.com/hep/accounts/ifauth.htm"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Instructions for Authors</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://preflight.paperpal.com/partner/lww/hepatol/submit"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Submit an Article</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="/hep/_layouts/1033/oaks.journals/editservices.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Language Editing Services</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fedmgr.ovid.com%2Fhep%2Faccounts%2FAASLD_Visual_Abstract_Template_Hepatology.pptx&wdOrigin=BROWSELINK"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Graphical Abstract Guidelines</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://journals.lww.com/aasldpubs/Pages/Author-Promotion-Toolkit.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Author Promotion Toolkit</span></span></a></li> </ul></li><li class="static dynamic-children"><span class="static dynamic-children menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode"><span aria-haspopup="true" class="additional-background ms-navedit-flyoutArrow dynamic-children"><span class="menu-item-text">Resources</span></span></span><ul aria-hidden="true" class="dynamic"> <li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://journals.lww.com/aasldpubs/Pages/Publish-with-Us.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Publish with Us</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://careercenter.aasld.org/"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">AASLD Career Center</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://journals.lww.com/aasldpubs/Documents/GISociety-JointStatement-Racism-FINAL.pdf"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Joint GI Society Statement on Racism</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://journals.lww.com/hep/Citation/9900/What_is_Hepatology_looking_for_version_2_0_.90.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">What is Hepatology looking for 2.0?</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://www.aasld.org/covid-19-and-liver"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">COVID-19 Resources</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://liverlearning.aasld.org/"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">LiverLearning</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://www.aasld.org/forums"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Liver Connect Forums</span></span></a></li><li class="dynamic"><a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://www.aasld.org/become-member"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Become a Member</span></span></a></li> </ul></li><li class="static"><a class="static menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://journals.lww.com/aasldpubs/Pages/AASLD-Practice-Guidelines-new.aspx"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">AASLD Guidelines</span></span></a></li><li class="static"><a class="static menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" href="https://preflight.paperpal.com/partner/lww/hepatol/submit"><span class="additional-background ms-navedit-flyoutArrow"><span class="menu-item-text">Submit an Article</span></span></a></li> </ul> </div> <div class="search-v2"> <div class="search-wrapper"> <select name="ctl00$ctl51$SearchBox$ddlContentScope" id="ctl00_ctl51_SearchBox_ddlContentScope"> <option value="All">All</option> <option selected="selected" value="Articles">Articles</option> <option value="Images">Images</option> <option value="Videos">Videos</option> <option value="Podcasts">Podcasts</option> <option value="Blogs">Blogs</option> </select> <div class="input-group" id="globalSearch"> <input name="ctl00$ctl51$SearchBox$txtKeywords" type="text" value="Search" id="ctl00_ctl51_SearchBox_txtKeywords" class="form-control searchText" /> <span class="input-group-btn"> <button id="ctl00_ctl51_SearchBox_btnGlobalSearchMagnifier" type="submit" class="btn btn-default"><i class="fa fa-search"></i></button> </span> <input type="hidden" name="ctl00$ctl51$SearchBox$IsAutoCompleteEnabled" id="ctl00_ctl51_SearchBox_IsAutoCompleteEnabled" value="false" /> <input type="hidden" name="ctl00$ctl51$SearchBox$AutocompleteApiUrl" id="ctl00_ctl51_SearchBox_AutocompleteApiUrl" value="https://platformservices.wolterskluwerhealth.com/autocomplete/HEPA/shingle/" /> </div> </div> <div class="advance-search" style=""> <a id="ctl00_ctl51_SearchBox_lnkAdvanceSearch" href="https://journals.lww.com/hep/pages/advancedsearch.aspx">Advanced Search</a> <input type="submit" name="ctl00$ctl51$SearchBox$btnGlobalSearch" value="" id="ctl00_ctl51_SearchBox_btnGlobalSearch" disabled="disabled" class="aspNetDisabled btnGlobalSearch" style="display: none;" /> <input name="ctl00$ctl51$SearchBox$hfldKeywords" type="hidden" id="ctl00_ctl51_SearchBox_hfldKeywords" class="hfldKeywords" value="disableButton" /> </div> </div> <script> $(function() { try { var objSearchBox = { btnGlobalSearchMagnifierId: 'ctl00_ctl51_SearchBox_btnGlobalSearchMagnifier', searchButtonId: 'ctl00_ctl51_SearchBox_btnGlobalSearch', txtKeywordsId: 'ctl00_ctl51_SearchBox_txtKeywords', hfldKeywordsHiddenId: 'ctl00_ctl51_SearchBox_hfldKeywords', defaultSearchText: 'Search' }; new Searchbox(objSearchBox).Init(); } catch (e) { console.error(e); } }); //autocomplete functionality for basic search //this functionality will call the SBA url and start suggesting after typing 3rd character var textKeywords = null; var hiddenAutocompleteApiUrl = null; var buttonGlobalSearch = null; $(function () { try { var objAutocomplete = { hiddenIsAutoCompleteEnabled: $('#ctl00_ctl51_SearchBox_IsAutoCompleteEnabled'), textKeywords: $('#ctl00_ctl51_SearchBox_txtKeywords'), hiddenAutocompleteApiUrl: $('#ctl00_ctl51_SearchBox_AutocompleteApiUrl'), buttonGlobalSearch: $('#ctl00_ctl51_SearchBox_btnGlobalSearch'), enableNewAutoComplete: true, newAutoCompleteUrl: 'https://dxg-search-na-prd.wkgposvc.cloud/Query.svc/Query_Expand', newAutoCompleteMaxSuggestions: '10', newAutoCompleteDictionaryIds: 'ovid_sted28_mesh22' }; autoComplete(objAutocomplete); } catch (e) { console.error(e); } }); $(function () { let searchSelect = $('select[id$="ddlContentScope"]');; if (searchSelect.length){ searchSelect.selectize(); } }); </script> </nav> </div> </div> </header>     <div id="main-container-content" class="wk-grid-page-container"> <div id="DeltaWebPartAdderUpdatePanelContainer" class="ms-core-webpartadder"> <div id="WebPartAdderUpdatePanelContainer"> <div id="ctl00_WebPartAdderUpdatePanel"> <span id="ctl00_WebPartAdder"></span> </div> </div> </div> <div id="notificationArea" class="ms-notif-box"></div> <div id="DeltaPageStatusBar"> <div id="pageStatusBar"></div> </div> <div id="DeltaPlaceHolderMain" class="delta-place-holder-main"> <a id="mainContent" name="mainContent" tabindex="-1"></a> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_responsivePageLayoutContainer" class="main-content ejp-page-container"> <div class="wk-grid-container-no-margin" id="AddRowTopContainer"> </div> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl00_ResponsiveLayoutRowContainer" class="wk-grid-container-no-margin"> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl00_ResponsiveLayoutRow" class="wk-grid"> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl00_ResponsiveLayoutColumnRepeater_ctl00_ResponsiveLayoutColumn" class=" wk-column-12 wk-column-12-m wk-column-12-l wk-column-12-xl wk-column-12-xxl"> <div class="ms-webpart-zone ms-fullWidth"> <div id="MSOZoneCell_WebPartctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="e49ed9af-7fd4-441c-b621-1aa76f20fffa" HasPers="false" id="WebPartctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa">  <div class="ejp-article-breadcrumb"> <div class="ejp-article-breadcrumb__left"> <a title href="/hep/toc/2015/09000" class="ejp-article-nav__list-link-back">September 2015 - Volume 62 - Issue 3 </a> </div> <div class="ejp-article-breadcrumb__right"> <nav id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa__ffe92852f65fa470_ArticleNavigator"> <ul class="ejp-article-nav__list"> <li id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa__ffe92852f65fa470_liArticleNavigatorPrev"> <a title href="/hep/fulltext/2015/09000/rejection_triggers_liver_transplant_tolerance_.28.aspx" onmouseover="javascript:Tooltip_Article('Rejection triggers liver transplant tolerance: Involvement of mesenchyme‐mediated immune control mechanisms in mice', 'Morita Miwa; Joyce, Daniel; Miller, Charles; Fung, John J.; Lu, Lina; Qian, Shiguang', 'Hepatology', 'September 2015', '62', '3' , 'p 915-931')" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-article-nav__list-link-prev"> <span>Previous</span> <span class="ejp-article-nav__list-link-mobile-hide">Article</span> </a> </li> <li id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa__ffe92852f65fa470_liArticleNavigatorNext"> <a title href="/hep/fulltext/2015/09000/liver_capsule__hepatic_encephalopathy.30.aspx" onmouseover="javascript:Tooltip_Article('Liver capsule: Hepatic encephalopathy', 'Bajaj Jasmohan S.', 'Hepatology', 'September 2015', '62', '3' , 'p 955')" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-article-nav__list-link-next"> <span>Next</span> <span class="ejp-article-nav__list-link-mobile-hide">Article</span> </a> </li> </ul> </nav> </div> </div> </div><div class="ms-clear"></div></div> </div> </div> </div></div> </div> </div> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutRowContainer" class="wk-grid-container-no-margin"> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutRow" class="wk-grid"> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutColumnRepeater_ctl00_ResponsiveLayoutColumn" class=" wk-column-12 wk-column-8-m wk-column-8-l wk-column-8-xl wk-column-8-xxl"> <div class="ms-webpart-zone ms-fullWidth"> <div id="MSOZoneCell_WebPartctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="66d092b4-9819-4479-a267-faf7b1636d3d" HasPers="false" id="WebPartctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d">  <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/article.min.js?v=05.24.00.023"> </script> <link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/1033/OAKS.Journals/MediaElement/mediaelementplayer.css?v=05.24.00.023" media="print" /> <span class="js-custom-event" data-config="{"name":"articleView","detail":{"articleDetails":{"journalName":"Hepatology","articleTopicName":"","articleName":"Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","publicationDate":"09/01/2015","accessionNumber":"01515467-201509000-00000","doi":"10.1002/hep.27950","authors":"AASLD/IDSA HCV Guidance Panel","societyName":"American Association for the Study of Liver Diseases","collectionName":"","abstractValues":"","sku":"0270-9139","format":"HTML","articleKeywords":"","articleMetadata":"","systemIndicators":["Free"],"meshTerms":["Hepatitis C","Hepacivirus","Infections","Hepatovirus","Communicable Diseases","HIV","HIV Infections","Americas","Glomerular Filtration Rate","Alanine Transaminase"],"pageSource":"ArticleViewer"},"articleDisplayType":"Fulltext"},"order":2147483647,"config":{"bubbles":true,"cancelable":true,"composed":false}}"></span><span class="js-custom-event" data-config="{"name":"omni:article:view","detail":{"viewType":"Fulltext","publisher":"LWW","journalTitle":"Hepatology","issueNumber":"09000","volumeNumber":"62","accessionNumber":"01515467-201509000-00029","doi":"10.1002/hep.27950","articleTitle":"Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","publicationDate":"09/01/2015","flags":"Free","keywords":"","tocSection":"Practice Guidance","firstPage":"932"},"order":2147483647,"config":{"bubbles":true,"cancelable":true,"composed":false}}"></span>  <link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/1033/styles/oaks.journals/print-article.css?v=05.24.00.023" media="print" /> <script type="text/javascript"> var articleContainer = document.getElementById('ArticleContainer'); function getElementReferences() { textDiv = articleContainer; // textDiv = document.getElementById('ArticleContainer'); } function getArticleContainer() { return articleContainer; } $(function () { // Change the '+', '-' icon when panels are collapsed. $('a.toggle-content').click(function () { var isExpanded = $(this).attr('aria-expanded'); var i = $(this).children('i'); if (isExpanded === 'true') { i.removeClass('fa fa-minus-square-o').addClass('fa fa-plus-square-o'); } else { i.removeClass('fa fa-plus-square-o').addClass('fa fa-minus-square-o'); } }); var articleAbstractLink = $('#article-abstract-content4>ul>li>a')[0]; if ($(articleAbstractLink).html() === 'Abstract') { $(articleAbstractLink).click($.proxy(clickAbstractLink, this)); } }); function LogArticleSubTabClickEventToCounterData(subTabType) { var dualAccessHelper = new DualAccess(); if (subTabType === "AISummary") { //handle it for other sub tab types dualAccessHelper.SendCounterDataRequestByAn(dualAccessHelper.EventTypes.Investigation, dualAccessHelper.ContentTypes.AISummary, '01515467-201509000-00029'); } else { dualAccessHelper.SendCounterDataRequestByAn(dualAccessHelper.EventTypes.Investigation, dualAccessHelper.ContentTypes.ArticleTab, '01515467-201509000-00029'); } }; function ArticleTabClickLogToCounterService() { var dualAccessHelper = new DualAccess(); dualAccessHelper.SendCounterDataRequestByAn(dualAccessHelper.EventTypes.Investigation, dualAccessHelper.ContentTypes.ArticleTab, '01515467-201509000-00029'); }; window.addEventListener("load", () => { HighlightSearchTerms(); }); document.addEventListener('DOMContentLoaded', function() { function dispatchCustomEvent(eventName, linkUrl) { document.dispatchEvent(new CustomEvent(eventName, { detail: { link_url: linkUrl } })); } var anchors = { 'omni:articleviewer:buy': document.getElementById('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_hypPurchase'), 'omni:articleviewer:subscribe': document.getElementById('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_hypSubscribe'), 'omni:articleviewer:permission': document.getElementById('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_hypliPatentOrCaregiver'), 'omni:articleviewer:society': document.getElementById('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_hypSociety') }; Object.keys(anchors).forEach(function(eventName) { var anchor = anchors[eventName]; if (anchor) { anchor.addEventListener('click', function(event) { dispatchCustomEvent(eventName, anchor.href); }); } }); }); </script> <script> function closeArticleViewerModalDialog() { $('#articleViewerDialog').hide(); return false; } </script> <div class="ejp-article-wrapper"> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_container" data-article-config="{"title":"ReadAloud: Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","doi":"10.1002/hep.27950"}" data-read-along="false" data-ppt-event-detail="" data-has-ce="false" data-is-social-sharing-enabled="false" data-ce-cme-redirect="false" data-ppt-visible="false" data-email-to-colleague-control-id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl" data-images-slideshow-visible="false" data-social-sharing-title="Hepatitis C guidance: AASLD‐IDSA recommendations for... : Hepatology" data-pdf-visible="true" class="js-ejp-article-tools lww-ejp-article-tools" data-ce-cme-url="" data-has-permissions="true" data-epub-enabled="true" data-article-accession-number="01515467-201509000-00029" data-epub-visible="true" data-image-gallery-url="/hep/pages/imagegallery.aspx?year=2015&issue=09000&article=00029" data-social-sharing-source="https://journals.lww.com/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx" data-favorites-event-detail="{"eventName":"AddToFavorites","eventDetail":{"items":["Article|hep:2015:09000:00029|10.1002/hep.27950|"],"an":"01515467-201509000-00029"},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":false,"promptLogin":true,"loginPromptText":"To save this item, login or register"},"isNull":false}" data-ce-cme-title="" data-is-fulltext="true" data-has-cme="false" data-pdf-enabled="true" data-images-gallery-visible="false" data-pdf-event-detail="{"eventName":"PDFDownloadInit","eventDetail":{"url":"https://journals.lww.com/hep/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=ArticleViewer&an=01515467-201509000-00029","gating":false},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}" data-epub-event-detail="{"eventName":"EPUBDownload","eventDetail":{"url":"https://journals.lww.com:443/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx?generateEpub=Article|hep:2015:09000:00029|10.1002/hep.27950|","gating":false},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}" data-pdf-url="https://journals.lww.com/hep/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=ArticleViewer&an=01515467-201509000-00029"> </div> <div style="display: none;"> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_epubContainer"> <a an="01515467-201509000-00029" rel="opener" title href="#epub-link" class="ej-art-as-epub">Article as EPUB</a> </div> <a href="/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx?Ppt=Article|hep:2015:09000:00029|10.1002/hep.27950|" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_lnkExportImagesToPPT_fileLink" rel="nofollow">Export All Images to PowerPoint File</a> <button class="user-menu__link user-menu__link--add-to-favorites js-ejp-login-btn addToMyFavoriteLink" type="button" data-config="{"eventName":"AddToFavorites","eventDetail":{"items":["Article|hep:2015:09000:00029|10.1002/hep.27950|"],"an":"01515467-201509000-00029"},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":false,"promptLogin":true,"loginPromptText":"To save this item, login or register"},"isNull":false}"> <span>Add to My Favorites</span> </button> </div> <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/EmailToColleague.js?v=05.24.00.023" defer="true"> </script> <a id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hypEmailToColleague" href="javascript:" style="display:none;"></a> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlEmailToColleague" class="wk-modal-table" style="display: none"> <div class="wk-modal-cell"> <div id="ej-box-modal-drop-shadow" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal email-to-colleague" tabindex="-1" role="dialog" style="position: static;"> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlMain" class="js-main-panel" onkeypress="javascript:return WebForm_FireDefaultButton(event, 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_btnSend')"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"> <strong> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblEmailToColleague">Email to Colleague</span></strong> </div> <button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "> <i class="fa fa-times"></i> </button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <div class="wk-field-header"> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_divErrorMessage" class="js-error-message-div ej-error-message-panel" style="display: none; color: red; font-style: italic"> <p class="ej-error-message-icon"> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblErrorMessage" class="js-error-message-label">Colleague's E-mail is Invalid</span> </p> </div> </div> </div> <div class="wk-field-item"> <div class="wk-field-header"> Your Name: </div> <div class="wk-field-body"> <input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$txtYourName" type="text" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_txtYourName" class="js-name" /> </div> </div> <div class="wk-field-item"> <div class="wk-field-header"> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblColleaguesEmail" class="js-collegaues-email-lbl">Colleague's Email:</span> </div> <div class="wk-field-body no-bottom-margin"> <input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$txtColleaguesEmail" type="text" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_txtColleaguesEmail" class="js-collegaues-email" /> </div> <div class="wk-field-header"><span class="ej-form-comments">Separate multiple e-mails with a (;).</span></div> </div> <div class="wk-field-item"> <div class="wk-field-header"> Message: </div> <div class="wk-field-body"> <textarea name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$txtMessage" rows="2" cols="20" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_txtMessage" class="js-message"> Thought you might appreciate this item(s) I saw in Hepatology.</textarea> </div> </div> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$btnSend" value="Send" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_btnSend" class="js-send-button primary-button grecaptcha-email-colleague-da79012557ff4431a7744e25a3c4eac4" /> <input type="button" value="Cancel" id="btnCancel" class="secondary-button js-close" /> </div> </div> <div class="wk-field-item wk-email-colleague-captcha-bar"> <div class="wk-field-body"> <div id="div-recaptcha-da79012557ff4431a7744e25a3c4eac4" class="div-recaptcha-container" data-uniqueclassidentifier="grecaptcha-email-colleague-da79012557ff4431a7744e25a3c4eac4" data-sitekey="6LeeoSAUAAAAACFv8yNuINPv8IWyXHJ6uN447qEK" data-callback="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_captchaCallBack" data-badge="inline" data-size="invisible" data-type="image" > </div> </div> </div> </div> </section> </div> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlSuccessMessage" class="js-success-message-panel" style="display: none;"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"></div> <button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <br /> <p> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblMessageSent">Your message has been successfully sent to your colleague.</span> </p> <br /> </div> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="button" value="Close Window" id="btnClose" class="primary-button js-close" /> </div> </div> </div> </section> </div> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlErrorMessage" class="js-error-message-panel" style="display: none;"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"></div> <button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button> </header> <div class="wk-modal-body"> <br /> <div class="wk-field-item"> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblInvalidEmail" style="color:Red;">Some error has occurred while processing your request. Please try after some time.</span> </div> <br /> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="button" value="Close Window" id="btnEClose" class="primary-button js-close" /> </div> </div> </div> </section> </div> </div> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$hiddenEmailToColleague" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenEmailToColleague" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$hiddenIsUser" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenIsUser" /> </div> </div> <script type="text/javascript"> window.emailToColleaguePopups = window.emailToColleaguePopups || []; var ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_captchaCallBack = function () { ejpAnalytics.track('emailColleaguereCAPTCHA'); ejpAnalytics.track('emailColleagueComplete'); __doPostBack('ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$btnSend','') }; var initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl = function () { window.emailToColleaguePopups['ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl'] = new EmailToColleagueComponent('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlEmailToColleague', 'div-recaptcha-da79012557ff4431a7744e25a3c4eac4', 'grecaptcha-email-colleague-da79012557ff4431a7744e25a3c4eac4', 'emailToColleaguePopupExtender__1604761164', 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenEmailToColleague', 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenIsUser', '01515467-201509000-00029' ); } Sys.WebForms.PageRequestManager.getInstance().add_pageLoaded(initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl); </script> <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/ExportToCitationManager.js?v=05.24.00.023" defer="true"> </script> <a id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hypExportToCitationManager" href="javascript:" style="display:none;"></a> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlExportTo" style="display: none"> <div id="ej-box-modal-drop-shadow"> <div id="ej-box-modal-style-1" tabindex="-1" role="dialog" class="wk-modal wk-modal-with-overlay wk-modal-small ejp-modal horizontally-centered" data-behaviorid="OpenExportToPopupExtender_1745200279"> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlMainExport"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"><strong>Export to</strong></div> <button onclick="return closeExportToModalPopUp();" aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close "><i class="fa fa-times"></i></button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <fieldset> <table id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes"> <tr> <td><input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_0" type="radio" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$radioBtnExportTypes" value="EndNote" checked="checked" /><label for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_0">End Note</label></td> </tr><tr> <td><input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_1" type="radio" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$radioBtnExportTypes" value="Procite" /><label for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_1">Procite</label></td> </tr><tr> <td><input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_2" type="radio" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$radioBtnExportTypes" value="ReferenceManager" /><label for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_2">Reference Manager</label></td> </tr> </table> </fieldset> <p> <label for="default"> <input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_checkBoxSaveMySelection" type="checkbox" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$checkBoxSaveMySelection" /><label for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_checkBoxSaveMySelection">Save my selection</label> </label> </p> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnOpenExportDialog" value="Export" onclick="return validateExportType();WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnOpenExportDialog", "", true, "", "", false, false))" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_btnOpenExportDialog" class="primary-button" /> <input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnCancelOpenExportDialog" value="Cancel" onclick="return closeExportToModalPopUp();WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnCancelOpenExportDialog", "", true, "", "", false, false))" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_btnCancelOpenExportDialog" class="secondary-button" /> <p id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pUnsubscribeButtons"> </p> </div> </div> </div> </div> </section> </div> </div> </div> <div id="ej-clear-float"></div> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$hiddenExportType" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hiddenExportType" /> </div> <script type="text/javascript"> var hiddenExportType = $get('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hiddenExportType'); function getExportPopup() { return $find('OpenExportToPopupExtender_1745200279'); } var pnlMainExport = $get('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlMainExport'); document.addEventListener('DOMContentLoaded', function () { function dispatchCustomEvent(eventName) { try { document.dispatchEvent(new CustomEvent(eventName)); } catch (error) { console.error('Error dispatching custom event:', error); } } try { var exportButton = document.getElementById('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_btnOpenExportDialog'); var radioButtons = document.querySelectorAll('#ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes input[type=radio]'); exportButton.addEventListener('click', function (event) { var selectedRadioButton = Array.from(radioButtons).find(rb => rb.checked); if (selectedRadioButton) { var selectedValue = selectedRadioButton.value; var eventName = ''; switch (selectedValue) { case "Procite": case "ReferenceManager": eventName = 'omni:articletools:cite:ris'; break; case 'EndNote': eventName = 'omni:articletools:cite:endnote'; break; default: eventName = ''; } if (eventName) { dispatchCustomEvent(eventName); } else { console.warn('No event name matched for the selected radio button value:', selectedValue); } } else { console.warn('No radio button selected'); } }); } catch (error) { console.error('Error initializing event listeners:', error); } }); </script> <script type="text/javascript"> $(document).ready(function () { $('p').filter(function () { return this.innerHTML.trim() === "" }).remove(); }); function showPrinterFriendlyView() { open("https://journals.lww.com/hep/pages/printerfriendly.aspx?year=2015&issue=09000&article=00029&type=Fulltext", ""); } function showExportToCitationPopUp() { return "OpenExportToPopupExtender_1745200279"; } function getPermissionsClick() { showRightsLinkPopUp( 'https://s100.copyright.com/AppDispatchServlet', 'WoltersKluwer', 'HEP', 'Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus', '08042015', ' ', '62', '3', '\u00A9 2015 by the American Association for the Study of Liver Diseases', '01515467-201509000-00029', '', true, ''); } </script> <div id="ArticleContainer"> <article id="ej-article-view" class="js-article-view ej-article-view" xmlns:ssr="http://ssr-eus-go-csi.cloudapp.net/v1/assets" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xhtml="http://www.w3.org/1999/xhtml"><section class="ejp-r-article-subsection"><div class="ejp-r-article-subsection__text">Practice Guidance</div></section><header class="ejp-article-header"><h1 class="ejp-article-title">Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus</h1></header><section id="ejp-article-authors"><p id="P7"> AASLD/IDSA HCV Guidance Panel</p><section><a href="#" id="ejp-article-authors-link"> Author Information <i class="wk-icon-arrow-down-r"></i></a></section></section><section id="ejp-article-authors-info" class="ejp-article-authors-info ejp-article-authors-info--hidden"><div class="ejp-article-authors-info-holder"> <p id="correspondenceTo">Address reprint request to: Gary L. Davis, M.D., 201 S Ocean Grande Dr., PH4, Ponte Vedra Beach, FL 32082. E‐mail: <span><a href="/cdn-cgi/l/email-protection#f499959d98809bce9095829d879398b487969793989b969598da9a9180" onclick="javascript:window.open('mailto:mailto:davisgl@sbcglobal.net');return false"><span class="__cf_email__" data-cfemail="3a5e5b4c53495d567a4958595d5655585b5614545f4e">[email protected]</span></a></span>; tel: +1‐214‐783‐2563 or to Raymond T Chung, M.D., Liver Center, GI Division, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114. E-mail: <span><a href="/cdn-cgi/l/email-protection#9cf1fdf5f0e8f3a6eee8fff4e9f2fbdcecfdeee8f2f9eeefb2f3eefb" onclick="javascript:window.open('mailto:mailto:rtchung@partners.org');return false"><span class="__cf_email__" data-cfemail="5b292f38332e353c1b2b3a292f353e29287534293c">[email protected]</span></a></span>.</p> <p id="hep27950-note-0004"><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">†</sup>The names and affiliations of all authors are listed at the end of the article.</p> </div></section><section id="article-journal-info"><div class="ej-journal-info"><span class="ej-journal-name">Hepatology </span><span id="ej-journal-date-volume-issue-pg"><a href="/hep/toc/2015/09000">62(3):p 932-954, September 2015.</a></span><span> | </span><span class="ej-journal-doi">DOI: </span>10.1002/hep.27950</div></section><section id="ejp-article-indicators" class="ejp-article-indicators"><ul class="ejp-article-indicators__list"> <li id="ej-article-indicators-free" class="ejp-article-indicators__list-item" onmouseover="javascript:Tooltip_Free()" onmouseout="javascript:Tooltip_MouseOut()"><span class="ejp-indicator">Free</span></li> </ul><button id="openArticleMetricsPopupButton" type="button" class="wk-button wk-button-ghost wk-button-icon-left ejp-article-metrics-btn" data-articleMetricsEndpoint="//services.journals.lww.com/IntegrationServices/ArticleMetricsService.svc" data-articleMetricsDetailsUrl="https://wolterskluwer.altmetric.com/details/" data-doi="10.1002/hep.27950" data-suiteId="vrs_woltere_journalsglobalvrs" data-articlePublicationDate="2015-08-04" data-articlePublicationDateString="August 04, 2015" data-receivedDate="2015-06-03" data-revisionReceivedDate="" data-acceptedDate="2015-06-03" data-crossrefRefLinkRoot="https://doi.org/" data-medlineRefLinkRoot="http://www.ncbi.nlm.nih.gov/pubmed/" data-pubMedId="26111063"><i class="wk-icon-filled-chart-r"></i><i class="wk-icon-filled-chart-white-r"></i> Metrics </button></section><div class="ejp-fulltext-content js-ejp-fulltext-content"><section id="ArticleBody"><p id="hep27950-note-1001">Potential conflict of interest: Listed at the end of the article for all authors.</p> <p id="hep27950-note-0001">These recommendations have been approved by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.</p> <p id="hep27950-note-0002">Potential conflict of interest: Listed at the end of the article for all authors.</p> <p id="hep27950-note-0003">All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit <span><a href="http://www.aasld.org" onclick="javascript:window.open('http://www.aasld.org');return false">www.aasld.org</a></span> for an update in the material.</p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0001">Preamble</h2> <p id="JCL-P-24">The pace of hepatitis C virus (HCV) drug development in recent years has accelerated dramatically. For patients to benefit from these impressive advances, practitioners need access to the most up‐to‐date data and to advice from experienced experts. Such information and advice can be difficult to access readily given the diverse sources from which information is available and the sometimes lengthy time needed for publication of original articles and scholarly perspectives. Traditional practice guidelines for more established areas of medicine and care often take years to develop and bring to publication. In the new era in hepatitis C treatment, such a process would not be nimble or timely enough to address the needs of patients with HCV infection, practitioners caring for these patients, or payers approving therapies for use. A living document made available in a web‐based system, such as that used by the US Department of Health and Human Services for human immunodeficiency virus (HIV) treatment recommendations (<span><a href="http://aidsinfo.nih.gov/guidelines" onclick="javascript:window.open('http://aidsinfo.nih.gov/guidelines');return false">http://aidsinfo.nih.gov/guidelines</a></span>), was selected as the best model to provide timely recommendations for hepatitis C management. In 2013, the two major membership societies supporting liver and infectious disease specialists (American Association for the Study of Liver Diseases [AASLD] and Infectious Diseases Society of America [IDSA]) joined forces to develop guidance for the management of hepatitis C in this rapidly moving field. The International Antiviral Society‐USA, which has experience in developing treatment guidelines in HIV disease, was invited to join the effort as a collaborating partner responsible for managing the panel and the guidance development process.</p> <p id="JCL-P-25">The goal of the hepatitis C guidance is to provide up‐to‐date recommendations for HCV care practitioners on the optimal screening, management, and treatment for adults with HCV infection in the United States, using a rigorous review process to evaluate the best available evidence. This review provides a condensed summary of recommendations from the guidance. The complete guidance, which is updated regularly, is available at <span><a href="http://www.hcvguidelines.org" onclick="javascript:window.open('http://www.hcvguidelines.org');return false">www.hcvguidelines.org</a></span>.</p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0002">Process</h2> <p id="JCL-P-26">This was conceived to be a living document that would reside online and undergo real‐time revisions as the field evolved. To lead the process, two cochairs selected by the governing boards of each founding society were joined by a fifth cochair representing the International Antiviral Society‐USA. These cochairs selected 10 panel members from each society. The panel members were chosen to represent expertise in the diagnosis, management, treatment, research, and patient care from the fields of hepatology and infectious diseases. At least 51% of the panelists could have no substantive industry support other than research advisory boards, data safety monitoring boards, or research funding that went to the member's employer.</p> <p id="JCL-P-27">The panel first convened in person in October 2013. Panel members were divided into teams to review available data and to propose preliminary guidance in three areas: (1) testing and linkage to care, (2) initial treatment of HCV infection, and (3) retreatment of patients in whom prior HCV treatment had failed. The treatment section teams also reviewed data for special considerations in patients with hepatitis C, including those with HCV/HIV coinfection, with decompensated cirrhosis, and who had undergone liver transplantation. The teams and cochairs met regularly by conference call. All panel members reviewed and approved the final recommendations. Each society's governing board peer‐reviewed the final recommendations. The first version of the guidance was uploaded (<span><a href="http://www.hcvguidelines.org" onclick="javascript:window.open('http://www.hcvguidelines.org');return false">www.hcvguidelines.org</a></span>) on January 29, 2014. By September 2014, three additional sections were developed: (1) treatment of acute HCV infection, (2) monitoring during and after therapy, and (3) when and whom to treat. In October 2014, the panel reconvened in person to update recommendations to consider data on pending new treatments. The updated recommendations (and appropriate revisions of all current guidance) were uploaded on December 20, 2014. This report was prepared on May 20, 2015.</p> <p id="JCL-P-28">Funding for the guidance itself was provided by the AASLD and the IDSA. No industry funding was solicited or accepted. The Centers for Disease Control and Prevention (CDC) provided separate funding for identifying and reviewing data pertaining to testing and linkage to care.</p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0003">Collecting, Evaluating, and Rating the Evidence</h2> <p id="JCL-P-29">The panel, comprising experts in the fields of hepatology and infectious diseases, used an evidence‐based approach to review available information for the guidance. Information sources considered were research published in peer‐reviewed journals or presented at major national or international research conferences; safety warnings from the US Food and Drug Administration (FDA), other regulatory agencies, or the manufacturer; drug interaction data; prescribing information from FDA‐approved products; and registration data for new products under FDA review. An initial search of the literature yielded 3939 unique citations on November 4, 2013. To be considered, articles needed to be published in English from 2010 to the present. Review studies, studies using mice or rats, and in vitro studies were excluded. Panel members monitor the literature and other sources regularly and update the guidance as new evidence warrants.</p> <p id="JCL-P-30">Each recommendation is rated in terms of the level of evidence (depicted by Roman numeral I, II, or III) and the strength of the recommendation (depicted by letter A, B, or C) using a scale (Table <a href="#hep27950-tbl-0001">1</a>) adapted from the American College of Cardiology and the American Heart Association Practice Guidelines.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0001 hep27950-bib-0002">1</a></sup></p> <div class="wk-clearfix-article-table"></div> <div class="article-table"><a id="hep27950-tbl-0001"></a><div class="article-table-title"><span>Table 1 - </span> Rating by Classification and Level of Evidence<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div> </div> <div class="scroll-message"></div> <div class="dummy-scroll"> <div></div> </div> <div class="article-table-body"> <div class="article-table-container"> <table> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <thead valign="bottom" xmlns="http://www.w3.org/1999/xhtml"> <tr style="border-bottom:solid 1px #000000"> <th align="left" valign="bottom" rowspan="1" colspan="1"> <b>Classification</b> </th> <th align="center" valign="bottom" rowspan="1" colspan="1"> <b>Description</b> </th> </tr> </thead> <tbody valign="top" xmlns="http://www.w3.org/1999/xhtml"> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Class I</td> <td align="left" valign="top" rowspan="1" colspan="1">Conditions for which there is evidence and/or general agreement that a given diagnostic evaluation, procedure, or treatment is beneficial, useful, and effective</td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Class II</td> <td align="left" valign="top" rowspan="1" colspan="1">Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness and efficacy of a diagnostic evaluation, procedure, or treatment</td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Class IIa</td> <td align="left" valign="top" rowspan="1" colspan="1">Weight of evidence and/or opinion is in favor of usefulness and efficacy</td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Class IIb</td> <td align="left" valign="top" rowspan="1" colspan="1">Usefulness and efficacy are less established by evidence and/or opinion</td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Class III</td> <td align="left" valign="top" rowspan="1" colspan="1">Conditions for which there is evidence and/or general agreement that a diagnostic evaluation, procedure, or treatment is not useful and effective or if it in some cases may be harmful</td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1"> <b>Level of Evidence</b> </td> <td align="left" valign="top" rowspan="1" colspan="1"> <b>Description</b> </td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Level A<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-note-0005">a</a></sup></td> <td align="left" valign="top" rowspan="1" colspan="1">Data derived from multiple randomized clinical trials, meta‐analyses, or equivalent</td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Level B<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-note-0005">a</a></sup></td> <td align="left" valign="top" rowspan="1" colspan="1">Data derived from a single randomized trial, nonrandomized studies, or equivalent</td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1">Level C</td> <td align="left" valign="top" rowspan="1" colspan="1">Consensus opinion of experts, case studies, or standard of care</td> </tr> </tbody> </table> <div class="article-table-descriptions"> <div class="article-table-descriptions-content"><span id="hep27950-note-0005"><div class="dib"><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">a</sup>In some situations, such as for PEG‐IFN–sparing HCV treatments, randomized clinical trials with an existing standard‐of‐care arm cannot ethically or practicably be conducted. The FDA has suggested alternative study designs, including historical controls or immediate versus deferred, placebo‐controlled trials. For additional examples and definitions see <span><a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf" onclick="javascript:window.open('http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf');return false">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf</a></span>. In those instances for which there was a single predetermined, FDA‐approved equivalency established, panel members considered the evidence as equivalent to a randomized controlled trial for levels A and B.</div></span><span id="hep27950-note-0006"><div class="dib">Adapted from the American College of Cardiology and the American Heart Association Practice Guidelines.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0001 hep27950-bib-0002">1</a></sup></div></span></div> </div> </div> </div> </div><br><h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0004">HCV Testing and Linkage to Care</h2> <p id="JCL-P-31">Of the estimated 2.2 million to 3.2 million persons<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0003">3</a></sup> chronically infected with HCV in the United States, half are unaware that they are infected.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0004">4</a></sup> Identification of those with active infection is the first step toward improving health outcomes and preventing transmission.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0005 hep27950-bib-0006 hep27950-bib-0007">5</a></sup> Accordingly, HCV testing is recommended in select populations based on demography, prior exposures, risk behaviors, and medical conditions (Table <a href="#hep27950-tbl-0002">2</a>). In 2012, the CDC expanded its risk‐based HCV testing guidelines originally issued in 1998<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">7</sup> with a recommendation to offer a one‐time HCV test to all persons born from 1945 through 1965, regardless of whether HCV risk factors have been identified. This recommendation was supported by the failure of the risk‐based screening strategy to identify more than 50% of HCV infections. Furthermore, persons in the 1945 to 1965 birth cohort accounted for nearly three‐fourths of all HCV infections, with a five times higher prevalence (3.25%) than other cohorts. A retrospective review showed that 68% of persons with HCV infection would have been identified through a birth cohort testing strategy, whereas only 27% would have been screened with the risk‐based approach.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0008">8</a></sup> The cost‐effectiveness of one‐time birth cohort testing is comparable to that of current risk‐based screening strategies.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0005">5</a></sup></p> <div class="wk-clearfix-article-table"></div> <div class="article-table"><a id="hep27950-tbl-0002"></a><div class="article-table-title"><span>Table 2 - </span> Summary of Recommendations for Screening for HCV Infection<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div> </div> <div class="scroll-message"></div> <div class="dummy-scroll"> <div></div> </div> <div class="article-table-body"> <div class="article-table-container"> <table> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <tbody valign="top" xmlns="http://www.w3.org/1999/xhtml"> <tr> <td align="left" valign="top" rowspan="1" colspan="1"> <ol style="list-style-type: none"> <li> <p>1. <i>Birth</i> c<i>ohort</i> </p> </li> <li> <p>• Persons born between the years of 1945 and 1965</p> </li> <li> <p>2 <i>Risk behaviors</i> </p> <ol style="list-style-type: none"> <li> <p>• Injection‐drug use (current or ever, including those who injected once)</p> </li> <li> <p>• Intranasal illicit drug use</p> </li> </ol> </li> <li> <p>3. <i>Risk exposures</i> </p> <ol style="list-style-type: none"> <li> <p>• Long‐term hemodialysis (ever)</p> </li> <li> <p>• Getting a tattoo in an unregulated setting</p> </li> <li> <p>• Health care, emergency medical, and public safety workers after needlesticks, sharps, or mucosal exposures to HCV‐infected blood</p> </li> <li> <p>• Children born to HCV‐infected women</p> </li> <li> <p>• Prior recipients of transfusions or organ transplants, including persons who</p> <ol style="list-style-type: none"> <li> <p>— were notified that they received blood from a donor who later tested positive for HCV infection</p> </li> <li> <p>— received a transfusion of blood or blood components or underwent an organ transplant before July 1992</p> </li> <li> <p>— received clotting factor concentrates produced before 1987</p> </li> </ol> </li> <li> <p>— were ever incarcerated</p> </li> </ol> </li> <li> <p>4. <i>Other</i> </p> <ol style="list-style-type: none"> <li> <p>• HIV infection</p> </li> <li> <p>• Unexplained chronic liver disease and chronic hepatitis including elevated ALT levels</p> </li> <li> <p>• Solid organ donors (deceased and living)</p> </li> </ol> </li> </ol> </td> </tr> </tbody> </table> <div class="article-table-descriptions"></div> </div> </div> </div><br><h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0005">Recommendation</h3> <p id="JCL-P-32"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>1. Consistent with the CDC and the US Preventive Services Task Force, a one‐time HCV test is recommended in asymptomatic persons in the 1945‐1965 birth cohort and other persons based on exposures, behaviors, and conditions that increase risk for HCV infection. (I‐B)</strong></em></li> </ul> </p> <p id="JCL-P-34">Testing for HCV antibody (anti‐HCV) should be performed using FDA‐approved methods such as testing for anti‐HCV<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">9,</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0010">10</a></sup> with laboratory‐based assays or a point‐of‐care assay.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0011">11</a></sup> A positive anti‐HCV test result indicates current (active) HCV infection (acute or chronic), past infection that has resolved, or a false‐positive test result.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0012">12</a></sup> Therefore, FDA‐approved quantitative or qualitative nucleic acid testing with a detection level of 25 IU/mL or lower should be used to detect HCV RNA to confirm active HCV infection and guide clinical management. Testing for HCV RNA should also be performed in persons with a negative anti‐HCV test who are immunocompromised (e.g., persons receiving chronic hemodialysis)<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0013">13</a></sup> or who might have been exposed to HCV in the prior 6 months because these persons may be anti‐HCV‐negative. An HCV RNA test is also needed to detect reinfection in anti‐HCV‐positive persons after previous spontaneous or treatment‐related viral clearance. Further details for interpreting results of different antibody and nucleic acid testing can be found in the CDC testing algorithm at <span><a href="http://www.hcvguidelines.org" onclick="javascript:window.open('http://www.hcvguidelines.org');return false">www.hcvguidelines.org</a></span>.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0006">Recommendation</h3> <p id="JCL-P-35"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>2. All persons recommended for HCV testing should first be tested for anti‐HCV using an FDA‐approved test. Positive results should be confirmed by nucleic acid testing for HCV RNA. (I‐A)</strong></em></li> </ul> </p> <p id="JCL-P-37">Evidence regarding the optimal frequency of testing in persons at risk for ongoing exposure to HCV is lacking; therefore, clinicians should determine the periodicity of testing based on the risk of reinfection. Because of the high incidence of HCV infection among persons who inject drugs and among HIV‐infected men who have sex with men who have unprotected sex,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0014 hep27950-bib-0015 hep27950-bib-0016 hep27950-bib-0017 hep27950-bib-0018 hep27950-bib-0019">14</a></sup> at least annual HCV testing is recommended in these subgroups.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0007">Recommendation</h3> <p id="JCL-P-38"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>3. Annual HCV testing is recommended for persons who inject drugs and for HIV‐seropositive men who have unprotected sex with men. Periodic testing should be offered to other persons at ongoing risk of HCV exposure. (IIa‐C)</strong></em></li> </ul> </p> <p id="JCL-P-40">Persons infected with HCV should be educated about preventing further damage to their liver. Most important is prevention of the potential deleterious effect of alcohol, which may lead to more rapid progression of liver fibrosis and the development of hepatocellular carcinoma (HCC).<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0020 hep27950-bib-0021 hep27950-bib-0022 hep27950-bib-0023 hep27950-bib-0024 hep27950-bib-0025 hep27950-bib-0026">20</a></sup> Persons with HCV should be tested for HIV antibody and hepatitis B surface antigen as coinfection with hepatitis B virus or HIV has been associated with poorer prognosis of HCV,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0027 hep27950-bib-0028">27</a></sup> they share overlapping risk factors, and additional benefits accrue from their diagnosis and treatment<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0029 hep27950-bib-0030">29</a></sup> (<span><a href="http://www.aafp.org/afp/200/0315/p819.html" onclick="javascript:window.open('http://www.aafp.org/afp/200/0315/p819.html');return false">http://www.aafp.org/afp/200/0315/p819.html</a></span> and <span><a href="http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm" onclick="javascript:window.open('http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm');return false">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm</a></span>).</p> <p id="JCL-P-41">Patients with obesity and metabolic syndrome who have underlying insulin resistance are more prone to have nonalcoholic fatty liver disease, which may accelerate fibrosis progression in HCV‐infected persons.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0031 hep27950-bib-0032">31</a></sup> Therefore, HCV‐infected persons who are overweight or obese (defined by a body mass index of 25 kg/m<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">2</sup> or higher or 30 kg/m<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">2</sup> or higher, respectively) should be counseled regarding strategies to reduce weight and improve insulin resistance through diet, exercise, and medical therapies.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0033 hep27950-bib-0034">33</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0008">Recommendation</h3> <p id="JCL-P-42"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>4. Persons infected with HCV should be educated about their disease and how to prevent further damage to their liver. (IIa‐B)</strong></em></li> </ul> </p> <p id="JCL-P-44">Improvements in identification of current hepatitis C and advances in treatment will have limited impact on HCV‐related morbidity and mortality unless patients have access to appropriate medical care. In the United States, it is estimated that only 13%‐18% of persons with chronic HCV infection receive treatment.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0035">35</a></sup> Indeed, in many cases referral to practitioners who are able and willing to evaluate such patients and provide treatment is delayed or never occurs.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0036 hep27950-bib-0037 hep27950-bib-0038">36</a></sup> Thus, it is crucial that all patients with current hepatitis C and a positive HCV RNA test result be referred to and evaluated by a practitioner with expertise in the assessment of liver disease severity and HCV treatment. Further, those with advanced fibrosis or cirrhosis require specialized management, including consideration of liver transplantation as indicated.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0009">Recommendation</h3> <p id="JCL-P-45"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>5. Evaluation by a practitioner who is prepared to provide comprehensive management, including consideration of antiviral therapy, is recommended for all persons with current (active) HCV infection. (IIa‐C)</strong></em></li> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0010">When and in Whom to Initiate HCV Therapy</h2> <p id="JCL-P-47">Successful hepatitis C treatment is achievable in nearly all infected patients and is reflected by a sustained virological response (SVR), defined as the continued absence of detectable HCV RNA for 12 or more weeks after completion of therapy. SVR is a marker for virological cure of HCV infection and has been shown to be durable in large prospective studies in more than 99% of patients followed up for at least 5 years.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0039 hep27950-bib-0040">39</a></sup> Patients who are cured of their HCV infection experience numerous health benefits, including a decrease in liver inflammation, regression of fibrosis in most cases, and resolution of cirrhosis in half.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0041">41</a></sup> Among the latter group, portal hypertension, splenomegaly, and other clinical manifestations of advanced liver disease also improve. An SVR is associated with a more than 70% reduction in the risk of liver cancer (HCC) and a 90% reduction in the risk of liver‐related mortality and liver transplantation.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0042 hep27950-bib-0043 hep27950-bib-0044">42</a></sup></p> <p id="JCL-P-48">Cure of HCV infection may also reduce symptoms and mortality from severe extrahepatic manifestations, including cryoglobulinemic vasculitis, a condition affecting up to 15% of HCV‐infected individuals.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0045 hep27950-bib-0046">45</a></sup> Persons infected with HCV with non‐Hodgkin lymphoma and other lymphoproliferative disorders achieve complete or partial remission in up to 75% of cases following successful HCV treatment.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0047 hep27950-bib-0048 hep27950-bib-0049 hep27950-bib-0050 hep27950-bib-0051">47</a></sup> These reductions in disease severity contribute to dramatic reductions in all‐cause mortality.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0043 hep27950-bib-0052">43</a></sup> Lastly, patients achieving an SVR have substantially improved quality of life, including physical, emotional, and social health.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0053 hep27950-bib-0054">53</a></sup></p> <p id="JCL-P-49">Evidence clearly supports treatment for all HCV‐infected persons, except those with limited life expectancy (less than 12 months) due to non–liver‐related comorbid conditions. Although treatment is best administered early in the course of the disease before fibrosis progression and the development of complications, the most immediate benefits of treatment will be realized by populations at highest risk for liver‐related complications. Thus, where resources limit the ability to treat all infected patients immediately as recommended, it is most appropriate to treat first those at greatest risk of disease complications and those at risk for transmitting HCV or in whom treatment may reduce transmission risk. Where such limitations exist, prioritization of immediate treatment for those listed in Tables <a href="#hep27950-tbl-0003">3</a> and <a href="#hep27950-tbl-0004">4</a> is recommended, including patients with progressive liver disease (Metavir stage F3 or F4), transplant recipients, or those with severe extrahepatic manifestations.</p> <div class="wk-clearfix-article-table"></div> <div class="article-table"><a id="hep27950-tbl-0003"></a><div class="article-table-title"><span>Table 3 - </span> Settings of Liver‐Related Complications and Extrahepatic Disease in Which HCV Treatment Is Most Likely to Provide the Most Immediate and Impactful Benefits*<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div> </div> <div class="scroll-message"></div> <div class="dummy-scroll"> <div></div> </div> <div class="article-table-body"> <div class="article-table-container"> <table> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <tbody valign="top" xmlns="http://www.w3.org/1999/xhtml"> <tr> <td align="left" valign="top" rowspan="1" colspan="1"> <p> <b> <i>Highest priority for treatment owing to highest risk for severe complications</i> </b> </p> <p>• Advanced fibrosis (Metavir F3) or compensated cirrhosis (Metavir F4)</p> <p>Rating: Class I, Level A</p> <p>• Organ transplant recipients</p> <p>Rating: Class I, Level B</p> <p>• Type 2 or 3 cryoglobulinemia with end‐organ manifestations (e.g., vasculitis)</p> <p>Rating: Class I, Level B</p> <p>• Proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis</p> <p>Rating: Class IIa, Level B</p> <p> <b> <i>High priority for treatment owing to high risk for complications</i> </b> </p> <p>• Fibrosis (Metavir F2)</p> <p>Rating: Class I, Level B</p> <p>• HIV‐1 coinfection</p> <p>Rating: Class I, Level B</p> <p>• Hepatitis B virus coinfection</p> <p>Rating: Class IIa, Level C</p> <p>• Other coexistent liver disease (e.g., nonalcoholic steatohepatitis)</p> <p>Rating: Class IIa, Level C</p> <p>• Debilitating fatigue</p> <p>Rating: Class IIa, Level B</p> <p>• Type 2 Diabetes mellitus (insulin‐resistant)</p> <p>Rating: Class IIa, Level B</p> <p>• Porphyria cutanea tarda</p> <p>Rating: Class IIb, Level C</p> </td> </tr> <tr> <td align="left" valign="top" rowspan="1" colspan="1" /> </tr> </tbody> </table> <div class="article-table-descriptions"> <div class="article-table-descriptions-content"><span id="hep27950-note-0107"><div class="dib">Ratings refer to the strength and level of evidence with regard to benefits of treatment in these settings.</div></span></div> </div> </div> </div> </div><br><div class="wk-clearfix-article-table"></div> <div class="article-table"><a id="hep27950-tbl-0004"></a><div class="article-table-title"><span>Table 4 - </span> Persons With Risk of HCV Transmission<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-note-0007">a</a></sup> or in Whom Treatment May Reduce Transmission<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div> </div> <div class="scroll-message"></div> <div class="dummy-scroll"> <div></div> </div> <div class="article-table-body"> <div class="article-table-container"> <table> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <tbody valign="top" xmlns="http://www.w3.org/1999/xhtml"> <tr> <td align="left" valign="top" rowspan="1" colspan="1"> <p>• Men who have sex with men with high‐risk sexual practices</p> <p>• Active injection‐drug users</p> <p>• Incarcerated persons</p> <p>• Persons on long‐term hemodialysis</p> <p>• HCV‐infected women of childbearing potential wishing to get pregnant</p> <p>• Infected health care workers who perform exposure‐prone procedures</p> <p>Rating: Class IIa, Level C</p> </td> </tr> </tbody> </table> <div class="article-table-descriptions"> <div class="article-table-descriptions-content"><span id="hep27950-note-0007"><div class="dib"><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">a</sup>Patients at substantial risk of transmitting HCV should be counseled on ways to decrease transmission and minimize the risk of reinfection.</div></span></div> </div> </div> </div> </div><br><p id="JCL-P-50">Recent reports suggest that initiating therapy in patients with lower‐stage fibrosis may extend the benefits of an SVR. In a long‐term follow‐up study, 820 patients with Metavir stage F0 or F1 fibrosis confirmed by biopsy were followed for more than 20 years. The 15‐year survival rate was significantly better in those who experienced an SVR than in those whose treatment had failed or those who were untreated (93%, 82%, and 88%, respectively; <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> = 0.003) and argues for consideration of earlier initiation of treatment.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0055">55</a></sup> Several other modeling studies suggest greater mortality benefit if treatment is initiated at stages prior to F3.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0056 hep27950-bib-0057 hep27950-bib-0058">56</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0011">Recommendations</h3> <p id="JCL-P-51"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>6. Antiviral treatment is recommended for all patients with chronic HCV infection, except those with limited life expectancy due to nonhepatic causes. (I‐A)</strong></em></li> </ul> <ul id="-2" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>7. If resources limit the ability to treat all infected patients immediately as recommended, then it is most appropriate to treat those at greatest risk of disease complications before treating those with less advanced disease (see</strong></em><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"> Tables</em><a href="#hep27950-tbl-0003">3</a><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">and</em><a href="#hep27950-tbl-0004">4</a><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>for ratings)</em></strong><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">.</strong></li> </ul> </p> <p id="JCL-P-54">An accurate assessment of fibrosis is vital in assessing the urgency for treatment, in some instances the duration of treatment, and the need for more intensive clinical monitoring. The degree of hepatic fibrosis is one of the most robust prognostic factors used to predict disease progression and clinical outcomes.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0059">59</a></sup> In addition to being in more urgent need for antiviral therapy, individuals with severe fibrosis require screening for HCC and esophageal varices.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0060 hep27950-bib-0061">60</a></sup></p> <p id="JCL-P-55">There are several acceptable approaches to staging. Individuals with clinically apparent cirrhosis, such as those with endoscopic evidence of varices or imaging showing cirrhosis or portal hypertension, do not require additional staging. However, the majority of patients require testing to determine stage. Although liver biopsy is the diagnostic standard, sampling error and observer variability limit test performance, particularly when inadequate sampling occurs.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0062">62</a></sup> In addition, the test is invasive and minor complications are common, limiting patient and practitioner acceptance. Serious complications such as bleeding, although rare, are well recognized. Recently, noninvasive tests to stage the degree of fibrosis in patients with chronic HCV infection include models incorporating indirect serum biomarkers (routine tests such as aspartate transaminase, alanine transaminase [ALT], and platelet count), direct serum biomarkers (components of the extracellular matrix produced by activated hepatic stellate cells), and vibration‐controlled transient liver elastography.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0063 hep27950-bib-0064 hep27950-bib-0065 hep27950-bib-0066">63</a></sup> No single method is recognized to have high accuracy alone, and the results of each test must be interpreted carefully. The most efficient approach to fibrosis assessment is to combine direct biomarkers and vibration‐controlled transient liver elastography.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0067">67</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0013">Recommendation</h3> <p id="JCL-P-56"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>8. Use of noninvasive testing or liver biopsy is recommended in order to assess the degree of hepatic fibrosis and, hence, the urgency of immediate treatment. (I‐A)</strong></em></li> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0014">Initial Treatment of HCV Infection</h2> <p id="JCL-P-58">This section addresses treatment of patients with chronic hepatitis C who are naive to any type of therapy. Although regimens containing peginterferon (PEG‐IFN) and ribavirin (RBV) plus direct‐acting antiviral (DAA) drugs are approved by the FDA for many HCV genotypes, the initial regimen for patients who are treatment‐naive with HCV genotype 1 generally has been superseded by treatments incorporating regimens using only DAAs. Recommended treatments are viewed as equivalent, and the decision of which to use may involve consideration of drug interactions between the DAAs and concomitant medications (see <span><a href="http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection#drug-interactions" onclick="javascript:window.open('http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection#drug-interactions');return false">http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection#drug-interactions</a></span>). For example, the daily fixed‐dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) (hereafter ledipasvir/sofosbuvir) has a potential interaction with proton pump inhibitors. Similarly, the daily fixed‐dose combination of paritaprevir (150 mg), ritonavir (100 mg), and ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) (hereafter paritaprevir/ritonavir/ombitasvir plus dasabuvir [PrOD]) has a substantial interaction with the long‐acting inhaled beta‐adrenoceptor agonist salmeterol and other drugs that interface with the cytochrome P450 3A4 isoenzyme.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0015">Genotype 1a</h3> <p id="JCL-P-59">Patients with HCV genotype 1a tend to have higher relapse rates than patients with HCV genotype 1b with certain regimens. Genotype 1 HCV infection that cannot be subtyped should be treated as genotype 1a infection.</p> <p id="JCL-P-60">For HCV genotype 1a–infected, treatment‐naive patients, there are three regimens of comparable efficacy: ledipasvir/sofosbuvir,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0068 hep27950-bib-0069">68</a></sup> PrOD and weight‐based RBV,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0070 hep27950-bib-0071">70</a></sup> and sofosbuvir plus simeprevir.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0072">72</a></sup> For PrOD, the use of RBV and the length of therapy differ for those with compensated cirrhosis versus those who do not have cirrhosis. The standard weight‐based dosing of RBV is 1000 mg for individuals who weigh less than 75 kg to 1200 mg for those who weigh 75 kg or more. The known safety profiles of each of these recommended regimens are excellent. Across numerous phase 3 studies, fewer than 1% of patients without cirrhosis discontinued treatment early and adverse events were mild. Most adverse events occurred in RBV‐containing arms. Patients with cirrhosis and HCV genotype 1a who were harboring the nonstructural protein 3 (NS3) Q80K polymorphism had lower SVR rates after treatment with sofosbuvir and simeprevir than those who did not harbor the Q80K polymorphism;<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">73</sup> in these patients, one of the other recommended regimens for cirrhosis should be used.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0016">Recommendation</h3> <p id="JCL-P-61"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>9. Treatment options for treatment‐naive patients with HCV genotype 1a who are initiating therapy (regimens are listed in alphabetical order)</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) and weight‐based RBV for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis). (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight‐based RBV for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis) for patients with a negative test result for the Q80K variant using commercially available resistance assays. In patients with HCV genotype 1a and cirrhosis who have the Q80K variant, one of the other regimens for cirrhosis detailed above is recommended. (IIa‐B)</em></li> </ul> </ul> </p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0017">Genotype 1b</h3> <p id="JCL-P-66">For HCV genotype 1b–infected, treatment‐naive patients, there are three regimens of comparable efficacy: ledipasvir/sofosbuvir for 12 weeks, PrOD for 12 weeks<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0070 hep27950-bib-0071">70</a></sup> and sofosbuvir plus simeprevir with or without weight‐based RBV for 12 weeks (or 24 weeks for patients with cirrhosis).<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0072 hep27950-bib-0074 hep27950-bib-0075">72</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0018">Recommendation</h3> <p id="JCL-P-67"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>10. Treatment options for treatment‐naive patients with HCV genotype 1b who are initiating therapy (regimens are listed in alphabetical order)</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) for 12 weeks. (I-A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight‐based RBV for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis). (IIa‐B)</em></li> </ul> </ul> </p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0019">Genotype 2</h3> <p id="JCL-P-72">Sofosbuvir plus weight‐based RBV is the recommended therapy for treatment‐naive patients with HCV genotype 2 infection.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0075 hep27950-bib-0076 hep27950-bib-0077 hep27950-bib-0078">75</a></sup> Until more data are available, extending treatment to 16 weeks in HCV genotype 2–infected patients with cirrhosis is recommended.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0020">Recommendation</h3> <p id="JCL-P-73"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>11. Regimen for treatment‐naive patients with HCV genotype 2 infection</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV for 12 weeks. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Extending treatment to 16 weeks is recommended for patients with cirrhosis. (IIb‐C)</em></li> </ul> </ul> </p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0021">Genotype 3</h3> <p id="JCL-P-77">Genotype 3 is the most difficult genotype to treat with available DAAs. Sofosbuvir plus weight‐based RBV for 24 weeks is the recommended DAA‐only regimen in the United States.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0076 hep27950-bib-0079">76</a></sup> Based on recent data from a randomized trial demonstrating higher SVR rates than those seen with sofosbuvir and RBV for 24 weeks, the combination of sofosbuvir plus PEG‐IFN and RBV for 12 weeks is recommended for interferon (IFN)–eligible patients,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0080">80</a></sup> although the adverse effects and increased monitoring requirements of PEG‐IFN may make this a less attractive therapeutic option. Daclatasvir plus sofosbuvir for 12 weeks has been studied, but daclatasvir is not FDA‐approved.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0081">81</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0022">Recommendation</h3> <p id="JCL-P-78"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>12. Treatment for treatment‐naive patients with HCV genotype 3 infection</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV plus weekly PEG‐IFN for 12 weeks for IFN‐eligible patients. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV for 24 weeks for IFN‐ineligible patients. (I‐B)</em></li> </ul> </ul> </p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0023">Genotype 4</h3> <p id="JCL-P-82">For the treatment of therapy‐naive patients with HCV genotype 4, three therapeutic options are recommended: daily combination of paritaprevir/ritonavir/ombitasvir with weight‐based RBV,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0082">82</a></sup> ledipasvir/sofosbuvir,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0083 hep27950-bib-0084">83</a></sup> or sofosbuvir plus weight‐based RBV.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0085 hep27950-bib-0086 hep27950-bib-0087">85</a></sup> Given the demonstrated activity <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vitro</em> and <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em> of simeprevir against HCV genotype 4, simeprevir plus sofosbuvir may be considered; but supportive clinical data are limited.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0024">Recommendation</h3> <p id="JCL-P-83"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>13. Treatment options for treatment‐naive patients with HCV genotype 4 infection (listed in alphabetical order)</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks. (IIb‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) and weight‐based RBV for 12 weeks. (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV for 24 weeks. (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Alternatives</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV plus weekly PEG‐IFN for 12 weeks. (II‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight‐based RBV for 12 weeks. (IIb‐B)</em></li> </ul> </ul> </p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0025">Genotype 5 or 6</h3> <p id="JCL-P-91">Few data are available to help guide decision making for patients infected with HCV genotype 5 or 6. Nonetheless, based on emerging data, sofosbuvir plus ledipasvir is recommended.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0083">83</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">,</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0084">84</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">,</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0088">88</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0026">Recommendation</h3> <p id="JCL-P-92"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>14. Treatment for treatment‐naive patients with HCV genotype 5 or 6 infection</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks. (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Alternative</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV plus weekly PEG‐IFN for 12 weeks for patients who are IFN‐eligible. (IIa‐B)</em></li> </ul> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0027">Retreatment of Persons in Whom Prior Therapy Has Failed</h2> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0028">Prior Failure of PEG‐IFN and RBV Without a DAA</h3> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0029">Genotype 1a</h4> <p id="JCL-P-97">Three regimens are recommended in this setting: ledipasvir/sofosbuvir,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0089">89</a></sup> PrOD and RBV,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0079">79</a></sup> and simeprevir plus sofosbuvir.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0074 hep27950-bib-0075 hep27950-bib-0076 hep27950-bib-0090">74</a></sup> In patients with cirrhosis, treatment with ledipasvir/sofosbuvir for 24 weeks produced higher SVR rates than did 12 weeks of treatment, supporting the recommendation that HCV treatment–experienced patients with cirrhosis receive 24 weeks of treatment.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0089 hep27950-bib-0091">89</a></sup> However, ledipasvir/sofosbuvir with weight‐based RBV given for 12 weeks produced equivalent SVR rates to 24 weeks of ledipasvir/sofosbuvir in patients with cirrhosis in whom a prior course of PEG‐IFN and RBV plus telaprevir or boceprevir had failed. For patients with cirrhosis who are treated with PrOD and RBV, 24 weeks of therapy is recommended.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0071">71</a></sup> Similarly, patients with cirrhosis who are being treated with simeprevir plus sofosbuvir should receive 24 weeks of therapy.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0092 hep27950-bib-0093">92</a></sup></p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0030">Genotype 1b</h4> <p id="JCL-P-98">The recommended treatment options in this setting are ledipasvir/sofosbuvir,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0089">89</a></sup> PrOD,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0094">94</a></sup> or simeprevir plus sofosbuvir.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0074 hep27950-bib-0075 hep27950-bib-0076 hep27950-bib-0090">74</a></sup> For those with cirrhosis in whom a prior PEG‐IFN–based regimen has failed, the recommendations for treatment are the same as those for genotype 1a patients with cirrhosis, except the treatment duration of PrOD can be reduced to 12 weeks and RBV can be omitted.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0071">71</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0031">Recommendation</h3> <p id="JCL-P-99"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>15. Options for retreatment of patients with genotype 1 HCV in whom previous PEG‐IFN and RBV treatment had failed (regimens listed in alphabetical order)</em></strong>:</li> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">HCV Genotype 1a Infection Without Cirrhosis</strong></li> <ul id="-1-1-3" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dasabuvir (250 mg) and weight‐based RBV for 12 weeks. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) plus simeprevir (150 mg) for 12 weeks. (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">HCV Genotype 1b Infection Without Cirrhosis</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) for 12 weeks. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) plus simeprevir (150 mg) for 12 weeks. (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">HCV Genotype 1a or 1b Infection With Compensated Cirrhosis </strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks, regardless of subtype. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight‐based RBV for 12 weeks, regardless of subtype. (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) and weight‐based RBV for 24 weeks (HCV genotype 1a) or PrOD without RBV for 12 weeks (HCV genotype 1b). (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight‐based RBV for 24 weeks for patients with a negative test result for the Q80K variant using commercially available resistance assays and for HCV genotype 1b infection. In patients with HCV genotype 1a and cirrhosis who have the Q80K variant, one of the other regimens for cirrhosis detailed above is recommended. (IIa‐B)</em></li> </ul> </ul> </p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0032">Prior Failure of PEG‐IFN and RBV and a DAA</h3> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0033">Genotypes 1a and 1b</h4> <h5 class="ejp-article-outline-heading" data-level="4" id="hep27950-sec-0034">Prior Failure of Telaprevir‐ or Boceprevir‐Containing Regimens</h5> <p id="JCL-P-114">The recommended treatment for patients without cirrhosis with HCV genotype 1 in whom a prior regimen that contained telaprevir or boceprevir has failed is ledipasvir/sofosbuvir for 12 weeks.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0089">89</a></sup> For patients with cirrhosis, relapse rates were higher in the 12‐week than the 24‐week treatment group;<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">89</sup> thus, those patients with cirrhosis should have ledipasvir/sofosbuvir treatment duration extended to 24 weeks.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0089">89</a></sup> In a randomized retreatment study of patients with cirrhosis whose treatment with PEG‐IFN and RBV plus telaprevir or boceprevir failed,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0095">95</a></sup> SVR12 rates were identical between those receiving 12 weeks of ledipasvir/sofosbuvir and RBV and those receiving 24 weeks of ledipasvir/sofosbuvir. Thus, ledipasvir/sofosbuvir and RBV for 12 weeks is another recommended regimen for patients with cirrhosis in whom prior treatment with PEG‐IFN and RBV and telaprevir or boceprevir failed.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0095">95</a></sup></p> <p id="JCL-P-115">There are few data for PEG‐IFN, RBV, and simeprevir treatment failures. However, based on expected patterns of resistance, treatment with ledipasvir/sofosbuvir may be given to this group of patients as well. Treatment with sofosbuvir and simeprevir or PrOD should be avoided.</p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0035">Recommendation</h4> <p id="JCL-P-116"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>16. Options for retreatment of patients with genotype 1 HCV in whom a previous IFN‐based and protease inhibitor–containing regimen had failed (regimens listed in alphabetical order in each subgroup)</strong></em>:</li> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Patients Without Cirrhosis</strong></li> <ul id="-1-1-3" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks, regardless of subtype. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Patients With Cirrhosis (Any Subtype)</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks, regardless of subtype. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight‐based RBV for 12 weeks, regardless of subtype. (IIa‐B)</em></li> </ul> </ul> </p> <h5 class="ejp-article-outline-heading" data-level="4" id="hep27950-sec-0036">Prior Failure of Sofosbuvir‐Containing Regimens</h5> <p id="JCL-P-123">Treatment failure with sofosbuvir‐containing regimens appears to be more common in persons infected with HCV genotype 1a than with 1b and more common in those with cirrhosis than in those without cirrhosis. Treatment failure of simeprevir plus sofosbuvir is associated with resistance to simeprevir and other HCV NS3/4A protease inhibitors such as paritaprevir. Conversely, sofosbuvir resistance‐associated variants (RAVs) are uncommon.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0074 hep27950-bib-0075 hep27950-bib-0076 hep27950-bib-0090">74</a></sup> Some data exist for retreatment after a sofosbuvir‐containing treatment failure with a regimen of sofosbuvir plus other drugs. Treatment with ledipasvir/sofosbuvir plus weight‐based RBV is recommended for either prior sofosbuvir and RBV failures<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0096 hep27950-bib-0097">96</a></sup> or prior sofosbuvir plus PEG‐IFN and RBV failures.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0097">97</a></sup> Owing to the paucity of data in this setting, referral to a clinical trial may be appropriate for some patients. For patients with minimal liver disease, consideration should be given to deferral of retreatment until more information is available. In patients who have cirrhosis and require retreatment more urgently, treatment with ledipasvir/sofosbuvir with RBV for 24 weeks is recommended until more data are available.</p> <p id="JCL-P-124">In the absence of data, for patients in whom prior treatment with simeprevir plus sofosbuvir failed, strong consideration should be given to enrollment in a clinical trial. For patients with minimal liver disease, consideration should be given to deferral of retreatment pending the availability of data. In patients who require retreatment more urgently, based on emerging data and the expected pattern of HCV drug resistance, ledipasvir/sofosbuvir with or without RBV is recommended.</p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0037">Recommendation</h4> <p id="JCL-P-125"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>17. Options for retreatment of patients with genotype 1 HCV who failed a previous sofosbuvir‐containing regimen (regimens listed in alphabetical order in each subgroup)</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Based on the limited data available for effective therapy, it is recommended that patients without an urgent need for HCV treatment, regardless of subtype, should defer antiviral therapy until additional data are available or consider enrollment in a clinical trial. (IIb‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Patients with cirrhosis who have an urgent need for treatment should receive a daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with weight‐based RBV for 24 weeks, regardless of subtype. (IIa‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Patients without cirrhosis who have an urgent need for treatment should receive a daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with weight‐based RBV for 12 weeks, regardless of subtype. (IIa‐C)</em></li> </ul> </ul> </p> <h5 class="ejp-article-outline-heading" data-level="4" id="hep27950-sec-0038">Prior Failure of NS5A Regimen (Including Ledipasvir/Sofosbuvir and PrOD)</h5> <p id="JCL-P-130">There are limited data to guide retreatment of patients whose treatment with NS5A inhibitor–containing regimens has failed. Retreatment of those whose prior treatment with sofosbuvir/ledipasvir failed with sofosbuvir/ledipasvir for 24 weeks resulted in a high frequency of failure, which was predicted by the presence of NS5A RAVs.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0073">73</a></sup> Thus, those patients with minimal liver disease should defer therapy pending further data. Those who have cirrhosis or who require urgent retreatment should undergo RAV testing.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0039">Recommendation</h3> <p id="JCL-P-131"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>18. Options for retreatment of patients with HCV genotype 1 whose previous NS5A inhibitor–containing regimen failed</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients without an urgent need for treatment, deferral of retreatment is recommended pending the availability of additional data. (III‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients with cirrhosis or an urgent need for retreatment, testing RAVs which confer decreased susceptibility to NS3 protease inhibitors (e.g., Q80K) and to NS5A inhibitors should be performed using commercially available assays. (IIb‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients with no NS5A RAVs detected, retreatment with a daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with RBV for 24 weeks is recommended. (IIb‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients who have NS5A RAVs detected but do not have NS3 RAVs detected, treatment with sofosbuvir (400 mg) and simeprevir (150 mg) with RBV for 24 weeks is recommended. (IIb‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients who have both NS3 and NS5A RAVs detected, referral to a clinical trial is recommended. (IIb‐C)</em></li> </ul> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0040">Genotype 2</h4> <p id="JCL-P-138">Individuals with genotype 2 HCV infection who have failed a prior course of IFN‐based therapy should receive sofosbuvir plus weight‐based RBV for 12 weeks.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0078 hep27950-bib-0090">78</a></sup> Extending treatment from 12 weeks to 16 weeks in HCV genotype 2–infected patients with cirrhosis is recommended. Recent data also suggest that sofosbuvir plus PEG‐IFN and RBV for 12 weeks produces high rates of SVR compared with sofosbuvir plus RBV for 24 weeks and is an alternative for patients who are IFN‐eligible.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0080">80</a></sup></p> <p id="JCL-P-139">Currently, no data are available to support a recommendation for patients who have failed previous treatment with a sofosbuvir‐containing regimen. Consideration should be given to deferral of retreatment until more information is available.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0041">Recommendation</h3> <p id="JCL-P-140"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>19. Patients with HCV genotype 2 infection in whom prior PEG‐IFN and RBV treatment has failed should be treated with daily sofosbuvir (400 mg) and weight‐based RBV for 12 weeks (in patients without cirrhosis) to 16 weeks (in patients with cirrhosis). (I‐A)</strong></em></li> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Alternative</strong></li> <ul id="-1-1-3" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Retreatment with daily sofosbuvir (400 mg) and weight‐based RBV plus weekly PEG‐IFN for 12 weeks is an alternative for patients in whom prior PEG‐IFN and RBV treatment failed who are eligible to receive IFN</em>.</li> </ul> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0042">Genotype 3</h4> <p id="JCL-P-144">Individuals with genotype 3 HCV infection who have failed a prior course of IFN‐based therapy should receive sofosbuvir plus weight‐based RBV for 24 weeks.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0078 hep27950-bib-0090">78</a></sup> Retreatment with daily sofosbuvir (400 mg) and weight‐based RBV plus weekly PEG‐IFN for 12 weeks is also highly effective, particularly among those with cirrhosis. It is recommended for those eligible to receive PEG‐IFN.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0080">80</a></sup> This regimen may also be effective in those patients with HCV genotype 3 infection who have failed a prior course of sofosbuvir and ribavirin.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0043">Recommendation</h3> <p id="JCL-P-145"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>20. Patients with HCV genotype 3 infection in whom prior PEG‐IFN and RBV treatment has failed should receive</strong></em></li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV plus weekly PEG‐IFN for 12 weeks for patients who are eligible to receive IFN. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV for 24 weeks for IFN‐ineligible patients. (I‐B)</em></li> </ul> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0044">Genotype 4</h4> <p id="JCL-P-149">Data are limited to help guide retreatment decision making for patients infected with HCV genotype 4. Nonetheless, for patients in whom retreatment is required after prior failure of PEG‐IFN and RBV, four equivalent regimens are recommended: ledipasvir/sofosbuvir for 12 weeks,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0083">83</a></sup> paritaprevir/ritonavir/ombitasvir and weight‐based RBV for 12 weeks for patients without cirrhosis,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0098">98</a></sup> sofosbuvir plus weight‐based RBV and weekly PEG‐IFN for 12 weeks,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0076">76</a></sup> or sofosbuvir plus weight‐based RBV for 24 weeks.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0086">86</a></sup> Patients with cirrhosis who were treated with ledipasvir/sofosbuvir for 24 weeks had higher SVR rates than those treated for 12 weeks. Thus, for those with cirrhosis, 24 weeks of treatment without RBV is recommended.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0091 hep27950-bib-0095">91</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0045">Recommendation</h3> <p id="JCL-P-150"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>21. Options for retreatment of patients with genotype 4 who failed a previous IFN‐based regimen (regimens listed in alphabetical order)</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks (no cirrhosis) or 24 (cirrhosis). (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) and weight‐based RBV for 12 weeks (no cirrhosis). (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) for 12 weeks and daily weight‐based RBV plus weekly PEG‐IFN for 12 weeks for patients who are eligible to receive IFN. (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV for 24 weeks. (IIa‐B)</em></li> </ul> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0046">Genotypes 5 and 6</h4> <p id="JCL-P-156">Few data are available to help guide decision making for patients infected with HCV genotype 5 or 6 in whom prior therapy has failed. Nonetheless, based on emerging data, sofosbuvir plus ledipasvir is recommended.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0083 hep27950-bib-0084 hep27950-bib-0088">83</a></sup></p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0047">Recommendation</h3> <p id="JCL-P-157"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>22. Patients with HCV genotype 5 or 6 infection in whom prior PEG‐IFN and RBV treatment has failed should receive</strong></em></li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks. (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Alternative</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV plus weekly PEG‐IFN for 12 weeks for patients who are IFN‐eligible. (IIa‐B)</em></li> </ul> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0048">Monitoring Patients Before, During, and After Antiviral Therapy</h2> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0049">Recommendation</h3> <p id="JCL-P-162"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>23. Patients should be evaluated prior to starting therapy, during treatment, and following discontinuation of treatment in order to determine the severity of their liver disease and the efficacy and safety of their HCV treatment. The recommended evaluations (and ratings) are listed in</strong></em><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"> Tables 5-7</em>.</li> </ul> </p> <div class="wk-clearfix-article-table"></div> <div class="article-table"><a id="hep27950-tbl-0005"></a><div class="article-table-title"><span>Table 5 - </span> Recommended Assessments Prior to Starting Antiviral Therapy<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div> </div> <div class="scroll-message"></div> <div class="dummy-scroll"> <div></div> </div> <div class="article-table-body"> <div class="article-table-container"> <table> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <tbody valign="top" xmlns="http://www.w3.org/1999/xhtml"> <tr> <td align="left" valign="top" rowspan="1" colspan="1"> <p>Assessment of potential drug–drug interactions with concomitant medications is recommended prior to starting HCV therapy.</p> <p>The following laboratory tests are recommended within 12 weeks prior to starting antiviral therapy:</p> <p>• Complete blood count, international normalized ratio</p> <p>• Hepatic function panel (albumin, total and direct bilirubin, ALT, aspartate aminotransferase, and alkaline phosphatase levels)</p> <p>• Thyroid‐stimulating hormone if IFN is used</p> <p>• Calculated GFR</p> <p>The following laboratory testing is recommended at any time prior to starting antiviral therapy:</p> <p>• HCV genotype and subtype</p> <p>• Quantitative HCV viral load, except in the circumstance that a quantitative viral load will influence duration of therapy</p> <p>Rating: Class I, Level C</p> </td> </tr> </tbody> </table> <div class="article-table-descriptions"></div> </div> </div> </div><br><div class="wk-clearfix-article-table"></div> <div class="article-table"><a id="hep27950-tbl-0006"></a><div class="article-table-title"><span>Table 6 - </span> Recommended Monitoring During Antiviral Therapy<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div> </div> <div class="scroll-message"></div> <div class="dummy-scroll"> <div></div> </div> <div class="article-table-body"> <div class="article-table-container"> <table> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <tbody valign="top" xmlns="http://www.w3.org/1999/xhtml"> <tr> <td align="left" valign="top" rowspan="1" colspan="1"> <p>Clinic visits or telephone contacts are recommended as clinically indicated during treatment to ensure medication adherence and to monitor for adverse events and potential drug–drug interactions with newly prescribed medications.</p> <p>The following laboratory testing is recommended:</p> <p>• Complete blood count, creatinine level, calculated GFR, and hepatic function panel are recommended after 4 weeks of treatment and as clinically indicated.</p> <p>• Thyroid‐stimulating hormone is recommended every 12 weeks for patients receiving IFN.</p> <p>• More frequent assessment for drug‐related toxic effects (e.g., complete blood count for patients receiving RBV) is recommended as clinically indicated.</p> <p>• Quantitative HCV viral load testing is recommended after 4 weeks of therapy and at 12 weeks following completion of therapy. Antiviral drug therapy should not be interrupted or discontinued if HCV RNA levels are not performed or available during treatment.</p> <p>• Quantitative HCV viral load testing can be considered at the end of treatment and 24 weeks or longer following the completion of therapy.</p> <p>Rating: Class I, Level B</p> <p> Prompt discontinuation of therapy is recommended for (1) a 10‐fold increase in ALT activity at week 4 or (2) any increase in ALT of less than 10‐fold at week 4 that is accompanied by any weakness, nausea, vomiting, or jaundice or by increased bilirubin, alkaline phosphatase, or international normalized ratio. Asymptomatic increases in ALT of less than 10‐fold elevated at week 4 should be closely monitored and repeated at week 6 and week 8.</p> <p>Rating: Class I, Level B</p> </td> </tr> </tbody> </table> <div class="article-table-descriptions"></div> </div> </div> </div><br><div class="wk-clearfix-article-table"></div> <div class="article-table"><a id="hep27950-tbl-0007"></a><div class="article-table-title"><span>Table 7 - </span> Recommendations for Discontinuation of Treatment Because of Lack of Efficacy<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div> </div> <div class="scroll-message"></div> <div class="dummy-scroll"> <div></div> </div> <div class="article-table-body"> <div class="article-table-container"> <table> <col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1" xmlns="http://www.w3.org/1999/xhtml" /> <tbody valign="top" xmlns="http://www.w3.org/1999/xhtml"> <tr> <td align="left" valign="top" rowspan="1" colspan="1"> <p>• If quantitative HCV viral load is detectable at week 4 of treatment, repeat quantitative HCV RNA viral load testing is recommended after 2 additional weeks of treatment (treatment week 6). If quantitative HCV viral load has increased by greater than 10‐fold (>1 log<sub>10</sub> IU/mL) on repeat testing at week 6 (or thereafter), then discontinuation of HCV treatment is recommended.</p> <p>• The significance of a positive HCV RNA test result at week 4 that remains positive but lower at week 6 or week 8 is unknown. No recommendation to stop therapy or extend therapy can be provided at this time.</p> <p>Rating: Class III, Level C</p> </td> </tr> </tbody> </table> <div class="article-table-descriptions"></div> </div> </div> </div><br><p id="JCL-P-164">Patients who do not achieve SVR because of failure of the treatment or who relapse or are reinfected after treatment completion may have continued liver injury and will have the potential to transmit HCV. Such patients should be monitored for progressive liver disease, counseled to prevent transmission, and considered for retreatment.</p> <p id="JCL-P-165">Patients in whom treatment fails should be monitored for signs and symptoms of cirrhosis and should be considered for treatment when alternative effective treatment is available.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0072 hep27950-bib-0099">72</a></sup> Such patients may have a virus that is resistant to one or more of the antivirals used at the time of virological “breakthrough.”<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0072 hep27950-bib-0100">72</a></sup> However, there is no evidence to date that the presence of RAVs causes more liver injury than does wild‐type virus. Further, the long‐term persistence of such RAVS remains unknown. Subsequent retreatment with combination antivirals may overcome the presence of resistance to one or more antivirals. However, with the exception of testing for the Q80K polymorphism at baseline in patients with HCV genotype 1a infection before treatment with simeprevir plus PEG‐IFN and RBV or treatment with sofosbuvir plus simeprevir in patients with cirrhosis, routine testing for RAVs before initial treatment is not recommended. Emerging data suggest that assessment for RAVs in patients whose treatment with NS5A‐containing regimens failed is warranted for those who require retreatment.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0050">Recommendation</h3> <p id="JCL-P-166"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>24. Patients who fail to achieve SVR should receive the following</em></strong>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Disease progression assessment every 6 months to 12 months with a hepatic function panel, complete blood count, and international normalized ration. (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Surveillance for HCC with ultrasound testing every 6 months for patients with advanced fibrosis (i.e., Metavir stage F3 or F4). (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Endoscopic surveillance for esophageal varices if cirrhosis is present. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Evaluation for retreatment as effective alternative treatments become available. (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Routine monitoring for HCV drug RAVs during or after therapy is not recommended except prior to treatment of (1) persons with HCV genotype 1a infection who are being considered for treatment with simeprevir with PEG‐IFN and RBV, simeprevir, or sofosbuvir (cirrhosis) or (2) persons with HCV genotype 1 infection who were previously treated with an NS5A inhibitor and are being considered for retreatment. (III‐C)</em></li> </ul> </ul> </p> <p id="JCL-P-173">Patients who have undetectable HCV RNA in the serum when assessed 12 or more weeks after completion of treatment are deemed to have achieved an SVR. In these patients, hepatitis C–related liver injury stops, although they remain at risk for non–hepatitis C–related liver disease, such as fatty liver or alcoholic liver disease. Patients with cirrhosis remain at risk for developing HCC.</p> <p id="JCL-P-174">An SVR typically aborts progression of liver injury, with regression of liver fibrosis in most, but not all, patients with an SVR.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0042 hep27950-bib-0101 hep27950-bib-0102 hep27950-bib-0103 hep27950-bib-0104">42</a></sup> Because of lack of progression, patients without advanced liver fibrosis (i.e., Metavir stage F0‐F2) who achieve an SVR should receive standard medical care that is recommended for patients who were never infected with HCV.</p> <p id="JCL-P-175">Among patients with advanced liver fibrosis (i.e., Metavir stage F3 or F4) who achieve an SVR, decompensated liver disease (with the exception of HCC) rarely develops during follow‐up and overall survival is prolonged.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0042 hep27950-bib-0101 hep27950-bib-0102 hep27950-bib-0103 hep27950-bib-0104">42</a></sup> Patients who have advanced fibrosis or cirrhosis continue to be at risk for development of HCC even after achieving an SVR, although their risk is much lower than the risk associated with persistent viremia.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0042 hep27950-bib-0101 hep27950-bib-0102 hep27950-bib-0103 hep27950-bib-0104">42</a></sup> Although liver fibrosis regresses in most patients who achieve an SVR<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">42,</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0101 hep27950-bib-0102 hep27950-bib-0103 hep27950-bib-0104">101</a></sup> and bleeding from esophageal varices is rare,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0042 hep27950-bib-0101 hep27950-bib-0102 hep27950-bib-0103 hep27950-bib-0104">42</a></sup> patients with cirrhosis should undergo screening endoscopy for detection of esophageal varices; and these should be treated or monitored as indicated.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0060">60</a></sup></p> <p id="JCL-P-176">Patients in whom an SVR is achieved but who have another potential cause of liver disease (e.g., excessive alcohol use, metabolic syndrome with or without confirmed fatty liver disease, iron overload, or hepatitis B virus) remain at risk for progression of fibrosis. It is recommended that such patients be educated about the risk of liver disease and monitored for liver disease progression. Periodic testing is recommended for patients with ongoing risk for HCV infection (e.g., illicit drug use or high‐risk sexual exposure) or HCV reinfection. Flares in liver enzyme test results should prompt evaluation of possible <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">de novo</em> reinfection with HCV through a new exposure. Anti‐HCV remains positive in most patients following an SVR. Thus, testing for HCV reinfection should be performed with an assay that detects HCV RNA (e.g., a quantitative HCV RNA test).</p> <p id="JCL-P-177">Individuals with inactive (no detectable virus) or past hepatitis B viral infection may experience reactivation and clinically apparent hepatitis during immunosuppressive treatment or chemotherapy. This does not occur with hepatitis C infection. Thus, routine HCV RNA testing during immunosuppressive treatment or prophylactic administration of antivirals during immunosuppressive treatment is not recommended.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0051">Recommendation</h3> <p id="JCL-P-178"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><strong>25. Patients who achieve an SVR should receive the following</strong></em>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients without advanced fibrosis (i.e., Metavir fibrosis stage F0‐F2), no additional follow‐up is recommended. (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Patients with advanced fibrosis (i.e., Metavir fibrosis stage F3 or F4) should undergo surveillance for HCC with twice‐yearly abdominal imaging. (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Continue endoscopy to screen for varices if cirrhosis is present. Patients in whom varices are found should be treated and followed up as indicated. (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Assessment of other causes of liver disease for patients who have persistently abnormal liver function test results after achieving an SVR. (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Assessment for HCV recurrence or reinfection is only necessary if the patient has ongoing risk for HCV infection or experiences otherwise unexplained hepatic dysfunction. In such cases, a quantitative HCV RNA assay, rather than an anti‐HCV serology test, is recommended to test for HCV recurrence or reinfection. (I‐A)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Routine prospective monitoring for HCV infection recurrence among patients who achieved an SVR and who are receiving immunosuppressive treatment (e.g., systemic corticosteroids, antimetabolites, chemotherapy) is not recommended. (III‐C)</em></li> </ul> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0052">Unique Patient Populations</h2> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0053">Decompensated Cirrhosis</h3> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0054">Recommendation</h4> <p id="JCL-P-186"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>26. Patients with HCV who have decompensated cirrhosis (moderate or severe hepatic impairment; Child‐Turcotte‐Pugh [CTP] class B or C) should be referred to a medical practitioner who is highly experienced in the management of advanced liver disease and HCV treatment (ideally in a liver transplant center). (I‐C)</em></strong></li> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0055">Genotypes 1 and 4</h4> <p id="JCL-P-188">Emerging data support the use of DAA combinations in patients with decompensated cirrhosis. Treatment‐naive or ‐experienced patients with HCV genotype 1 or 4 with CTP class B or C cirrhosis who received daily ledipasvir/sofosbuvir and RBV (600 mg, increased as tolerated) for 12 weeks or 24 weeks had similar SVR12 rates. Thus, a 12‐week course of ledipasvir/sofosbuvir and RBV is an appropriate regimen for patients with decompensated cirrhosis who are infected with HCV genotype 1 or 4. For patients with decompensated cirrhosis who are awaiting liver transplant, the impact of SVR on their priority for transplantation is unknown; analysis of outcomes in this population is required. As of December 2014, there are no data from studies of ledipasvir/sofosbuvir without RBV in patients with decompensated cirrhosis.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0056">Recommendation</h3> <p id="JCL-P-189"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>27. Recommended treatment for patients with genotype 1 or 4 HCV and decompensated cirrhosis (moderate or severe hepatic impairment, CTP class B or C) who may or may not be candidates for liver transplantation, including those with HCC</em></strong>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) and RBV (initial dose of 600 mg, increased as tolerated) for 12 weeks. (IIb‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients with anemia or RBV intolerance, daily fixed‐dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks. (IIb‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Alternative</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients in whom prior sofosbuvir‐based treatment has failed, daily fixed‐dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) and RBV (initial dose of 600 mg, increased as tolerated) for 24 weeks. (IIb‐C)</em></li> </ul> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0057">Genotypes 2 and 3</h4> <p id="JCL-P-195">In one study, 61 patients with HCV infection and HCC meeting Milan criteria for liver transplant were treated with sofosbuvir plus RBV for up to 48 weeks.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0105">105</a></sup> At 12 weeks posttransplant, 30 of the 43 patients who had undergone liver transplant, (70%) had undetectable HCV RNA, consistent with prevention of HCV recurrence. Ten patients experienced recurrent HCV, nine of whom had undetectable HCV RNA levels for less than 30 days pretransplant. Ten of the 11 (91%) patients with HCV genotype 2 or 3 achieved SVR12. These data suggest that sofosbuvir and RBV can be given to liver transplant candidates with HCC and mildly decompensated cirrhosis.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0058">Recommendation</h3> <p id="JCL-P-196"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>28. Recommended treatment for patients with genotype 2 or 3 and decompensated cirrhosis (moderate or severe hepatic impairment, CTP class B or C) who may or may not be candidates for liver transplantation, including those with HCC</em></strong><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">.</strong></li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV (with consideration of the patient's creatinine clearance rate and hemoglobin level) for up to 48 weeks. (IIb‐B)</em></li> </ul> </ul> </p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0059">Patients Who Develop Recurrent HCV Infection After Liver Transplantation</h3> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0060">Genotypes 1 and 4</h4> <p id="JCL-P-199">In a randomized controlled trial of 222 liver transplant recipients with recurrent genotype 1 or 4 HCV, participants were randomized to ledipasvir/sofosbuvir and RBV for 12 or 24 weeks.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0106">106</a></sup> In both the 12‐week and 24‐week arms SVR12 was achieved in 96% of patients with Metavir stage F0 to F3 fibrosis and compensated cirrhosis. Efficacy was lower in CTP class B (85% SVR12) or C (60% SVR12) cirrhosis, with no increase in SVR with 24‐week duration. Because all patients received RBV, the safest presumption is that RBV contributes to the high SVR12 rates. However, based on other data,<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0091">91</a></sup> 24 weeks of ledipasvir/sofosbuvir is an alternative for RBV‐intolerant patients.</p> <p id="JCL-P-200">In a study of liver transplant recipients with mild recurrence of HCV genotype 1, PrOD plus weight‐based RBV for 24 weeks achieved an SVR24 rate of 96%.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0107">107</a></sup> Because of the interaction between ritonavir and calcineurin inhibitors, prospective dose adjustments are required for cyclosporine and tacrolimus. In a retrospective analysis of sofosbuvir plus simeprevir with or without RBV in liver transplant recipients, the SVR4 rate was 92%.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0108">108</a></sup> Simeprevir should not be coadministered with cyclosporine but may be coadministered with tacrolimus with careful monitoring.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0061">Recommendation</h3> <p id="JCL-P-201"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>29. Recommended regimen for treatment‐naive and treatment‐experienced patients with HCV genotype 1 or 4 infection in the allograft, including those with compensated cirrhosis</em></strong>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with weight‐based RBV for 12 weeks for patients with HCV genotype 1 or 4 infection in the allograft. (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks is recommended for those who are RBV‐intolerant or RBV‐ineligible. (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Alternatives (for Patients Who Were not Previously Treated With Telaprevir‐ or Boceprevir‐Containing Regimens)</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients with HCV genotype 1 in the allograft, including those with compensated cirrhosis, daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight‐based RBV for 12 weeks. (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">For patients with genotype 1 HCV in the allograft, including early (Metavir fibrosis stage F0‐F2) recurrence, daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) and weight‐based RBV for 24 weeks. (I‐B)</em></li> </ul> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0062">Non‐1 Genotypes</h4> <p id="JCL-P-208">Few data are available to guide treatment of patients with HCV genotype 2 or 3 in the posttransplant setting; recommendations largely mirror those in the nontransplant population.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0063">Recommendations</h3> <p id="JCL-P-209"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>30. Treatment‐naive and treatment‐experienced patients with HCV genotype 2 in the allograft, including those with compensated cirrhosis, should receive daily sofosbuvir (400 mg) and weight‐based RBV for 24 weeks. (IIb‐C)</em></strong></li> </ul> <ul id="-2" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>31. Treatment‐naive and treatment‐experienced patients with HCV genotype 3 in the allograft should receive the following</em></strong>:</li> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Compensated Cirrhosis</strong></li> <ul id="-2-1-3" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and weight‐based RBV for 24 weeks (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Decompensated Cirrhosis (CTP Class B or C)</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daily sofosbuvir (400 mg) and low initial dose of RBV (600 mg, increasing as tolerated) for 24 weeks. (I‐B)</em></li> </ul> </ul> </p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0065">Patients With Renal Impairment</h4> <p id="JCL-P-216">The currently approved DAAs can be safely dosed in persons with mild‐to‐moderate renal impairment (CrCl rate 30‐80 mL/min). However, there are few data to guide dosing of these agents in severe renal impairment/end‐stage renal disease (CrCl < 30 mL/min). Studies of PrOD with or without RBV (for HCV genotype 1a or 1b) in treatment‐naive patients without cirrhosis with severe renal impairment show early promising efficacy [109]. Caution is warranted in managing anemia related to RBV, and RBV should not be given if the baseline hemoglobin level is less than 10 g/dL.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0066">Recommendations</h3> <p id="JCL-P-217"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>32. For patients with mild to moderate renal impairment (CrCl rate >30‐80 mL/min), no dosage adjustment is required when using sofosbuvir, simeprevir, fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg), or fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) to treat or retreat HCV infection in patients with appropriate genotypes. (I‐A)</em></strong></li> </ul> <ul id="-2" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>33. For treatment‐naive patients with HCV genotype 1 without cirrhosis and with CrCl rates <30 mL/min, treatment with the daily fixed‐dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice‐daily dosed dasabuvir (250 mg) with (1a) or without (1b) RBV (200 mg) once daily is recommended. RBV should only be given if the baseline hemoglobin level is >10 g/dL. For patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30‐50 mL/min), initial RBV dosing should be 200 mg or 400 mg alternating every other day. For patients with severe renal impairment or who are on hemodialysis (eGFR <30 mL/min), initial RBV dosing should be 200 mg daily. (II‐B)</em></strong></li> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0068">HIV/HCV Coinfection</h2> <p id="JCL-P-220">Compared to those with HCV infection alone, persons with HCV/HIV coinfection have a higher rate of HCV persistence, faster progression to cirrhosis and end‐stage liver disease, and higher HCV RNA levels.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0110 hep27950-bib-0111 hep27950-bib-0112">110</a></sup> Persons coinfected with HIV/HCV also had lower responses to PEG‐IFN and RBV than those with HCV infection alone, an observation largely explained by the higher baseline HCV RNA levels.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0113 hep27950-bib-0114">113</a></sup> However, with the advent of DAAs, differences in treatment responses between mono‐ and coinfected patients have not been detected.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0115 hep27950-bib-0116">115</a></sup> Thus, the treatment recommendations for HIV/HCV‐coinfected persons are the same as for those with just HCV infection, with consideration of potential drug–drug interactions with HIV medications.</p> <p id="JCL-P-221">In some instances pharmacokinetic testing has been done in HIV/HCV‐coinfected persons, and there is clinical experience with the combinations (see <span><a href="http://www.hcvguidelines.org" onclick="javascript:window.open('http://www.hcvguidelines.org');return false">www.hcvguidelines.org</a></span>). In others, the pharmacology is predicted or based on healthy volunteer studies. The chief concern with the combination of ledipasvir/sofosbuvir is potentiation of the nephrotoxicity of tenofovir disoproxil fumarate (tenofovir). Tenofovir levels are increased by ledipasvir/sofosbuvir and may be even higher with coadministration of other antiretroviral drugs that raise tenofovir levels, particularly ritonavir‐boosted protease inhibitors. With PrOD, the inclusion of 100 mg of ritonavir in the fixed combination will also “boost” HIV protease inhibitors (and some other medications) and additional ritonavir should be discontinued, then restarted when HCV treatment is finished. In healthy volunteers, when PrOD was combined with efavirenz, emtricitabine, and tenofovir, gastrointestinal and neurologic adverse events occurred along with elevations of ALT. When the regimen was combined with rilpivirine, exposures to rilpivirine were substantially increased. Therefore, rilpivirine and efavirenz should not be used with the PrOD regimen.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0117 hep27950-bib-0118">117</a></sup></p> <p id="JCL-P-222">Clinical trials have demonstrated the safety and efficacy of ledipasvir/sofosbuvir in HIV‐infected persons with HCV genotype 1 or 4 who were generally taking antiretroviral therapy that included tenofovir and emtricitabine with rilpivirine, raltegravir, or efavirenz.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0119 hep27950-bib-0120">119</a></sup> Data are derived from studies that included 335 HCV treatment‐naive and ‐experienced HIV/HCV‐coinfected persons as well as those with or without cirrhosis. Clinical trial data in HIV‐infected individuals with HCV genotype 1 or 4 infection have demonstrated the safety and efficacy of ledipasvir/sofosbuvir for 12 weeks<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0119 hep27950-bib-0120">119</a></sup> and of PrOD with or without RBV<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">121</sup> for 12 weeks.</p> <p id="JCL-P-223">Data on treatment of HIV/HCV‐coinfected persons with HCV genotype 2 or 3 support use of similar regimens as are recommended for persons without HIV infection.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0115 hep27950-bib-0122">115</a></sup> Antiretroviral regimens allowed included combinations of tenofovir and emtricitabine with efavirenz, raltegravir, ritonavir‐boosted atazanavir, ritonavir‐boosted darunavir, or rilpivirine. High SVR12 rates were observed for genotype 2 (89%) and genotype 3 (84%). Treatment was generally well tolerated.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0069">Recommendations</h3> <p id="JCL-P-224"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>34. HIV/HCV‐coinfected persons should be treated and retreated the same as persons without HIV infection, after recognizing and managing interactions with antiretroviral medications. (I‐B)</em></strong></li> </ul> <ul id="-2" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>35. Antiretroviral treatment interruption to allow HCV therapy is not recommended. (III‐A)</em></strong></li> </ul> <ul id="-3" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>36. Antiretroviral and HCV drug interactions should be assessed prior to initiating therapy. Drug switches, when needed, should be done in collaboration with the HIV practitioner. For HIV antiretroviral and HCV DAA combinations not addressed below, expert consultation is recommended. (I‐A)</em></strong></li> </ul> <ul id="-4" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>37. The following are recommendations related to specific drug combinations which need to be considered in coinfected patients</em></strong>:</li> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Ledipasvir</strong></li> <ul id="-4-1-3" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Ledipasvir increases tenofovir levels and should be avoided in those with CrCl <60 mL/min. Because potentiation of this effect is expected when tenofovir is used with ritonavir‐boosted HIV protease inhibitors, ledipasvir should be avoided with this combination (pending further data) unless antiretroviral regimen cannot be changed and the urgency of treatment is high. (IIa‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Sofosbuvir and Ledipasvir/Sofosbuvir</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Fixed‐dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) (hereafter ledipasvir/sofosbuvir) should not be used with cobicistat and elvitegravir, pending further data. (III‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Sofosbuvir or ledipasvir/sofosbuvir should not be used with tipranavir. (III‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PrOD</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PrOD should be used with antiretroviral drugs with which it does not have substantial interactions: raltegravir (and probably dolutegravir), enfuvirtide, tenofovir, emtricitabine, lamivudine, and atazanavir. The dose of ritonavir used for boosting HIV protease inhibitors may need to be adjusted (or held) when administered with PrOD and then restored when HCV treatment is completed. The HIV protease inhibitor should be administered at the same time as the fixed‐dose HCV combination. (IIa‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PrOD should not be used with efavirenz, rilpivirine, darunavir, or ritonavir‐boosted lopinavir. (III‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PrOD should not be used in HIV/HCV‐coinfected individuals who are not taking antiretroviral therapy. (III‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Simeprevir</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Simeprevir should not be used with efavirenz, etravirine, nevirapine, cobicistat, or any HIV protease inhibitor. (III‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Simeprevir should only be used with antiretroviral drugs with which it does not have clinically significant interactions: raltegravir (and probably dolutegravir), rilpivirine, maraviroc, enfuvirtide, tenofovir, emtricitabine, lamivudine, and abacavir. (IIa‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">RBV</strong></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">RBV should not be used with didanosine, stavudine, or zidovudine. (III‐B)</em></li> </ul> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0073">Acute HCV Infection</h2> <p id="JCL-P-243">Infection with HCV is considered to be acute during the first 6 months. Infections of less than 6‐month duration spontaneously resolve in 15%‐50% of cases, whereas spontaneous resolution occurs in fewer than 5% once infection persists for several years.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0123 hep27950-bib-0124 hep27950-bib-0125 hep27950-bib-0126">123</a></sup> Within the first months of HCV infection, there is also a transition to (particularly in patients with unfavorable <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">IL28B</em> genotypes and genotype 1 HCV infection) decreasing responsiveness of HCV infection to PEG‐IFN.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0127 hep27950-bib-0128">127</a></sup></p> <p id="JCL-P-244">Aside from instances in which there is a single exposure such as a health care worker with a needlestick injury, it is often impossible to know exactly when infection occurred. With the transition to IFN‐free treatments, this determination is less crucial because acute HCV infection can now be managed like chronic infection. However, better methods of differentiating acute from chronic infection would be useful for public health surveillance.</p> <p id="JCL-P-245">The decision of when to treat acute HCV infection is largely based on the likelihood of spontaneous resolution, the possibility of transmission to others, the efficacy and safety of treatment in the acute compared with the chronic phase of infection, and patient preference. Previously when PEG‐IFN was used, responses were better if genotype 1 HCV infection was treated within the first 12‐16 weeks rather than a year after infection.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0127 hep27950-bib-0128">127</a></sup> Because the majority of spontaneous resolutions also occur in the first 12‐16 weeks, treatment was recommended within that window.<sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep27950-bib-0129">129</a></sup> With 12‐week PEG‐IFN–sparing regimens, SVR rates for treatment of chronic infection are higher than 90% and much safer. Consequently, unless necessary to prevent transmission to others or strongly preferred by the patient or practitioner for other reasons, persons with acute HCV infection should be monitored for 6 or more months. If spontaneous clearance has not occurred, treatment should follow the same recommendations as for chronic infection. Likewise, even when treatment is provided earlier than 6 months after infection, it is recommended to monitor at least 12 weeks for spontaneous resolution and use the same regimens as with chronic infection until studies demonstrate the superiority (or noninferiority) of alternatives.</p> <p id="JCL-P-246">The optimal timing and intensity of monitoring in acute infection vary depending on the treatment considerations described above and whether there is evidence of severe hepatitis. At a minimum, HCV RNA should be assessed 4‐6 months after the estimated onset of infection to establish if chronic infection occurred. Often, more frequent testing of HCV RNA and liver enzymes is preferred.</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0074">Recommendations</h3> <p id="JCL-P-247"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>38. The following are recommended in the diagnosis and initial management of acute hepatitis C</em></strong>:</li> <ul id="-1-1-2" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">HCV antibody and HCV RNA testing are recommended when acute HCV infection is suspected due to exposure, clinical presentation, or elevated aminotransferase levels. (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Regular laboratory monitoring (every 4‐8 weeks for 6‐12 months) is recommended in the setting of acute HCV infection until the ALT level normalizes and HCV RNA becomes repeatedly undetectable, suggesting spontaneous resolution. (I‐B)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">If a decision has been made to initiate treatment during the acute infection period, monitoring HCV RNA for at least 12‐16 weeks is recommended to detect spontaneous clearance before starting treatment. (IIa‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">If the practitioner and patient have decided that a delay in treatment initiation is acceptable, monitoring for spontaneous clearance is recommended for a minimum of 6 months. (IIa‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Counseling is recommended for patients with acute HCV infection to avoid hepatotoxic insults, including hepatotoxic drugs (e.g., acetaminophen) and alcohol consumption, and to reduce the risk of HCV transmission to others. (I‐C)</em></li> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Referral to an addiction medicine specialist is recommended for patients with acute HCV infection related to injection drug use. (I‐B)</em></li> </ul> </ul> </p> <p id="JCL-P-255"> <ul id="-1" class="wk-article__list wk-article__list--plain"> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>39. Treatment of individuals with acute hepatitis C should be the same as that recommended for chronic HCV infection (see When and in Whom to Initiate HCV Therapy)</em></strong><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">.</strong><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><em>(IIa‐C)</em></strong></li> <li class="wk-article__list-item wk-article__list-item--plain"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Alternative</strong></li> <ul id="-1-1-3" class="wk-article__list wk-article__list--bullet"> <li class="wk-article__list-item wk-article__list-item--bullet"><em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PEG‐IFN with or without RBV for 16 weeks (for those with HCV genotype 2 or 3 who have a rapid virological response) to 24 weeks (for those with HCV genotype 1). (II‐A)</em></li> </ul> </ul> </p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0077">AASLD/IDSA HCV Guidance Panel Members and Authors</h2> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0078">Current Panel Members Involved in the Development of This Guidance</h3> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0079">Cochairs</h4> <p id="JCL-P-259"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Raymond T. Chung, M.D.</strong></p> <p id="JCL-P-260">Director of Hepatology and Vice Chief of Gastroenterology</p> <p id="JCL-P-261">Massachusetts General Hospital</p> <p id="JCL-P-262">Boston, MA</p> <p id="JCL-P-263"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Gary L. Davis, M.D.</strong></p> <p id="JCL-P-264">Director, Hepatology</p> <p id="JCL-P-265">Medical Director, Liver Transplantation</p> <p id="JCL-P-266">Baylor University Medical Center (retired)</p> <p id="JCL-P-267">Dallas, TX</p> <p id="JCL-P-268"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Donald M. Jensen, MD (Immediate Past Chair)</strong></p> <p id="JCL-P-269">Professor of Medicine (retired)</p> <p id="JCL-P-270">University of Chicago Medical Center</p> <p id="JCL-P-271">Chicago, IL</p> <p id="JCL-P-272"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Henry Masur, M.D.</strong></p> <p id="JCL-P-273">Clinical Professor of Medicine</p> <p id="JCL-P-274">Chief, Critical Care Medicine Department</p> <p id="JCL-P-275">National Institutes of Health</p> <p id="JCL-P-276">Bethesda, MD</p> <p id="JCL-P-277"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Michael S. Saag, M.D.</strong></p> <p id="JCL-P-278">Professor of Medicine and Associate Dean for Global Health</p> <p id="JCL-P-279">The University of Alabama at Birmingham School of Medicine</p> <p id="JCL-P-280">Birmingham, AL</p> <p id="JCL-P-281"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">David L. Thomas, M.D., M.P.H.</strong></p> <p id="JCL-P-282">Professor of Medicine and Director of Infectious Diseases</p> <p id="JCL-P-283">The Johns Hopkins University School of Medicine</p> <p id="JCL-P-284">Baltimore, MD</p> <h4 class="ejp-article-outline-heading" data-level="3" id="hep27950-sec-0080">Members</h4> <p id="JCL-P-285"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Andrew I. Aronsohn, M.D.</strong></p> <p id="JCL-P-286">Assistant Professor of Medicine</p> <p id="JCL-P-287">University of Chicago Medical Center</p> <p id="JCL-P-288">Chicago, IL</p> <p id="JCL-P-289"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Michael R. Charlton, M.D.</strong></p> <p id="JCL-P-290">Director of Hepatology and Medical Director of Liver Transplantation</p> <p id="JCL-P-291">Intermountain Medical Center</p> <p id="JCL-P-292">Murray, UT</p> <p id="JCL-P-293"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Jordan J. Feld, M.D., M.P.H.</strong></p> <p id="JCL-P-294">Assistant Professor of Medicine and Research Director of Gastroenterology, Medicine</p> <p id="JCL-P-295">Toronto Western Hospital Liver Center</p> <p id="JCL-P-296">Toronto, Canada</p> <p id="JCL-P-297"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Robert J. Fontana, M.D.</strong></p> <p id="JCL-P-298">Professor of Medicine and Medical Director of Liver Transplantation</p> <p id="JCL-P-299">University of Michigan Medical School</p> <p id="JCL-P-300">Ann Arbor, MI</p> <p id="JCL-P-301"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Marc G. Ghany, M.D.</strong></p> <p id="JCL-P-302">Staff Physician, Liver Diseases Branch</p> <p id="JCL-P-303">National Institute of Diabetes and Digestive and Kidney Diseases</p> <p id="JCL-P-304">National Institutes of Health</p> <p id="JCL-P-305">Bethesda, MA</p> <p id="JCL-P-306"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Eliot W. Godofsky, M.D., F.A.C.P.</strong></p> <p id="JCL-P-307">Director of Infectious Diseases</p> <p id="JCL-P-308">Bach and Godofsky</p> <p id="JCL-P-309">Bradenton, FL</p> <p id="JCL-P-310"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Camilla S. Graham, M.D., M.P.H.</strong></p> <p id="JCL-P-311">Assistant Professor of Medicine</p> <p id="JCL-P-312">Harvard Medical School</p> <p id="JCL-P-313">Beth Israel Deaconess Medical Center</p> <p id="JCL-P-314">Boston, MA</p> <p id="JCL-P-315"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Arthur Y. Kim, M.D.</strong></p> <p id="JCL-P-316">Assistant Professor of Medicine</p> <p id="JCL-P-317">Harvard Medical School</p> <p id="JCL-P-318">Director of Viral Hepatitis Clinic, ID Division</p> <p id="JCL-P-319">Massachusetts General Hospital</p> <p id="JCL-P-320">Boston, MA</p> <p id="JCL-P-321"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Jennifer J. Kiser, Pharm.D.</strong></p> <p id="JCL-P-322">Assistant Professor of Pharmacology and Associate Director, Center for Translational Pharmacokinetics and Pharmacogenomics</p> <p id="JCL-P-323">University of Colorado</p> <p id="JCL-P-324">Skaggs School of Pharmacy and Pharmaceutical Sciences</p> <p id="JCL-P-325">Aurora, CO</p> <p id="JCL-P-326"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Shyam Kottilil, M.D., Ph.D.</strong></p> <p id="JCL-P-327">Professor of Medicine and Associate Chief of Division of Clinical Care and Research</p> <p id="JCL-P-328">Institute of Human Virology/University of Maryland</p> <p id="JCL-P-329">Baltimore, MD</p> <p id="JCL-P-330"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Kristen M. Marks, M.D.</strong></p> <p id="JCL-P-331">Assistant Professor of Medicine</p> <p id="JCL-P-332">Weill Cornell Medical College</p> <p id="JCL-P-333">New York, NY</p> <p id="JCL-P-334"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Paul Martin, M.D.</strong></p> <p id="JCL-P-335">Professor of Medicine and Chief of the Division of Hepatology</p> <p id="JCL-P-336">University of Miami School of Medicine</p> <p id="JCL-P-337">Miami, FL</p> <p id="JCL-P-338"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Kiren Mitruka, M.D., M.P.H.*</strong></p> <p id="JCL-P-339">Medical Officer, Division of Viral Hepatitis</p> <p id="JCL-P-340">National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention</p> <p id="JCL-P-341">Centers for Disease Control and Prevention</p> <p id="JCL-P-342">Atlanta, GA</p> <p id="JCL-P-343"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Timothy R. Morgan, M.D.</strong></p> <p id="JCL-P-344">Chief of Hepatology</p> <p id="JCL-P-345">Veterans Affairs Long Beach Healthcare System</p> <p id="JCL-P-346">Long Beach, CA</p> <p id="JCL-P-347"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Susanna Naggie, M.D., M.H.S.</strong></p> <p id="JCL-P-348">Assistant Professor of Medicine</p> <p id="JCL-P-349">Duke University School of Medicine</p> <p id="JCL-P-350">Director of Infectious Diseases Research, Duke Clinical Research Institute</p> <p id="JCL-P-351">Durham, NC</p> <p id="JCL-P-352"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Daniel Raymond</strong></p> <p id="JCL-P-353">Community Representative</p> <p id="JCL-P-354">Policy Director</p> <p id="JCL-P-355">Harm Reduction Coalition</p> <p id="JCL-P-356">New York, NY</p> <p id="JCL-P-357"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Nancy S. Reau, M.D.</strong></p> <p id="JCL-P-358">Associate Professor of Medicine</p> <p id="JCL-P-359">University of Chicago Medical Center</p> <p id="JCL-P-360">Chicago, IL</p> <p id="JCL-P-361"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Robert T. Schooley, M.D.</strong></p> <p id="JCL-P-362">Professor and Vice Chair of Medicine, Chief of the Division of Infectious Diseases</p> <p id="JCL-P-363">University of California San Diego</p> <p id="JCL-P-364">La Jolla, CA</p> <p id="JCL-P-365"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Kenneth E. Sherman, M.D., Ph.D.</strong></p> <p id="JCL-P-366">Gould Professor of Medicine and Director of the Division of Digestive Diseases</p> <p id="JCL-P-367">University of Cincinnati College of Medicine</p> <p id="JCL-P-368">Cincinnati, OH</p> <p id="JCL-P-369"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Mark S. Sulkowski, M.D.</strong></p> <p id="JCL-P-370">Professor of Medicine and Medical Director of the Viral Hepatitis Center</p> <p id="JCL-P-371">The Johns Hopkins University School of Medicine</p> <p id="JCL-P-372">Baltimore, MD</p> <p id="JCL-P-373"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Hugo E. Vargas, M.D.</strong></p> <p id="JCL-P-374">Professor of Medicine and Director of Hepatology</p> <p id="JCL-P-375">College of Medicine, Mayo Clinic</p> <p id="JCL-P-376">Phoenix, AZ</p> <p id="JCL-P-377"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">John W. Ward, M.D.*</strong></p> <p id="JCL-P-378">Director of the Division of Viral Hepatitis</p> <p id="JCL-P-379">National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention</p> <p id="JCL-P-380">Centers for Disease Control and Prevention</p> <p id="JCL-P-381">Atlanta, GA</p> <p id="JCL-P-382"><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">David L. Wyles, M.D.</strong></p> <p id="JCL-P-383">Associate Professor of Medicine</p> <p id="JCL-P-384">University of California San Diego</p> <p id="JCL-P-385">La Jolla, CA</p> <p id="JCL-P-386">*Nonvoting member.</p> <h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0081">AASLD/IDSA HCV Guidance Panel Financial Relationships With Commercial Entities</h2> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0082">Cochairs</h3> <p id="JCL-P-387">Dr. Chung has no relevant personal financial affiliations to disclose. He was awarded research grants, paid to his institution, from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, MassBiologics, and Merck & Co. (updated January 6, 2015).</p> <p id="JCL-P-388">Dr. Davis serves on data and safety monitoring boards for Bristol‐Myers Squibb (ceased as of August 2014) and Gilead Sciences (duties do not include any hepatitis drugs; updated January 14, 2015).</p> <p id="JCL-P-389">Dr. Masur has no relevant financial affiliations to disclose (updated April 13, 2015).</p> <p id="JCL-P-390">Dr. Saag has no relevant personal financial affiliations to disclose. He was awarded research grants, paid to his institution, from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., and ViiV Healthcare (updated May 4, 2015).</p> <p id="JCL-P-391">Dr. Thomas received royalties from UpToDate (updated January 14, 2015).</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0083">Immediate Past Chair</h3> <p id="JCL-P-392">Dr. Jensen receives honoraria from Gilead Sciences (updated April 1, 2015).</p> <h3 class="ejp-article-outline-heading" data-level="2" id="hep27950-sec-0084">Panel Members</h3> <p id="JCL-P-393">Dr. Aronsohn has no relevant financial affiliations to disclose (updated February 5, 2015).</p> <p id="JCL-P-394">Dr. Charlton serves on the advisory boards of or as a consultant to AbbVie, Gilead Sciences, and Janssen Therapeutics. He was awarded research grants, paid to his institution, from Gilead Sciences and Novartis International (updated January 26, 2015).</p> <p id="JCL-P-395">Dr. Feld serves on the advisory boards of AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., and Theravance. He was awarded research grants, paid to his institution, from AbbVie, Boehringer Ingelheim Pharmaceuticals, Gilead Sciences, Janssen Therapeutics, Merck & Co., and Santaris (updated January 14, 2015).</p> <p id="JCL-P-396">Dr. Fontana served on a data and safety monitoring board for Tibotec Therapeutics and serves as a consultant to Bristol‐Myers Squibb. He was awarded research grants, paid to his institution, from Bristol‐Myers Squibb, Gilead Sciences, Janssen Therapeutics, and Vertex Pharmaceuticals (updated January 16, 2015).</p> <p id="JCL-P-397">Dr. Ghany has no relevant financial affiliations to disclose (updated January 14, 2015).</p> <p id="JCL-P-398">Dr. Godofsky serves on the advisory boards of AbbVie, Gilead Sciences, and Janssen Therapeutics. He was awarded research grants, paid to his practice, from AbbVie, Achillion, Anadys, Boehringer Ingelheim Pharmaceuticals, Genentech, Gilead Sciences, Janssen Therapeutics, Merck & Co., Novartis, and Vertex Pharmaceuticals (updated May 8, 2015).</p> <p id="JCL-P-399">Dr. Graham has no relevant financial affiliations to disclose (updated March 26, 2015).</p> <p id="JCL-P-400">Dr. Kim serves on the advisory boards of AbbVie and Bristol‐Myers Squibb. He was awarded research grants, paid to his institution, from AbbVie and Gilead Sciences (updated February 5, 2015).</p> <p id="JCL-P-401">Dr. Kiser has no relevant personal financial affiliations to disclose. She was awarded research grants, paid to her institution, from Janssen Therapeutics, Merck & Co., and ViiV Healthcare (updated April 20, 2015).</p> <p id="JCL-P-402">Dr. Kottilil has no relevant financial affiliations to disclose (updated January 14, 2015).</p> <p id="JCL-P-403">Dr. Marks has no relevant personal financial affiliations to disclose. She was awarded research grants, paid to her institution, from Boehringer Ingelheim Pharmaceuticals, Bristol‐Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., and Vertex Pharmaceuticals (updated October 20, 2014).</p> <p id="JCL-P-404">Dr. Martin serves on an advisory board for Bristol‐Myers Squibb. He was awarded research grants, paid to his institution, from AbbVie, Gilead Sciences, and Merck & Co. (updated January 14, 2015).</p> <p id="JCL-P-405">Dr. Mitruka has no relevant financial affiliations to disclose (updated January 13, 2015).</p> <p id="JCL-P-406">Dr. Morgan has no relevant personal financial affiliations to disclose. He was awarded research grants, paid to his institution, from Bristol‐Myers Squibb, Genentech, Gilead Sciences, Merck & Co., and Roche (updated January 26, 2015).</p> <p id="JCL-P-407">Dr. Naggie serves on advisory boards for AbbVie, Bristol‐Myers Squibb, Gilead Sciences, and Merck & Co. She was awarded research grants, paid to her institution, from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Janssen, and Vertex Pharmaceuticals (updated March 2, 2015).</p> <p id="JCL-P-408">Mr. Raymond has no relevant personal financial affiliations to disclose. He was awarded educational grants, paid to his organization, from Genentech, Gilead Sciences, and Janssen Therapeutics (updated January 14, 2015).</p> <p id="JCL-P-409">Dr. Reau serves on the advisory boards of AbbVie, Bristol‐Myers Squibb, Gilead Sciences, and Merck & Co. and serves as a consultant for Accordant. She was awarded research grants, paid to her institution, from Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Bristol‐Myers Squibb, Gilead Sciences, Hyperion Therapeutics, and Merck & Co. (updated January 15, 2015).</p> <p id="JCL-P-410">Dr. Schooley serves as a consultant to and has stock options from CytoDyn. He has stock from GlobeImmune. He was awarded research grants, paid to his institution, from Boehringer Ingelheim Pharmaceuticals and Bristol‐Myers Squibb. His institution has received payment for his consultative advice or data safety monitoring committee service from Bristol‐Myers Squibb, GlobeImmune, Gilead Sciences, and Monogram Biosciences (updated April 26, 2015).</p> <p id="JCL-P-411">Dr. Sherman serves on a data and safety monitoring board for Janssen Therapeutics and SynteractHCR and has served on the advisory boards of Merck & Co. and MedImmune. He was awarded research grants, paid to his institution, from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, MedImmune, Merck & Co. and Vertex Pharmaceuticals (updated January 14, 2015).</p> <p id="JCL-P-412">Dr. Sulkowski serves on the advisory boards of AbbVie, Achillion Pharmaceuticals, Bristol‐Myers Squibb, Gilead Sciences, Janssen Therapeutics, and Merck & Co. He has also served on data and safety monitoring boards for Gilead Sciences. He was awarded research grants, paid to his institution from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Janssen Therapeutics, and Merck & Co. (updated March 9, 2015).</p> <p id="JCL-P-413">Dr. Vargas has no relevant personal financial affiliations to disclose. He was awarded research grants, paid to his institution, from AbbVie, Bristol‐Myers Squibb, and Gilead Sciences (updated January 14, 2015).</p> <p id="JCL-P-414">Dr. Ward has no relevant financial affiliations to disclose (updated January 14, 2015).</p> <p id="JCL-P-415">Dr. Wyles serves on the advisory board of Bristol‐Myers Squibb. He was awarded research grants, paid to his institution, from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Merck & Co., and Tacere Therapeutics (updated April 27, 2015).</p></section><section id="article-references" class="article-references js-article-references"><h2 class="ejp-article-outline-heading" data-level="1" id="hep27950-sec-0076">Acknowledgment</h2> <p id="JCL-P-416">We thank Judith Welsh of the National Institutes of Health Library, for providing regular literature searches to the panel, and the able staff of the International Antiviral Society‐USA, particularly Donna Jacobsen, Cindy Downing, and Michelle Tayag Valderama for managing the process and assistance in manuscript preparation.</p> <h2 class="ejp-article-outline-heading" data-level="1" id="">References</h2> <div id="hep27950-bib-0001" class="article-references__item js-article-reference">1. American Heart Association . Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. <span><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf" onclick="javascript:window.open('http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf');return false">http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf</a></span>. Accessed January 27, 2014.<div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-30"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0002" class="article-references__item js-article-reference">2. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003;139:493‐498. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-30"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-200309160-00013.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-200309160-00013.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/13679327" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/13679327');return false">PubMed</a> | <a href="https://doi.org/10.7326%2F0003-4819-139-6-200309160-00013" onclick="javascript:window.open('https://doi.org/10.7326%2F0003-4819-139-6-200309160-00013');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Standardized+reporting+of+clinical+practice+guidelines%3a+a+proposal+from+the+Conference+on+Guideline+Standardization&publication_year=2003&author=RN+Shiffman&author=P+Shekelle&author=JM+Overhage&author=J+Slutsky&author=J+Grimshaw&author=AM.+Deshpande" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Standardized+reporting+of+clinical+practice+guidelines%3a+a+proposal+from+the+Conference+on+Guideline+Standardization&publication_year=2003&author=RN+Shiffman&author=P+Shekelle&author=JM+Overhage&author=J+Slutsky&author=J+Grimshaw&author=AM.+Deshpande');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0003" class="article-references__item js-article-reference">3. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293‐300. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-31"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-201403040-00003.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-201403040-00003.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24737271" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24737271');return false">PubMed</a> | <a href="https://doi.org/10.7326%2FM13-1133" onclick="javascript:window.open('https://doi.org/10.7326%2FM13-1133');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Chronic+hepatitis+C+virus+infection+in+the+United+States%2c+National+Health+and+Nutrition+Examination+Survey+2003+to+2010&publication_year=2014&author=MM+Denniston&author=RB+Jiles&author=J+Drobeniuc&author=RM+Klevens&author=JW+Ward&author=GM+McQuillan" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Chronic+hepatitis+C+virus+infection+in+the+United+States%2c+National+Health+and+Nutrition+Examination+Survey+2003+to+2010&publication_year=2014&author=MM+Denniston&author=RB+Jiles&author=J+Drobeniuc&author=RM+Klevens&author=JW+Ward&author=GM+McQuillan');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0004" class="article-references__item js-article-reference">4. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow‐up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001‐2008. Hepatology 2012;55:1652‐1661. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-31"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201206000-00003.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201206000-00003.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/22213025" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/22213025');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.25556" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.25556');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Awareness+of+infection%2c+knowledge+of+hepatitis+C%2c+and+medical+follow%e2%80%90up+among+individuals+testing+positive+for+hepatitis+C%3a+National+Health+and+Nutrition+Examination+Survey+2001%e2%80%902008&publication_year=2012&author=MM+Denniston&author=RM+Klevens&author=GM+McQuillan&author=RB.+Jiles" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Awareness+of+infection%2c+knowledge+of+hepatitis+C%2c+and+medical+follow%e2%80%90up+among+individuals+testing+positive+for+hepatitis+C%3a+National+Health+and+Nutrition+Examination+Survey+2001%e2%80%902008&publication_year=2012&author=MM+Denniston&author=RM+Klevens&author=GM+McQuillan&author=RB.+Jiles');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0005" class="article-references__item js-article-reference">5. Smith BD, Morgan RL, Beckett GA, Falck‐Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945‐1965. MMWR Recomm Rep 2012;61:1‐32. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-31"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22895429" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/22895429');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Recommendations+for+the+identification+of+chronic+hepatitis+C+virus+infection+among+persons+born+during+1945%e2%80%901965&publication_year=2012&author=BD+Smith&author=RL+Morgan&author=GA+Beckett&author=Y+Falck%e2%80%90Ytter&author=D+Holtzman&author=CG+Teo" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Recommendations+for+the+identification+of+chronic+hepatitis+C+virus+infection+among+persons+born+during+1945%e2%80%901965&publication_year=2012&author=BD+Smith&author=RL+Morgan&author=GA+Beckett&author=Y+Falck%e2%80%90Ytter&author=D+Holtzman&author=CG+Teo');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0006" class="article-references__item js-article-reference">6. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:349‐357. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-31"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0007" class="article-references__item js-article-reference">7. Centers for Disease Control and Prevention . Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV‐related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47:1‐39. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-31"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Recommendations+for+prevention+and+control+of+hepatitis+C+virus+(HCV)+infection+and+HCV%e2%80%90related+chronic+disease&publication_year=1998" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Recommendations+for+prevention+and+control+of+hepatitis+C+virus+(HCV)+infection+and+HCV%e2%80%90related+chronic+disease&publication_year=1998');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0008" class="article-references__item js-article-reference">8. Mahajan R, Liu SJ, Klevens RM, Holmberg SD. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004‐2010. Am J Public Health 2013;103:1445‐1449. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-31"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000469-201308000-00034.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000469-201308000-00034.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23763404" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23763404');return false">PubMed</a> | <a href="https://doi.org/10.2105%2FAJPH.2013.301211" onclick="javascript:window.open('https://doi.org/10.2105%2FAJPH.2013.301211');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Indications+for+testing+among+reported+cases+of+HCV+infection+from+enhanced+hepatitis+surveillance+sites+in+the+United+States%2c+2004%e2%80%902010&publication_year=2013&author=R+Mahajan&author=SJ+Liu&author=RM+Klevens&author=SD.+Holmberg" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Indications+for+testing+among+reported+cases+of+HCV+infection+from+enhanced+hepatitis+surveillance+sites+in+the+United+States%2c+2004%e2%80%902010&publication_year=2013&author=R+Mahajan&author=SJ+Liu&author=RM+Klevens&author=SD.+Holmberg');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0009" class="article-references__item js-article-reference">9. Centers for Disease Control and Prevention . Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362‐365. <div> <ul class="article-references__item-links"> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/23657112" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23657112');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Testing+for+HCV+infection%3a+an+update+of+guidance+for+clinicians+and+laboratorians&publication_year=2013" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Testing+for+HCV+infection%3a+an+update+of+guidance+for+clinicians+and+laboratorians&publication_year=2013');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0010" class="article-references__item js-article-reference">10. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1‐13, 15. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-34"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/12585742" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/12585742');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+laboratory+testing+and+result+reporting+of+antibody+to+hepatitis+C+virus.+Centers+for+Disease+Control+and+Prevention&publication_year=2003&author=MJ+Alter&author=WL+Kuhnert&author=L.+Finelli" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Guidelines+for+laboratory+testing+and+result+reporting+of+antibody+to+hepatitis+C+virus.+Centers+for+Disease+Control+and+Prevention&publication_year=2003&author=MJ+Alter&author=WL+Kuhnert&author=L.+Finelli');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0011" class="article-references__item js-article-reference">11. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods 2011;172:27‐31. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-34"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/21182871" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/21182871');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.jviromet.2010.12.009" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.jviromet.2010.12.009');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+new%2c+rapid+test+for+detecting+HCV+infection%2c+suitable+for+use+with+blood+or+oral+fluid&publication_year=2011&author=SR+Lee&author=KW+Kardos&author=E+Schiff&author=CA+Berne&author=K+Mounzer&author=AT+Banks" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+new%2c+rapid+test+for+detecting+HCV+infection%2c+suitable+for+use+with+blood+or+oral+fluid&publication_year=2011&author=SR+Lee&author=KW+Kardos&author=E+Schiff&author=CA+Berne&author=K+Mounzer&author=AT+Banks');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0012" class="article-references__item js-article-reference">12. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36:S65‐S73. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-34"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200211002-00008.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200211002-00008.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/12407578" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/12407578');return false">PubMed</a> | <a href="https://doi.org/10.1053%2Fjhep.2002.36815" onclick="javascript:window.open('https://doi.org/10.1053%2Fjhep.2002.36815');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Use+and+interpretation+of+virological+tests+for+hepatitis+C&publication_year=2002&author=JM.+Pawlotsky" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Use+and+interpretation+of+virological+tests+for+hepatitis+C&publication_year=2002&author=JM.+Pawlotsky');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0013" class="article-references__item js-article-reference">13. Kidney Disease: Improving Global Outcomes (KDIGO) . KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;S1‐S99. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-34"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/18382440" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/18382440');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=KDIGO+clinical+practice+guidelines+for+the+prevention%2c+diagnosis%2c+evaluation%2c+and+treatment+of+hepatitis+C+in+chronic+kidney+disease&publication_year=2008" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=KDIGO+clinical+practice+guidelines+for+the+prevention%2c+diagnosis%2c+evaluation%2c+and+treatment+of+hepatitis+C+in+chronic+kidney+disease&publication_year=2008');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0014" class="article-references__item js-article-reference">14. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:e1‐e34. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-37"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01451458-201401010-00038.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01451458-201401010-00038.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24235263" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24235263');return false">PubMed</a> | <a href="https://doi.org/10.1093%2Fcid%2Fcit665" onclick="javascript:window.open('https://doi.org/10.1093%2Fcid%2Fcit665');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Primary+care+guidelines+for+the+management+of+persons+infected+with+HIV%3a+2013+update+by+the+HIV+medicine+association+of+the+Infectious+Diseases+Society+of+America&publication_year=2014&author=JA+Aberg&author=JE+Gallant&author=KG+Ghanem&author=P+Emmanuel&author=BS+Zingman&author=MA.+Horberg" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Primary+care+guidelines+for+the+management+of+persons+infected+with+HIV%3a+2013+update+by+the+HIV+medicine+association+of+the+Infectious+Diseases+Society+of+America&publication_year=2014&author=JA+Aberg&author=JE+Gallant&author=KG+Ghanem&author=P+Emmanuel&author=BS+Zingman&author=MA.+Horberg');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0015" class="article-references__item js-article-reference">15. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost‐effective screening for acute hepatitis C virus infection in HIV‐infected men who have sex with men. Clin Infect Dis 2012;55:279‐290. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-37"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01451458-201207150-00022.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01451458-201207150-00022.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/22491339" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/22491339');return false">PubMed</a> | <a href="https://doi.org/10.1093%2Fcid%2Fcis382" onclick="javascript:window.open('https://doi.org/10.1093%2Fcid%2Fcis382');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Cost%e2%80%90effective+screening+for+acute+hepatitis+C+virus+infection+in+HIV%e2%80%90infected+men+who+have+sex+with+men&publication_year=2012&author=BP+Linas&author=AY+Wong&author=BR+Schackman&author=AY+Kim&author=KA.+Freedberg" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Cost%e2%80%90effective+screening+for+acute+hepatitis+C+virus+infection+in+HIV%e2%80%90infected+men+who+have+sex+with+men&publication_year=2012&author=BP+Linas&author=AY+Wong&author=BR+Schackman&author=AY+Kim&author=KA.+Freedberg');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0016" class="article-references__item js-article-reference">16. Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012;55:1408‐1416. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-37"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01451458-201211150-00027.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01451458-201211150-00027.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/22893583" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/22893583');return false">PubMed</a> | <a href="https://doi.org/10.1093%2Fcid%2Fcis694" onclick="javascript:window.open('https://doi.org/10.1093%2Fcid%2Fcis694');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Hepatitis+C+virus+infections+in+the+Swiss+HIV+Cohort+Study%3a+a+rapidly+evolving+epidemic&publication_year=2012&author=G+Wandeler&author=T+Gsponer&author=A+Bregenzer&author=HF+G%c3%bcnthard&author=O+Clerc&author=A+Calmy" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Hepatitis+C+virus+infections+in+the+Swiss+HIV+Cohort+Study%3a+a+rapidly+evolving+epidemic&publication_year=2012&author=G+Wandeler&author=T+Gsponer&author=A+Bregenzer&author=HF+G%c3%bcnthard&author=O+Clerc&author=A+Calmy');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0017" class="article-references__item js-article-reference">17. Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984‐2011. Clin Infect Dis 2013;57:77‐84. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-37"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01451458-201307010-00013.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01451458-201307010-00013.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23532480" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23532480');return false">PubMed</a> | <a href="https://doi.org/10.1093%2Fcid%2Fcit197" onclick="javascript:window.open('https://doi.org/10.1093%2Fcid%2Fcit197');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Incident+hepatitis+C+virus+infection+in+men+who+have+sex+with+men%3a+a+prospective+cohort+analysis%2c+1984%e2%80%902011&publication_year=2013&author=MD+Witt&author=EC+Seaberg&author=A+Darilay&author=S+Young&author=S+Badri&author=CR+Rinaldo" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Incident+hepatitis+C+virus+infection+in+men+who+have+sex+with+men%3a+a+prospective+cohort+analysis%2c+1984%e2%80%902011&publication_year=2013&author=MD+Witt&author=EC+Seaberg&author=A+Darilay&author=S+Young&author=S+Badri&author=CR+Rinaldo');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0018" class="article-references__item js-article-reference">18. Bravo MJ, Vallejo F, Barrio G, Brugal MT, Molist G, Pulido J, et al. HCV seroconversion among never‐injecting heroin users at baseline: no predictors identified other than starting injection. Int J Drug Policy 2012;23:415‐419. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-37"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22421554" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/22421554');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.drugpo.2012.02.002" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.drugpo.2012.02.002');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=HCV+seroconversion+among+never%e2%80%90injecting+heroin+users+at+baseline%3a+no+predictors+identified+other+than+starting+injection&publication_year=2012&author=MJ+Bravo&author=F+Vallejo&author=G+Barrio&author=MT+Brugal&author=G+Molist&author=J+Pulido" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=HCV+seroconversion+among+never%e2%80%90injecting+heroin+users+at+baseline%3a+no+predictors+identified+other+than+starting+injection&publication_year=2012&author=MJ+Bravo&author=F+Vallejo&author=G+Barrio&author=MT+Brugal&author=G+Molist&author=J+Pulido');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0019" class="article-references__item js-article-reference">19. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982‐2006. Arch Intern Med 2011;171:242‐248. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-37"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000779-201102140-00014.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000779-201102140-00014.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/21325115" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/21325115');return false">PubMed</a> | <a href="https://doi.org/10.1001%2Farchinternmed.2010.511" onclick="javascript:window.open('https://doi.org/10.1001%2Farchinternmed.2010.511');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Incidence+and+transmission+patterns+of+acute+hepatitis+C+in+the+United+States%2c+1982%e2%80%902006&publication_year=2011&author=IT+Williams&author=BP+Bell&author=W+Kuhnert&author=MJ.+Alter" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Incidence+and+transmission+patterns+of+acute+hepatitis+C+in+the+United+States%2c+1982%e2%80%902006&publication_year=2011&author=IT+Williams&author=BP+Bell&author=W+Kuhnert&author=MJ.+Alter');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0020" class="article-references__item js-article-reference">20. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825‐832. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00005531-199703220-00010.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00005531-199703220-00010.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/9121257" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/9121257');return false">PubMed</a> | <a href="https://doi.org/10.1016%2FS0140-6736%2896%2907642-8" onclick="javascript:window.open('https://doi.org/10.1016%2FS0140-6736%2896%2907642-8');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Natural+history+of+liver+fibrosis+progression+in+patients+with+chronic+hepatitis+C.+The+OBSVIRC%2c+METAVIR%2c+CLINIVIR%2c+and+DOSVIRC+groups&publication_year=1997&author=T+Poynard&author=P+Bedossa&author=P.+Opolon" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Natural+history+of+liver+fibrosis+progression+in+patients+with+chronic+hepatitis+C.+The+OBSVIRC%2c+METAVIR%2c+CLINIVIR%2c+and+DOSVIRC+groups&publication_year=1997&author=T+Poynard&author=P+Bedossa&author=P.+Opolon');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0021" class="article-references__item js-article-reference">21. Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, et al. The relationship of acute transfusion‐associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120‐124. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-200101160-00012.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-200101160-00012.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/11177315" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/11177315');return false">PubMed</a> | <a href="https://doi.org/10.7326%2F0003-4819-134-2-200101160-00012" onclick="javascript:window.open('https://doi.org/10.7326%2F0003-4819-134-2-200101160-00012');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=The+relationship+of+acute+transfusion%e2%80%90associated+hepatitis+to+the+development+of+cirrhosis+in+the+presence+of+alcohol+abuse&publication_year=2001&author=DR+Harris&author=R+Gonin&author=HJ+Alter&author=EC+Wright&author=ZJ+Buskell&author=FB+Hollinger" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=The+relationship+of+acute+transfusion%e2%80%90associated+hepatitis+to+the+development+of+cirrhosis+in+the+presence+of+alcohol+abuse&publication_year=2001&author=DR+Harris&author=R+Gonin&author=HJ+Alter&author=EC+Wright&author=ZJ+Buskell&author=FB+Hollinger');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0022" class="article-references__item js-article-reference">22. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805‐809. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-199809000-00030.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-199809000-00030.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/9731576" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/9731576');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.510280330" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.510280330');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+alcohol+on+the+histological+and+clinical+progression+of+hepatitis+C+infection&publication_year=1998&author=TE+Wiley&author=M+McCarthy&author=L+Breidi&author=M+McCarthy&author=TJ.+Layden" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Impact+of+alcohol+on+the+histological+and+clinical+progression+of+hepatitis+C+infection&publication_year=1998&author=TE+Wiley&author=M+McCarthy&author=L+Breidi&author=M+McCarthy&author=TJ.+Layden');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0023" class="article-references__item js-article-reference">23. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914‐919. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-199804000-00004.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-199804000-00004.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/9537428" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/9537428');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.510270404" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.510270404');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Independent+and+combined+action+of+hepatitis+C+virus+infection+and+alcohol+consumption+on+the+risk+of+symptomatic+liver+cirrhosis&publication_year=1998&author=G+Corrao&author=S.+Arico" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Independent+and+combined+action+of+hepatitis+C+virus+infection+and+alcohol+consumption+on+the+risk+of+symptomatic+liver+cirrhosis&publication_year=1998&author=G+Corrao&author=S.+Arico');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0024" class="article-references__item js-article-reference">24. Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Crocè LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999;44:874‐880. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00003970-199906000-00024.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00003970-199906000-00024.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/10323892" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/10323892');return false">PubMed</a> | <a href="https://doi.org/10.1136%2Fgut.44.6.874" onclick="javascript:window.open('https://doi.org/10.1136%2Fgut.44.6.874');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Clinical+course+and+risk+factors+of+hepatitis+C+virus+related+liver+disease+in+the+general+population%3a+report+from+the+Dionysos+study&publication_year=1999&author=S+Bellentani&author=G+Pozzato&author=G+Saccoccio&author=M+Crovatto&author=LS+Croc%c3%a8&author=L+Mazzoran" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Clinical+course+and+risk+factors+of+hepatitis+C+virus+related+liver+disease+in+the+general+population%3a+report+from+the+Dionysos+study&publication_year=1999&author=S+Bellentani&author=G+Pozzato&author=G+Saccoccio&author=M+Crovatto&author=LS+Croc%c3%a8&author=L+Mazzoran');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0025" class="article-references__item js-article-reference">25. Noda K, Yoshihara H, Suzuki K, Yamada Y, Kasahara A, Hayashi N, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res 1996;20:95A‐100A. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/8659701" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/8659701');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Progression+of+type+C+chronic+hepatitis+to+liver+cirrhosis+and+hepatocellular+carcinoma%e2%80%94its+relationship+to+alcohol+drinking+and+the+age+of+transfusion&publication_year=1996&author=K+Noda&author=H+Yoshihara&author=K+Suzuki&author=Y+Yamada&author=A+Kasahara&author=N+Hayashi" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Progression+of+type+C+chronic+hepatitis+to+liver+cirrhosis+and+hepatocellular+carcinoma%e2%80%94its+relationship+to+alcohol+drinking+and+the+age+of+transfusion&publication_year=1996&author=K+Noda&author=H+Yoshihara&author=K+Suzuki&author=Y+Yamada&author=A+Kasahara&author=N+Hayashi');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0026" class="article-references__item js-article-reference">26. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis 2004;24:305‐315. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00007553-200424030-00008.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00007553-200424030-00008.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/15349807" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/15349807');return false">PubMed</a> | <a href="https://doi.org/10.1055%2Fs-2004-832942" onclick="javascript:window.open('https://doi.org/10.1055%2Fs-2004-832942');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Alcohol+and+hepatitis+C&publication_year=2004&author=K+Safdar&author=ER.+Schiff" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Alcohol+and+hepatitis+C&publication_year=2004&author=K+Safdar&author=ER.+Schiff');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0027" class="article-references__item js-article-reference">27. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV‐infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta‐analysis. AIDS 2008;22:1979‐1991. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00002030-200810010-00010.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00002030-200810010-00010.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/18784461" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/18784461');return false">PubMed</a> | <a href="https://doi.org/10.1097%2FQAD.0b013e32830e6d51" onclick="javascript:window.open('https://doi.org/10.1097%2FQAD.0b013e32830e6d51');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Natural+history+of+hepatitis+C+virus+infection+in+HIV%e2%80%90infected+individuals+and+the+impact+of+HIV+in+the+era+of+highly+active+antiretroviral+therapy%3a+a+meta%e2%80%90analysis&publication_year=2008&author=HH+Thein&author=Q+Yi&author=GJ+Dore&author=MD.+Krahn" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Natural+history+of+hepatitis+C+virus+infection+in+HIV%e2%80%90infected+individuals+and+the+impact+of+HIV+in+the+era+of+highly+active+antiretroviral+therapy%3a+a+meta%e2%80%90analysis&publication_year=2008&author=HH+Thein&author=Q+Yi&author=GJ+Dore&author=MD.+Krahn');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0028" class="article-references__item js-article-reference">28. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost‐Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27‐33. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00004843-199801000-00004.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00004843-199801000-00004.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/9537860" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/9537860');return false">PubMed</a> | <a href="https://doi.org/10.1016%2FS0168-8278%2898%2980198-0" onclick="javascript:window.open('https://doi.org/10.1016%2FS0168-8278%2898%2980198-0');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Characteristics+of+patients+with+dual+infection+by+hepatitis+B+and+C+viruses&publication_year=1998&author=JP+Zarski&author=B+Bohn&author=A+Bastie&author=JM+Pawlotsky&author=M+Baud&author=F+Bost%e2%80%90Bezeaux" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Characteristics+of+patients+with+dual+infection+by+hepatitis+B+and+C+viruses&publication_year=1998&author=JP+Zarski&author=B+Bohn&author=A+Bastie&author=JM+Pawlotsky&author=M+Baud&author=F+Bost%e2%80%90Bezeaux');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0029" class="article-references__item js-article-reference">29. Moyer VA. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013;159:51‐60. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-201307020-00008.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-201307020-00008.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23698354" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23698354');return false">PubMed</a> | <a href="https://doi.org/10.7326%2F0003-4819-159-1-201307020-00645" onclick="javascript:window.open('https://doi.org/10.7326%2F0003-4819-159-1-201307020-00645');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Screening+for+HIV%3a+U.S.+Preventive+Services+Task+Force+Recommendation+Statement&publication_year=2013&author=VA.+Moyer" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Screening+for+HIV%3a+U.S.+Preventive+Services+Task+Force+Recommendation+Statement&publication_year=2013&author=VA.+Moyer');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0030" class="article-references__item js-article-reference">30. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A; Centers for Disease Control and Prevention . Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1‐20. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-40"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/18802412" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/18802412');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Recommendations+for+identification+and+public+health+management+of+persons+with+chronic+hepatitis+B+virus+infection&publication_year=2008&author=CM+Weinbaum&author=I+Williams&author=EE+Mast&author=SA+Wang&author=L+Finelli&author=A+Wasley" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Recommendations+for+identification+and+public+health+management+of+persons+with+chronic+hepatitis+B+virus+infection&publication_year=2008&author=CM+Weinbaum&author=I+Williams&author=EE+Mast&author=SA+Wang&author=L+Finelli&author=A+Wasley');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0031" class="article-references__item js-article-reference">31. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215‐1219. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-41"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-199904000-00030.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-199904000-00030.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/10094967" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/10094967');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.510290401" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.510290401');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Fibrosis+in+chronic+hepatitis+C+correlates+significantly+with+body+mass+index+and+steatosis&publication_year=1999&author=LF+Hourigan&author=GA+Macdonald&author=D+Purdie&author=VH+Whitehall&author=C+Shorthouse&author=A+Clouston" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Fibrosis+in+chronic+hepatitis+C+correlates+significantly+with+body+mass+index+and+steatosis&publication_year=1999&author=LF+Hourigan&author=GA+Macdonald&author=D+Purdie&author=VH+Whitehall&author=C+Shorthouse&author=A+Clouston');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0032" class="article-references__item js-article-reference">32. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C–related fibrosis progression. Am J Gastroenterol 2002;97:2408‐2414. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-41"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000434-200209000-00046.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000434-200209000-00046.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/12358265" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/12358265');return false">PubMed</a> | <a href="https://doi.org/10.1111%2Fj.1572-0241.2002.05995.x" onclick="javascript:window.open('https://doi.org/10.1111%2Fj.1572-0241.2002.05995.x');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Contribution+of+obesity+to+hepatitis+C%e2%80%93related+fibrosis+progression&publication_year=2002&author=V+Ortiz&author=M+Berenguer&author=JM+Rayon&author=D+Carrasco&author=J.+Berenguer" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Contribution+of+obesity+to+hepatitis+C%e2%80%93related+fibrosis+progression&publication_year=2002&author=V+Ortiz&author=M+Berenguer&author=JM+Rayon&author=D+Carrasco&author=J.+Berenguer');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0033" class="article-references__item js-article-reference">33. Musso G, Gambino R, Cassader M, Pagano G. A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79‐104. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-41"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201007000-00011.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201007000-00011.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/20578268" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/20578268');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.23623" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.23623');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=A+meta%e2%80%90analysis+of+randomized+trials+for+the+treatment+of+nonalcoholic+fatty+liver+disease&publication_year=2010&author=G+Musso&author=R+Gambino&author=M+Cassader&author=G.+Pagano" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=A+meta%e2%80%90analysis+of+randomized+trials+for+the+treatment+of+nonalcoholic+fatty+liver+disease&publication_year=2010&author=G+Musso&author=R+Gambino&author=M+Cassader&author=G.+Pagano');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0034" class="article-references__item js-article-reference">34. Shaw K, Gennat H, O'Rourke P, Del MC. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006;CD003817. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-41"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/17054187" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/17054187');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Exercise+for+overweight+or+obesity&publication_year=2006&author=K+Shaw&author=H+Gennat&author=P+O%27Rourke&author=MC.+Del" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Exercise+for+overweight+or+obesity&publication_year=2006&author=K+Shaw&author=H+Gennat&author=P+O%27Rourke&author=MC.+Del');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0035" class="article-references__item js-article-reference">35. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368:1859‐1861. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-44"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201305160-00002.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201305160-00002.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23675657" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23675657');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMp1302973" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMp1302973');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Hepatitis+C+in+the+United+States&publication_year=2013&author=SD+Holmberg&author=PR+Spradling&author=AC+Moorman&author=MM.+Denniston" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Hepatitis+C+in+the+United+States&publication_year=2013&author=SD+Holmberg&author=PR+Spradling&author=AC+Moorman&author=MM.+Denniston');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0036" class="article-references__item js-article-reference">36. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005;20:754‐758. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-44"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00005125-200508000-00015.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00005125-200508000-00015.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/16050887" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/16050887');return false">PubMed</a> | <a href="https://doi.org/10.1111%2Fj.1525-1497.2005.0161.x" onclick="javascript:window.open('https://doi.org/10.1111%2Fj.1525-1497.2005.0161.x');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Barriers+to+the+treatment+of+hepatitis+C.+Patient%2c+provider%2c+and+system+factors&publication_year=2005&author=JA+Morrill&author=M+Shrestha&author=RW.+Grant" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Barriers+to+the+treatment+of+hepatitis+C.+Patient%2c+provider%2c+and+system+factors&publication_year=2005&author=JA+Morrill&author=M+Shrestha&author=RW.+Grant');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0037" class="article-references__item js-article-reference">37. Reilley B, Leston J, Redd JT, Geiger R. Lack of access to treatment as a barrier to HCV screening: a facility‐based assessment in the Indian health service. J Public Health Manag Pract 2014;20:420‐423. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-44"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00124784-201407000-00010.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00124784-201407000-00010.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23838897" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23838897');return false">PubMed</a> | <a href="https://doi.org/10.1097%2FPHH.0b013e31829e05b8" onclick="javascript:window.open('https://doi.org/10.1097%2FPHH.0b013e31829e05b8');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Lack+of+access+to+treatment+as+a+barrier+to+HCV+screening%3a+a+facility%e2%80%90based+assessment+in+the+Indian+health+service&publication_year=2014&author=B+Reilley&author=J+Leston&author=JT+Redd&author=R.+Geiger" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Lack+of+access+to+treatment+as+a+barrier+to+HCV+screening%3a+a+facility%e2%80%90based+assessment+in+the+Indian+health+service&publication_year=2014&author=B+Reilley&author=J+Leston&author=JT+Redd&author=R.+Geiger');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0038" class="article-references__item js-article-reference">38. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013;57:1325‐1332. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-44"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201304000-00007.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201304000-00007.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23315914" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23315914');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.26246" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.26246');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=A+global+view+of+hepatitis+C%3a+physician+knowledge%2c+opinions%2c+and+perceived+barriers+to+care&publication_year=2013&author=CE+McGowan&author=A+Monis&author=BR+Bacon&author=J+Mallolas&author=FL+Goncales&author=I+Goulis" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=A+global+view+of+hepatitis+C%3a+physician+knowledge%2c+opinions%2c+and+perceived+barriers+to+care&publication_year=2013&author=CE+McGowan&author=A+Monis&author=BR+Bacon&author=J+Mallolas&author=FL+Goncales&author=I+Goulis');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0039" class="article-references__item js-article-reference">39. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa‐2a and ribavirin. Gastroenterology 2010;139:1593‐1601. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-47"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20637202" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/20637202');return false">PubMed</a> | <a href="https://doi.org/10.1053%2Fj.gastro.2010.07.009" onclick="javascript:window.open('https://doi.org/10.1053%2Fj.gastro.2010.07.009');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=A+sustained+virologic+response+is+durable+in+patients+with+chronic+hepatitis+C+treated+with+peginterferon+alfa%e2%80%902a+and+ribavirin&publication_year=2010&author=MG+Swain&author=MY+Lai&author=ML+Shiffman&author=WG+Cooksley&author=S+Zeuzem&author=DT+Dieterich" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=A+sustained+virologic+response+is+durable+in+patients+with+chronic+hepatitis+C+treated+with+peginterferon+alfa%e2%80%902a+and+ribavirin&publication_year=2010&author=MG+Swain&author=MY+Lai&author=ML+Shiffman&author=WG+Cooksley&author=S+Zeuzem&author=DT+Dieterich');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0040" class="article-references__item js-article-reference">40. Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, et al. Long‐term clearance of hepatitis C virus following interferon alpha‐2b or peginterferon alpha‐2b, alone or in combination with ribavirin. J Viral Hepat 2013;20:524‐529. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-47"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/23808990" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23808990');return false">PubMed</a> | <a href="https://doi.org/10.1111%2Fjvh.12074" onclick="javascript:window.open('https://doi.org/10.1111%2Fjvh.12074');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Long%e2%80%90term+clearance+of+hepatitis+C+virus+following+interferon+alpha%e2%80%902b+or+peginterferon+alpha%e2%80%902b%2c+alone+or+in+combination+with+ribavirin&publication_year=2013&author=MP+Manns&author=PJ+Pockros&author=G+Norkrans&author=CI+Smith&author=TR+Morgan&author=D+H%c3%a4ussinger" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Long%e2%80%90term+clearance+of+hepatitis+C+virus+following+interferon+alpha%e2%80%902b+or+peginterferon+alpha%e2%80%902b%2c+alone+or+in+combination+with+ribavirin&publication_year=2013&author=MP+Manns&author=PJ+Pockros&author=G+Norkrans&author=CI+Smith&author=TR+Morgan&author=D+H%c3%a4ussinger');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0041" class="article-references__item js-article-reference">41. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa‐2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303‐1313. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-47"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/11984517" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/11984517');return false">PubMed</a> | <a href="https://doi.org/10.1053%2Fgast.2002.33023" onclick="javascript:window.open('https://doi.org/10.1053%2Fgast.2002.33023');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+pegylated+interferon+alfa%e2%80%902b+and+ribavirin+on+liver+fibrosis+in+patients+with+chronic+hepatitis+C&publication_year=2002&author=T+Poynard&author=J+McHutchison&author=M+Manns&author=C+Trepo&author=K+Lindsay&author=Z+Goodman" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Impact+of+pegylated+interferon+alfa%e2%80%902b+and+ribavirin+on+liver+fibrosis+in+patients+with+chronic+hepatitis+C&publication_year=2002&author=T+Poynard&author=J+McHutchison&author=M+Manns&author=C+Trepo&author=K+Lindsay&author=Z+Goodman');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0042" class="article-references__item js-article-reference">42. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck‐Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta‐analysis of observational studies. Ann Intern Med 2013;158:329‐337. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-47"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-201303050-00005.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-201303050-00005.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23460056" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23460056');return false">PubMed</a> | <a href="https://doi.org/10.7326%2F0003-4819-158-5-201303050-00005" onclick="javascript:window.open('https://doi.org/10.7326%2F0003-4819-158-5-201303050-00005');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Eradication+of+hepatitis+C+virus+infection+and+the+development+of+hepatocellular+carcinoma%3a+a+meta%e2%80%90analysis+of+observational+studies&publication_year=2013&author=RL+Morgan&author=B+Baack&author=BD+Smith&author=A+Yartel&author=M+Pitasi&author=Y.+Falck%e2%80%90Ytter" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Eradication+of+hepatitis+C+virus+infection+and+the+development+of+hepatocellular+carcinoma%3a+a+meta%e2%80%90analysis+of+observational+studies&publication_year=2013&author=RL+Morgan&author=B+Baack&author=BD+Smith&author=A+Yartel&author=M+Pitasi&author=Y.+Falck%e2%80%90Ytter');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0043" class="article-references__item js-article-reference">43. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all‐cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584‐2593. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-47"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00005407-201212260-00029.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00005407-201212260-00029.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23268517" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23268517');return false">PubMed</a> | <a href="https://doi.org/10.1001%2Fjama.2012.144878" onclick="javascript:window.open('https://doi.org/10.1001%2Fjama.2012.144878');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Association+between+sustained+virological+response+and+all%e2%80%90cause+mortality+among+patients+with+chronic+hepatitis+C+and+advanced+hepatic+fibrosis&publication_year=2012&author=AJ+van+der+Meer&author=BJ+Veldt&author=JJ+Feld&author=H+Wedemeyer&author=JF+Dufour&author=F+Lammert" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Association+between+sustained+virological+response+and+all%e2%80%90cause+mortality+among+patients+with+chronic+hepatitis+C+and+advanced+hepatic+fibrosis&publication_year=2012&author=AJ+van+der+Meer&author=BJ+Veldt&author=JJ+Feld&author=H+Wedemeyer&author=JF+Dufour&author=F+Lammert');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0044" class="article-references__item js-article-reference">44. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hoffmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677‐684. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-47"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-200711200-00003.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-200711200-00003.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/18025443" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/18025443');return false">PubMed</a> | <a href="https://doi.org/10.7326%2F0003-4819-147-10-200711200-00003" onclick="javascript:window.open('https://doi.org/10.7326%2F0003-4819-147-10-200711200-00003');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sustained+virologic+response+and+clinical+outcomes+in+patients+with+chronic+hepatitis+C+and+advanced+fibrosis&publication_year=2007&author=BJ+Veldt&author=EJ+Heathcote&author=H+Wedemeyer&author=J+Reichen&author=WP+Hoffmann&author=S+Zeuzem" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sustained+virologic+response+and+clinical+outcomes+in+patients+with+chronic+hepatitis+C+and+advanced+fibrosis&publication_year=2007&author=BJ+Veldt&author=EJ+Heathcote&author=H+Wedemeyer&author=J+Reichen&author=WP+Hoffmann&author=S+Zeuzem');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0045" class="article-references__item js-article-reference">45. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV‐associated mixed cryoglobulinemia: meta‐analysis of clinical studies. J Med Virol 2013;85:1019‐1027. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01445456-201306000-00011.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01445456-201306000-00011.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23588727" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23588727');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fjmv.23562" onclick="javascript:window.open('https://doi.org/10.1002%2Fjmv.23562');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Antiviral+therapy+of+symptomatic+HCV%e2%80%90associated+mixed+cryoglobulinemia%3a+meta%e2%80%90analysis+of+clinical+studies&publication_year=2013&author=F+Fabrizi&author=V+Dixit&author=P.+Messa" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Antiviral+therapy+of+symptomatic+HCV%e2%80%90associated+mixed+cryoglobulinemia%3a+meta%e2%80%90analysis+of+clinical+studies&publication_year=2013&author=F+Fabrizi&author=V+Dixit&author=P.+Messa');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0046" class="article-references__item js-article-reference">46. Landau DA, Scerra S, Sene D, Resche‐Rigon M, Saadoun D, Cacoub P. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus–related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 2010;37:615‐621. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20110523" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/20110523');return false">PubMed</a> | <a href="https://doi.org/10.3899%2Fjrheum.090790" onclick="javascript:window.open('https://doi.org/10.3899%2Fjrheum.090790');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Causes+and+predictive+factors+of+mortality+in+a+cohort+of+patients+with+hepatitis+C+virus%e2%80%93related+cryoglobulinemic+vasculitis+treated+with+antiviral+therapy&publication_year=2010&author=DA+Landau&author=S+Scerra&author=D+Sene&author=M+Resche%e2%80%90Rigon&author=D+Saadoun&author=P.+Cacoub" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Causes+and+predictive+factors+of+mortality+in+a+cohort+of+patients+with+hepatitis+C+virus%e2%80%93related+cryoglobulinemic+vasculitis+treated+with+antiviral+therapy&publication_year=2010&author=DA+Landau&author=S+Scerra&author=D+Sene&author=M+Resche%e2%80%90Rigon&author=D+Saadoun&author=P.+Cacoub');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0047" class="article-references__item js-article-reference">47. Gisbert JP, Garcia‐Buey L, Pajares JM, Moreno‐Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005;21:653‐662. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00001716-200503060-00003.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00001716-200503060-00003.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/15771751" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/15771751');return false">PubMed</a> | <a href="https://doi.org/10.1111%2Fj.1365-2036.2005.02395.x" onclick="javascript:window.open('https://doi.org/10.1111%2Fj.1365-2036.2005.02395.x');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Systematic+review%3a+regression+of+lymphoproliferative+disorders+after+treatment+for+hepatitis+C+infection&publication_year=2005&author=JP+Gisbert&author=L+Garcia%e2%80%90Buey&author=JM+Pajares&author=R.+Moreno%e2%80%90Otero" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Systematic+review%3a+regression+of+lymphoproliferative+disorders+after+treatment+for+hepatitis+C+infection&publication_year=2005&author=JP+Gisbert&author=L+Garcia%e2%80%90Buey&author=JM+Pajares&author=R.+Moreno%e2%80%90Otero');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0048" class="article-references__item js-article-reference">48. Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012;51:2745‐2747. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/23037466" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23037466');return false">PubMed</a> | <a href="https://doi.org/10.2169%2Finternalmedicine.51.8404" onclick="javascript:window.open('https://doi.org/10.2169%2Finternalmedicine.51.8404');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Regression+of+Hodgkin+lymphoma+in+response+to+antiviral+therapy+for+hepatitis+C+virus+infection&publication_year=2012&author=K+Takahashi&author=N+Nishida&author=H+Kawabata&author=H+Haga&author=T.+Chiba" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Regression+of+Hodgkin+lymphoma+in+response+to+antiviral+therapy+for+hepatitis+C+virus+infection&publication_year=2012&author=K+Takahashi&author=N+Nishida&author=H+Kawabata&author=H+Haga&author=T.+Chiba');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0049" class="article-references__item js-article-reference">49. Svoboda J, Andreadis C, Downs LH, Miller WT Jr, Tsai DE, Schuster SJ. Regression of advanced non‐splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma 2005;46:1365‐1368. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/16109616" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/16109616');return false">PubMed</a> | <a href="https://doi.org/10.1080%2F104281905001028289" onclick="javascript:window.open('https://doi.org/10.1080%2F104281905001028289');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Regression+of+advanced+non%e2%80%90splenic+marginal+zone+lymphoma+after+treatment+of+hepatitis+C+virus+infection&publication_year=2005&author=J+Svoboda&author=C+Andreadis&author=LH+Downs&author=WT+Miller&author=DE+Tsai&author=SJ.+Schuster" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Regression+of+advanced+non%e2%80%90splenic+marginal+zone+lymphoma+after+treatment+of+hepatitis+C+virus+infection&publication_year=2005&author=J+Svoboda&author=C+Andreadis&author=LH+Downs&author=WT+Miller&author=DE+Tsai&author=SJ.+Schuster');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0050" class="article-references__item js-article-reference">50. Mazzaro C, Little D, Pozzato G. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med 2002;347:2168‐2170. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-200212260-00019.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-200212260-00019.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/12501232" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/12501232');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJM200212263472614" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJM200212263472614');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Regression+of+splenic+lymphoma+after+treatment+of+hepatitis+C+virus+infection&publication_year=2002&author=C+Mazzaro&author=D+Little&author=G.+Pozzato" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Regression+of+splenic+lymphoma+after+treatment+of+hepatitis+C+virus+infection&publication_year=2002&author=C+Mazzaro&author=D+Little&author=G.+Pozzato');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0051" class="article-references__item js-article-reference">51. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache‐Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89‐94. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-200207110-00003.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-200207110-00003.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/12110736" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/12110736');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa013376" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa013376');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Regression+of+splenic+lymphoma+with+villous+lymphocytes+after+treatment+of+hepatitis+C+virus+infection&publication_year=2002&author=O+Hermine&author=F+Lefrere&author=JP+Bronowicki&author=X+Mariette&author=K+Jondeau&author=V+Eclache%e2%80%90Saudreau" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Regression+of+splenic+lymphoma+with+villous+lymphocytes+after+treatment+of+hepatitis+C+virus+infection&publication_year=2002&author=O+Hermine&author=F+Lefrere&author=JP+Bronowicki&author=X+Mariette&author=K+Jondeau&author=V+Eclache%e2%80%90Saudreau');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0052" class="article-references__item js-article-reference">52. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all‐cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509‐516. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01817247-201106000-00024.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01817247-201106000-00024.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/21397729" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/21397729');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.cgh.2011.03.004" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.cgh.2011.03.004');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=A+sustained+virologic+response+reduces+risk+of+all%e2%80%90cause+mortality+in+patients+with+hepatitis+C&publication_year=2011&author=LI+Backus&author=DB+Boothroyd&author=BR+Phillips&author=P+Belperio&author=J+Halloran&author=LA.+Mole" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=A+sustained+virologic+response+reduces+risk+of+all%e2%80%90cause+mortality+in+patients+with+hepatitis+C&publication_year=2011&author=LI+Backus&author=DB+Boothroyd&author=BR+Phillips&author=P+Belperio&author=J+Halloran&author=LA.+Mole');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0053" class="article-references__item js-article-reference">53. Neary MP, Cort S, Bayliss MS, Ware JE Jr. Sustained virologic response is associated with improved health‐related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999;19:77‐85. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/10349695" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/10349695');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sustained+virologic+response+is+associated+with+improved+health%e2%80%90related+quality+of+life+in+relapsed+chronic+hepatitis+C+patients&publication_year=1999&author=MP+Neary&author=S+Cort&author=MS+Bayliss&author=JE+Ware" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sustained+virologic+response+is+associated+with+improved+health%e2%80%90related+quality+of+life+in+relapsed+chronic+hepatitis+C+patients&publication_year=1999&author=MP+Neary&author=S+Cort&author=MS+Bayliss&author=JE+Ware');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0054" class="article-references__item js-article-reference">54. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Effects of sofosbuvir‐based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014;12:1349‐1359. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-48"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/24316172" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24316172');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.cgh.2013.11.032" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.cgh.2013.11.032');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+sofosbuvir%e2%80%90based+treatment%2c+with+and+without+interferon%2c+on+outcome+and+productivity+of+patients+with+chronic+hepatitis+C&publication_year=2014&author=ZM+Younossi&author=M+Stepanova&author=L+Henry&author=E+Gane&author=IM+Jacobson&author=E+Lawitz" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Effects+of+sofosbuvir%e2%80%90based+treatment%2c+with+and+without+interferon%2c+on+outcome+and+productivity+of+patients+with+chronic+hepatitis+C&publication_year=2014&author=ZM+Younossi&author=M+Stepanova&author=L+Henry&author=E+Gane&author=IM+Jacobson&author=E+Lawitz');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0055" class="article-references__item js-article-reference">55. Jezequel C, Bardou‐Jacquet E, Desille Y, Renard I, Lainé F, Lelan C, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 year follow‐up [Abstract]. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22‐26, 2015; Vienna, Austria. Abstract PO709. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-50"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=C+Jezequel&author=E+Bardou%e2%80%90Jacquet&author=Y+Desille&author=I+Renard&author=F+Lain%c3%a9&author=C+Lelan" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=C+Jezequel&author=E+Bardou%e2%80%90Jacquet&author=Y+Desille&author=I+Renard&author=F+Lain%c3%a9&author=C+Lelan');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0056" class="article-references__item js-article-reference">56. Øvrehus ALH, Blach S, Christensen PB, Gerstoft J, Weis N, Krarup H, et al. Impact of prioritizing treatment in a high resource setting—minimizing the burden of HCV related disease in 15 years [Abstract]. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22‐26, 2015; Vienna, Austria. Abstract PO714. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-50"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=ALH+%c3%98vrehus&author=S+Blach&author=PB+Christensen&author=J+Gerstoft&author=N+Weis&author=H+Krarup" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=ALH+%c3%98vrehus&author=S+Blach&author=PB+Christensen&author=J+Gerstoft&author=N+Weis&author=H+Krarup');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0057" class="article-references__item js-article-reference">57. Zahnd C, Salazar‐Vizcaya LP, Wandeler G, Bertisch B, Keiser O, Dufour, F J‐ , et al. Impact of deferring HCV treatment on liver‐related events in HIV+ patients [Abstract]. Proceedings of the Conference on Retroviruses and Opportunistic Infections; February 23‐26, 2015; Seattle, WA. Abstract 150. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-50"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=C+Zahnd&author=LP+Salazar%e2%80%90Vizcaya&author=G+Wandeler&author=B+Bertisch&author=O+Keiser&author=+Dufour&author=F+" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=C+Zahnd&author=LP+Salazar%e2%80%90Vizcaya&author=G+Wandeler&author=B+Bertisch&author=O+Keiser&author=+Dufour&author=F+');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0058" class="article-references__item js-article-reference">58. McCombs JS, Tonnu‐MiHara I, Matsuda T, McGinnis J, Fox S. Can hepatitis C treatment be safely delayed? Evidence from the Veterans Administration Healthcare System [Abstract]. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL). April 22‐26, 2015; Vienna, Austria. Abstract 0003. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-50"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=JS+McCombs&author=I+Tonnu%e2%80%90MiHara&author=T+Matsuda&author=J+McGinnis&author=S.+Fox" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=JS+McCombs&author=I+Tonnu%e2%80%90MiHara&author=T+Matsuda&author=J+McGinnis&author=S.+Fox');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0059" class="article-references__item js-article-reference">59. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long‐term treatment against cirrhosis trial. Hepatology 2010;51:585‐594. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201002000-00029.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201002000-00029.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/20101752" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/20101752');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.23315" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.23315');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Prognostic+value+of+Ishak+fibrosis+stage%3a+findings+from+the+hepatitis+C+antiviral+long%e2%80%90term+treatment+against+cirrhosis+trial&publication_year=2010&author=JE+Everhart&author=EC+Wright&author=ZD+Goodman&author=JL+Dienstag&author=JC+Hoefs&author=DE+Kleiner" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Prognostic+value+of+Ishak+fibrosis+stage%3a+findings+from+the+hepatitis+C+antiviral+long%e2%80%90term+treatment+against+cirrhosis+trial&publication_year=2010&author=JE+Everhart&author=EC+Wright&author=ZD+Goodman&author=JL+Dienstag&author=JC+Hoefs&author=DE+Kleiner');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0060" class="article-references__item js-article-reference">60. Garcia‐Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922‐938. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200709000-00037.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200709000-00037.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/17879356" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/17879356');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.21907" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.21907');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Prevention+and+management+of+gastroesophageal+varices+and+variceal+hemorrhage+in+cirrhosis&publication_year=2007&author=G+Garcia%e2%80%90Tsao&author=AJ+Sanyal&author=ND+Grace&author=W.+Carey" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Prevention+and+management+of+gastroesophageal+varices+and+variceal+hemorrhage+in+cirrhosis&publication_year=2007&author=G+Garcia%e2%80%90Tsao&author=AJ+Sanyal&author=ND+Grace&author=W.+Carey');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0061" class="article-references__item js-article-reference">61. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020‐1022. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201103000-00032.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201103000-00032.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/21374666" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/21374666');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.24199" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.24199');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Management+of+hepatocellular+carcinoma%3a+an+update&publication_year=2011&author=J+Bruix&author=M.+Sherman" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Management+of+hepatocellular+carcinoma%3a+an+update&publication_year=2011&author=J+Bruix&author=M.+Sherman');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0062" class="article-references__item js-article-reference">62. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449‐1457. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200312000-00018.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200312000-00018.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/14647056" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/14647056');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.hep.2003.09.022" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.hep.2003.09.022');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sampling+variability+of+liver+fibrosis+in+chronic+hepatitis+C&publication_year=2003&author=P+Bedossa&author=D+Darg%c3%a8re&author=V.+Paradis" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sampling+variability+of+liver+fibrosis+in+chronic+hepatitis+C&publication_year=2003&author=P+Bedossa&author=D+Darg%c3%a8re&author=V.+Paradis');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0063" class="article-references__item js-article-reference">63. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large‐scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009;49:1821‐1827. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200906000-00008.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200906000-00008.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/19291784" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/19291784');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.22859" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.22859');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=SAFE+biopsy%3a+a+validated+method+for+large%e2%80%90scale+staging+of+liver+fibrosis+in+chronic+hepatitis+C&publication_year=2009&author=G+Sebastiani&author=P+Halfon&author=L+Castera&author=S+Pol&author=DL+Thomas&author=A+Mangia" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=SAFE+biopsy%3a+a+validated+method+for+large%e2%80%90scale+staging+of+liver+fibrosis+in+chronic+hepatitis+C&publication_year=2009&author=G+Sebastiani&author=P+Halfon&author=L+Castera&author=S+Pol&author=DL+Thomas&author=A+Mangia');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0064" class="article-references__item js-article-reference">64. Castera L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non‐invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52:191‐198. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20006397" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/20006397');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.jhep.2009.11.008" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.jhep.2009.11.008');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Prospective+comparison+of+two+algorithms+combining+non%e2%80%90invasive+methods+for+staging+liver+fibrosis+in+chronic+hepatitis+C&publication_year=2010&author=L+Castera&author=G+Sebastiani&author=B+Le+Bail&author=V+de+L%c3%a9dinghen&author=P+Couzigou&author=A.+Alberti" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Prospective+comparison+of+two+algorithms+combining+non%e2%80%90invasive+methods+for+staging+liver+fibrosis+in+chronic+hepatitis+C&publication_year=2010&author=L+Castera&author=G+Sebastiani&author=B+Le+Bail&author=V+de+L%c3%a9dinghen&author=P+Couzigou&author=A.+Alberti');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0065" class="article-references__item js-article-reference">65. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med 2013;159:372. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-201309030-00021.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-201309030-00021.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24026329" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24026329');return false">PubMed</a> | <a href="https://doi.org/10.7326%2F0003-4819-159-5-201309030-00021" onclick="javascript:window.open('https://doi.org/10.7326%2F0003-4819-159-5-201309030-00021');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Blood+tests+to+diagnose+fibrosis+or+cirrhosis+in+patients+with+chronic+hepatitis+C+virus+infection&publication_year=2013&author=R+Chou&author=N.+Wasson" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Blood+tests+to+diagnose+fibrosis+or+cirrhosis+in+patients+with+chronic+hepatitis+C+virus+infection&publication_year=2013&author=R+Chou&author=N.+Wasson');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0066" class="article-references__item js-article-reference">66. Ziol M, Handra‐Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48‐54. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200501000-00010.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200501000-00010.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/15690481" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/15690481');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.20506" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.20506');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Noninvasive+assessment+of+liver+fibrosis+by+measurement+of+stiffness+in+patients+with+chronic+hepatitis+C&publication_year=2005&author=M+Ziol&author=A+Handra%e2%80%90Luca&author=A+Kettaneh&author=C+Christidis&author=F+Mal&author=F+Kazemi" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Noninvasive+assessment+of+liver+fibrosis+by+measurement+of+stiffness+in+patients+with+chronic+hepatitis+C&publication_year=2005&author=M+Ziol&author=A+Handra%e2%80%90Luca&author=A+Kettaneh&author=C+Christidis&author=F+Mal&author=F+Kazemi');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0067" class="article-references__item js-article-reference">67. Boursier J, de Lédinghen V, Zarski JP, Fouchard‐Hubert I, Gallois Y, Oberti F, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology 2012;55:58‐67. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201201000-00009.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201201000-00009.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/21898504" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/21898504');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.24654" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.24654');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+eight+diagnostic+algorithms+for+liver+fibrosis+in+hepatitis+C%3a+new+algorithms+are+more+precise+and+entirely+noninvasive&publication_year=2012&author=J+Boursier&author=V+de+L%c3%a9dinghen&author=JP+Zarski&author=I+Fouchard%e2%80%90Hubert&author=Y+Gallois&author=F+Oberti" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Comparison+of+eight+diagnostic+algorithms+for+liver+fibrosis+in+hepatitis+C%3a+new+algorithms+are+more+precise+and+entirely+noninvasive&publication_year=2012&author=J+Boursier&author=V+de+L%c3%a9dinghen&author=JP+Zarski&author=I+Fouchard%e2%80%90Hubert&author=Y+Gallois&author=F+Oberti');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0068" class="article-references__item js-article-reference">68. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889‐1898. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-60"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201405150-00006.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201405150-00006.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24725239" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24725239');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1402454" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1402454');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&publication_year=2014&author=N+Afdhal&author=S+Zeuzem&author=P+Kwo&author=M+Chojkier&author=N+Gitlin&author=M+Puoti" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&publication_year=2014&author=N+Afdhal&author=S+Zeuzem&author=P+Kwo&author=M+Chojkier&author=N+Gitlin&author=M+Puoti');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0069" class="article-references__item js-article-reference">69. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879‐1888. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-60"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201405150-00004.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201405150-00004.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24720702" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24720702');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1402355" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1402355');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Ledipasvir+and+sofosbuvir+for+8+or+12+weeks+for+chronic+HCV+without+cirrhosis&publication_year=2014&author=KV+Kowdley&author=SC+Gordon&author=KR+Reddy&author=L+Rossaro&author=DE+Bernstein&author=E+Lawitz" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Ledipasvir+and+sofosbuvir+for+8+or+12+weeks+for+chronic+HCV+without+cirrhosis&publication_year=2014&author=KV+Kowdley&author=SC+Gordon&author=KR+Reddy&author=L+Rossaro&author=DE+Bernstein&author=E+Lawitz');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0070" class="article-references__item js-article-reference">70. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT‐450/r‐ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983‐1992. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-60"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201405220-00006.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201405220-00006.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24795200" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24795200');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1402338" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1402338');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=ABT%e2%80%90450%2fr%e2%80%90ombitasvir+and+dasabuvir+with+or+without+ribavirin+for+HCV&publication_year=2014&author=P+Ferenci&author=D+Bernstein&author=J+Lalezari&author=D+Cohen&author=Y+Luo&author=C+Cooper" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=ABT%e2%80%90450%2fr%e2%80%90ombitasvir+and+dasabuvir+with+or+without+ribavirin+for+HCV&publication_year=2014&author=P+Ferenci&author=D+Bernstein&author=J+Lalezari&author=D+Cohen&author=Y+Luo&author=C+Cooper');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0071" class="article-references__item js-article-reference">71. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT‐450/r‐ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973‐1982. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-60"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201405220-00004.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201405220-00004.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24725237" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24725237');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1402869" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1402869');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=ABT%e2%80%90450%2fr%e2%80%90ombitasvir+and+dasabuvir+with+ribavirin+for+hepatitis+C+with+cirrhosis&publication_year=2014&author=F+Poordad&author=C+Hezode&author=R+Trinh&author=KV+Kowdley&author=S+Zeuzem&author=K+Agarwal" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=ABT%e2%80%90450%2fr%e2%80%90ombitasvir+and+dasabuvir+with+ribavirin+for+hepatitis+C+with+cirrhosis&publication_year=2014&author=F+Poordad&author=C+Hezode&author=R+Trinh&author=KV+Kowdley&author=S+Zeuzem&author=K+Agarwal');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0072" class="article-references__item js-article-reference">72. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed‐dose combination with and without ribavirin in treatment‐naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open‐label, randomised, phase 2 trial. Lancet 2014;383:515‐523. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-60"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/24209977" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24209977');return false">PubMed</a> | <a href="https://doi.org/10.1016%2FS0140-6736%2813%2962121-2" onclick="javascript:window.open('https://doi.org/10.1016%2FS0140-6736%2813%2962121-2');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sofosbuvir+and+ledipasvir+fixed%e2%80%90dose+combination+with+and+without+ribavirin+in+treatment%e2%80%90naive+and+previously+treated+patients+with+genotype+1+hepatitis+C+virus+infection+(LONESTAR)%3a+an+open%e2%80%90label%2c+randomised%2c+phase+2+trial&publication_year=2014&author=E+Lawitz&author=FF+Poordad&author=PS+Pang&author=RH+Hyland&author=X+Ding&author=H+Mo" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sofosbuvir+and+ledipasvir+fixed%e2%80%90dose+combination+with+and+without+ribavirin+in+treatment%e2%80%90naive+and+previously+treated+patients+with+genotype+1+hepatitis+C+virus+infection+(LONESTAR)%3a+an+open%e2%80%90label%2c+randomised%2c+phase+2+trial&publication_year=2014&author=E+Lawitz&author=FF+Poordad&author=PS+Pang&author=RH+Hyland&author=X+Ding&author=H+Mo');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0073" class="article-references__item js-article-reference">73. Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, et al. A phase 3, open‐label, single‐arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment‐naive or ‐experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST‐2 [Abstract]. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22‐26, 2015; Vienna, Austria. Abstract LP04. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-130"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=E+Lawitz&author=G+Matusow&author=E+DeJesus&author=E+Yoshida&author=F+Felizarta&author=R+Ghalib" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=E+Lawitz&author=G+Matusow&author=E+DeJesus&author=E+Yoshida&author=F+Felizarta&author=R+Ghalib');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0074" class="article-references__item js-article-reference">74. Jensen DM, O'Leary JG, Pockros P, Sherman K, Kwo P, Mailliard M, et al. Safety and efficacy of sofosbuvir‐containing regimens for hepatitis C: real‐world experience in a diverse, longitudinal observational cohort [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. Abstract 45. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=DM+Jensen&author=JG+O%27Leary&author=P+Pockros&author=K+Sherman&author=P+Kwo&author=M+Mailliard" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=DM+Jensen&author=JG+O%27Leary&author=P+Pockros&author=K+Sherman&author=P+Kwo&author=M+Mailliard');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0075" class="article-references__item js-article-reference">75. Dieterich D, Bacon B, Flamm SL, Kowdley K, Milligan S, Tsai N, et al. Evaluation of sofosbuvir and simeprevir‐based regimens in the TRIO network: academic and community treatment of a real‐world, heterogeneous population [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. Abstract 46. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=D+Dieterich&author=B+Bacon&author=SL+Flamm&author=K+Kowdley&author=S+Milligan&author=N+Tsai" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=D+Dieterich&author=B+Bacon&author=SL+Flamm&author=K+Kowdley&author=S+Milligan&author=N+Tsai');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0076" class="article-references__item js-article-reference">76. Lawitz E, Mangia A, Wyles D, Rodriguez‐Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878‐1887. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-72"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201305160-00008.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201305160-00008.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23607594" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23607594');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1214853" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1214853');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sofosbuvir+for+previously+untreated+chronic+hepatitis+C+infection&publication_year=2013&author=E+Lawitz&author=A+Mangia&author=D+Wyles&author=M+Rodriguez%e2%80%90Torres&author=T+Hassanein&author=SC+Gordon" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sofosbuvir+for+previously+untreated+chronic+hepatitis+C+infection&publication_year=2013&author=E+Lawitz&author=A+Mangia&author=D+Wyles&author=M+Rodriguez%e2%80%90Torres&author=T+Hassanein&author=SC+Gordon');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0077" class="article-references__item js-article-reference">77. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez‐Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867‐1877. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-72"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201305160-00006.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201305160-00006.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23607593" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23607593');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1214854" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1214854');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sofosbuvir+for+hepatitis+C+genotype+2+or+3+in+patients+without+treatment+options&publication_year=2013&author=IM+Jacobson&author=SC+Gordon&author=KV+Kowdley&author=EM+Yoshida&author=M+Rodriguez%e2%80%90Torres&author=MS+Sulkowski" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sofosbuvir+for+hepatitis+C+genotype+2+or+3+in+patients+without+treatment+options&publication_year=2013&author=IM+Jacobson&author=SC+Gordon&author=KV+Kowdley&author=EM+Yoshida&author=M+Rodriguez%e2%80%90Torres&author=MS+Sulkowski');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0078" class="article-references__item js-article-reference">78. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial [Abstract]. Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 1‐5, 2013; Washington, DC. Abstract 1085. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-72"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2013&author=S+Zeuzem&author=GM+Dusheiko&author=R+Salupere&author=A+Mangia&author=R+Flisiak&author=RH+Hyland" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2013&author=S+Zeuzem&author=GM+Dusheiko&author=R+Salupere&author=A+Mangia&author=R+Flisiak&author=RH+Hyland');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0079" class="article-references__item js-article-reference">79. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604‐1614. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-77"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201404240-00008.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201404240-00008.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24720679" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24720679');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1401561" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1401561');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Retreatment+of+HCV+with+ABT%e2%80%90450%2fr%e2%80%90ombitasvir+and+dasabuvir+with+ribavirin&publication_year=2014&author=S+Zeuzem&author=IM+Jacobson&author=T+Baykal&author=RT+Marinho&author=F+Poordad&author=M+Bourli%c3%a8re" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Retreatment+of+HCV+with+ABT%e2%80%90450%2fr%e2%80%90ombitasvir+and+dasabuvir+with+ribavirin&publication_year=2014&author=S+Zeuzem&author=IM+Jacobson&author=T+Baykal&author=RT+Marinho&author=F+Poordad&author=M+Bourli%c3%a8re');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0080" class="article-references__item js-article-reference">80. Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment‐experienced cirrhotic patients with genotype 2 HCV: the BOSON study. Presented at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22‐26, 2015; Vienna, Austria. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-77"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=Foster+GR&author=Pianko+S&author=Cooper+C&author=Brown+A&author=Forton+D&author=Nahass+RG" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=Foster+GR&author=Pianko+S&author=Cooper+C&author=Brown+A&author=Forton+D&author=Nahass+RG');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0081" class="article-references__item js-article-reference">81. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros P, Freilich BF, et al. All‐oral 12‐week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY‐3 phase 3 study [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. Abstract LB‐3. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-77"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=DR+Nelson&author=JN+Cooper&author=JP+Lalezari&author=E+Lawitz&author=P+Pockros&author=BF+Freilich" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=DR+Nelson&author=JN+Cooper&author=JP+Lalezari&author=E+Lawitz&author=P+Pockros&author=BF+Freilich');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0082" class="article-references__item js-article-reference">82. Pol S, Reddy KR, Hezode C, Hassanein T, Marcellin P, Berenguer M, et al. Interferon‐free regimens of ombitasvir and ABT‐450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL‐I study results [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-82"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=S+Pol&author=KR+Reddy&author=C+Hezode&author=T+Hassanein&author=P+Marcellin&author=M+Berenguer" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=S+Pol&author=KR+Reddy&author=C+Hezode&author=T+Hassanein&author=P+Marcellin&author=M+Berenguer');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0083" class="article-references__item js-article-reference">83. Kapoor R, Kohli A, Sidharthan S, Sims Z, Petersen TL, Osinusi A, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7‐11, 2014; Boston, MA. Abstract 240. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-82"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=R+Kapoor&author=A+Kohli&author=S+Sidharthan&author=Z+Sims&author=TL+Petersen&author=A+Osinusi" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=R+Kapoor&author=A+Kohli&author=S+Sidharthan&author=Z+Sims&author=TL+Petersen&author=A+Osinusi');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0084" class="article-references__item js-article-reference">84. Abergel A, Loustaud‐Ratti V, Metivier S, Jiang D, Kersey K, Knox SJ, et al. Ledipasvir/sofosbuvir for the treatment of patients with chronic genotype 4 or 5 HCV infection [Abstract]. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22‐26, 2015; Vienna, Austria. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-82"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=A+Abergel&author=V+Loustaud%e2%80%90Ratti&author=S+Metivier&author=D+Jiang&author=K+Kersey&author=SJ+Knox" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=A+Abergel&author=V+Loustaud%e2%80%90Ratti&author=S+Metivier&author=D+Jiang&author=K+Kersey&author=SJ+Knox');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0085" class="article-references__item js-article-reference">85. Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015;62:1040‐1046. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-82"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25450208" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25450208');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.jhep.2014.10.044" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.jhep.2014.10.044');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sofosbuvir+plus+ribavirin+for+the+treatment+of+chronic+genotype+4+hepatitis+C+virus+infection+in+patients+of+Egyptian+ancestry&publication_year=2015&author=PJ+Ruane&author=D+Ain&author=R+Stryker&author=R+Meshrekey&author=M+Soliman&author=PR+Wolfe" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sofosbuvir+plus+ribavirin+for+the+treatment+of+chronic+genotype+4+hepatitis+C+virus+infection+in+patients+of+Egyptian+ancestry&publication_year=2015&author=PJ+Ruane&author=D+Ain&author=R+Stryker&author=R+Meshrekey&author=M+Soliman&author=PR+Wolfe');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0086" class="article-references__item js-article-reference">86. Esmat GE, Omar RF, Khairy M, Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. Abstract 959. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-82"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=GE+Esmat&author=RF+Omar&author=M+Khairy&author=W+Doss&author=G+Shiha&author=M+Hassany" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=GE+Esmat&author=RF+Omar&author=M+Khairy&author=W+Doss&author=G+Shiha&author=M+Hassany');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0087" class="article-references__item js-article-reference">87. Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. All‐oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co‐infected with HIV (PHOTON‐2) [Abstract]. Proceedings of the 20th International AIDS Conference; July 20‐25, 2014; Melbourne, Australia. Abstract MOAB0105LB. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-82"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=JM+Molina&author=C+Orkin&author=DM+Iser&author=FX+Zamora&author=M+Nelson&author=C+Stephan" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=JM+Molina&author=C+Orkin&author=DM+Iser&author=FX+Zamora&author=M+Nelson&author=C+Stephan');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0088" class="article-references__item js-article-reference">88. Gane EJ, Hyland RH, An D, Svarovskaia ES, Pang PS, Symonds WT, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-91"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=EJ+Gane&author=RH+Hyland&author=D+An&author=ES+Svarovskaia&author=PS+Pang&author=WT+Symonds" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=EJ+Gane&author=RH+Hyland&author=D+An&author=ES+Svarovskaia&author=PS+Pang&author=WT+Symonds');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0089" class="article-references__item js-article-reference">89. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483‐1493. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-97"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-201404170-00004.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-201404170-00004.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24725238" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24725238');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa1316366" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa1316366');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Ledipasvir+and+sofosbuvir+for+previously+treated+HCV+genotype+1+infection&publication_year=2014&author=N+Afdhal&author=KR+Reddy&author=DR+Nelson&author=E+Lawitz&author=SC+Gordon&author=E+Schiff" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Ledipasvir+and+sofosbuvir+for+previously+treated+HCV+genotype+1+infection&publication_year=2014&author=N+Afdhal&author=KR+Reddy&author=DR+Nelson&author=E+Lawitz&author=SC+Gordon&author=E+Schiff');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0090" class="article-references__item js-article-reference">90. Jacobson IM, Ghalib RH, Rodriguez‐Torres M, Younossi ZM, Corregidor A, Sulkowski MS, et al. SVR results of a once‐daily regimen of simeprevir (TMC435) plus sofosbuvir (GS‐7977) with or without ribavirin in cirrhotic and non‐cirrhotic HCV genotype 1 treatment‐naive and prior null responder patients: The COSMOS study [Abstract]. Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 1‐5, 2013; Washington, DC. Abstract LB‐3. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-97"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2013&author=IM+Jacobson&author=RH+Ghalib&author=M+Rodriguez%e2%80%90Torres&author=ZM+Younossi&author=A+Corregidor&author=MS+Sulkowski" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2013&author=IM+Jacobson&author=RH+Ghalib&author=M+Rodriguez%e2%80%90Torres&author=ZM+Younossi&author=A+Corregidor&author=MS+Sulkowski');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0091" class="article-references__item js-article-reference">91. Bourliere M, Sulkowski MS, Omata M, Zeuzem S, Feld J, Lawitz E, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. Abstract 82. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-97"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=M+Bourliere&author=MS+Sulkowski&author=M+Omata&author=S+Zeuzem&author=J+Feld&author=E+Lawitz" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=M+Bourliere&author=MS+Sulkowski&author=M+Omata&author=S+Zeuzem&author=J+Feld&author=E+Lawitz');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0092" class="article-references__item js-article-reference">92. Simeprevir [package insert]. Titusville , NJ: Janssen Therapeutics; 2013. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-97"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2013" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2013');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0093" class="article-references__item js-article-reference">93. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez‐Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non‐responders to pegylated interferon and ribavirin and treatment‐naive patients: the COSMOS randomised study. Lancet 2014;384:1756‐1765. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-97"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25078309" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25078309');return false">PubMed</a> | <a href="https://doi.org/10.1016%2FS0140-6736%2814%2961036-9" onclick="javascript:window.open('https://doi.org/10.1016%2FS0140-6736%2814%2961036-9');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Simeprevir+plus+sofosbuvir%2c+with+or+without+ribavirin%2c+to+treat+chronic+infection+with+hepatitis+C+virus+genotype+1+in+non%e2%80%90responders+to+pegylated+interferon+and+ribavirin+and+treatment%e2%80%90naive+patients%3a+the+COSMOS+randomised+study&publication_year=2014&author=E+Lawitz&author=MS+Sulkowski&author=R+Ghalib&author=M+Rodriguez%e2%80%90Torres&author=ZM+Younossi&author=A+Corregidor" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Simeprevir+plus+sofosbuvir%2c+with+or+without+ribavirin%2c+to+treat+chronic+infection+with+hepatitis+C+virus+genotype+1+in+non%e2%80%90responders+to+pegylated+interferon+and+ribavirin+and+treatment%e2%80%90naive+patients%3a+the+COSMOS+randomised+study&publication_year=2014&author=E+Lawitz&author=MS+Sulkowski&author=R+Ghalib&author=M+Rodriguez%e2%80%90Torres&author=ZM+Younossi&author=A+Corregidor');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0094" class="article-references__item js-article-reference">94. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT‐450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment‐experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359‐365. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-98"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/24818763" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24818763');return false">PubMed</a> | <a href="https://doi.org/10.1053%2Fj.gastro.2014.04.045" onclick="javascript:window.open('https://doi.org/10.1053%2Fj.gastro.2014.04.045');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=ABT%e2%80%90450%2c+ritonavir%2c+ombitasvir%2c+and+dasabuvir+achieves+97%25+and+100%25+sustained+virologic+response+with+or+without+ribavirin+in+treatment%e2%80%90experienced+patients+with+HCV+genotype+1b+infection&publication_year=2014&author=P+Andreone&author=MG+Colombo&author=JV+Enejosa&author=I+Koksal&author=P+Ferenci&author=A+Maieron" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=ABT%e2%80%90450%2c+ritonavir%2c+ombitasvir%2c+and+dasabuvir+achieves+97%25+and+100%25+sustained+virologic+response+with+or+without+ribavirin+in+treatment%e2%80%90experienced+patients+with+HCV+genotype+1b+infection&publication_year=2014&author=P+Andreone&author=MG+Colombo&author=JV+Enejosa&author=I+Koksal&author=P+Ferenci&author=A+Maieron');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0095" class="article-references__item js-article-reference">95. Bourliere M, Bronowicki J, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease‐inhibitor based triple therapy [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7‐11, 2014; Boston, MA. Abstract LB‐6. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-114"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=M+Bourliere&author=J+Bronowicki&author=V+de+Ledinghen&author=C+Hezode&author=F+Zoulim&author=P+Mathurin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=M+Bourliere&author=J+Bronowicki&author=V+de+Ledinghen&author=C+Hezode&author=F+Zoulim&author=P+Mathurin');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0096" class="article-references__item js-article-reference">96. Osinusi A, Marti M, Kohli A, Meissner R, Townsend K, Nelson A, et al. Sofosbuvir/ledipasvir in retreatment of HCV genotype‐1 patients who previously failed sofosbuvir/ribavirin therapy [Abstract]. Proceedings of the 49th Annual Meeting of the European Association for the Study of the Liver (EASL); April 9‐13, 2014; London, UK. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-123"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=A+Osinusi&author=M+Marti&author=A+Kohli&author=R+Meissner&author=K+Townsend&author=A+Nelson" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=A+Osinusi&author=M+Marti&author=A+Kohli&author=R+Meissner&author=K+Townsend&author=A+Nelson');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0097" class="article-references__item js-article-reference">97. Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, et al. Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015;61:1793‐1797. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-123"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201506000-00008.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201506000-00008.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/25846014" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25846014');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.27814" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.27814');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Ledipasvir%e2%80%90sofosbuvir+plus+ribavirin+for+patients+with+genotype+1+hepatitis+C+virus+previously+treated+in+clinical+trials+of+sofosbuvir+regimens&publication_year=2015&author=D+Wyles&author=P+Pockros&author=G+Morelli&author=Z+Younes&author=E+Svarovskaia&author=JC+Yang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Ledipasvir%e2%80%90sofosbuvir+plus+ribavirin+for+patients+with+genotype+1+hepatitis+C+virus+previously+treated+in+clinical+trials+of+sofosbuvir+regimens&publication_year=2015&author=D+Wyles&author=P+Pockros&author=G+Morelli&author=Z+Younes&author=E+Svarovskaia&author=JC+Yang');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0098" class="article-references__item js-article-reference">98. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer‐Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment‐naive and treatment‐experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL‐I): a randomised, open‐label trial. Lancet 2015; doi:<span><a href="10.1016/S0140-6736(15)60159-3" onclick="javascript:window.open('10.1016/S0140-6736(15)60159-3');return false">10.1016/S0140-6736(15)60159-3</a></span>.<div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-149"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Ombitasvir+plus+paritaprevir+plus+ritonavir+with+or+without+ribavirin+in+treatment%e2%80%90naive+and+treatment%e2%80%90experienced+patients+with+genotype+4+chronic+hepatitis+C+virus+infection+(PEARL%e2%80%90I)%3a+a+randomised%2c+open%e2%80%90label+trial&publication_year=2015&author=C+Hezode&author=T+Asselah&author=KR+Reddy&author=T+Hassanein&author=M+Berenguer&author=K+Fleischer%e2%80%90Stepniewska" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Ombitasvir+plus+paritaprevir+plus+ritonavir+with+or+without+ribavirin+in+treatment%e2%80%90naive+and+treatment%e2%80%90experienced+patients+with+genotype+4+chronic+hepatitis+C+virus+infection+(PEARL%e2%80%90I)%3a+a+randomised%2c+open%e2%80%90label+trial&publication_year=2015&author=C+Hezode&author=T+Asselah&author=KR+Reddy&author=T+Hassanein&author=M+Berenguer&author=K+Fleischer%e2%80%90Stepniewska');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0099" class="article-references__item js-article-reference">99. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396‐405. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-165"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201108000-00003.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201108000-00003.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/21520194" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/21520194');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.24370" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.24370');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=A+prospective+study+of+the+rate+of+progression+in+compensated%2c+histologically+advanced+chronic+hepatitis+C&publication_year=2011&author=JL+Dienstag&author=MG+Ghany&author=TR+Morgan&author=AM+Di+Bisceglie&author=HL+Bonkovsky&author=HY+Kim" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=A+prospective+study+of+the+rate+of+progression+in+compensated%2c+histologically+advanced+chronic+hepatitis+C&publication_year=2011&author=JL+Dienstag&author=MG+Ghany&author=TR+Morgan&author=AM+Di+Bisceglie&author=HL+Bonkovsky&author=HY+Kim');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0100" class="article-references__item js-article-reference">100. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014;105:64‐71. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-165"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00078401-201405001-00011.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00078401-201405001-00011.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/24583028" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/24583028');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.antiviral.2014.02.011" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.antiviral.2014.02.011');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Antiviral+therapy+of+hepatitis+C+in+2014%3a+do+we+need+resistance+testing%3f&publication_year=2014&author=MD+Schneider&author=C.+Sarrazin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Antiviral+therapy+of+hepatitis+C+in+2014%3a+do+we+need+resistance+testing%3f&publication_year=2014&author=MD+Schneider&author=C.+Sarrazin');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0101" class="article-references__item js-article-reference">101. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793‐2798. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-174"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/');return false">PubMed</a> | <a href="https://doi.org/10.3748%2Fwjg.v19.i18.2793" onclick="javascript:window.open('https://doi.org/10.3748%2Fwjg.v19.i18.2793');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sustained+virological+response%3a+a+milestone+in+the+treatment+of+chronic+hepatitis+C&publication_year=2013&author=F+Morisco&author=R+Granata&author=T+Stroffolini&author=M+Guarino&author=L+Donnarumma&author=L+Gaeta" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sustained+virological+response%3a+a+milestone+in+the+treatment+of+chronic+hepatitis+C&publication_year=2013&author=F+Morisco&author=R+Granata&author=T+Stroffolini&author=M+Guarino&author=L+Donnarumma&author=L+Gaeta');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0102" class="article-references__item js-article-reference">102. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833‐844. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-174"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201009000-00006.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201009000-00006.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/20564351" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/20564351');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.23744" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.23744');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Outcome+of+sustained+virological+responders+with+histologically+advanced+chronic+hepatitis+C&publication_year=2010&author=TR+Morgan&author=MG+Ghany&author=HY+Kim&author=KK+Snow&author=ML+Shiffman&author=JL+De+Santo" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Outcome+of+sustained+virological+responders+with+histologically+advanced+chronic+hepatitis+C&publication_year=2010&author=TR+Morgan&author=MG+Ghany&author=HY+Kim&author=KK+Snow&author=ML+Shiffman&author=JL+De+Santo');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0103" class="article-references__item js-article-reference">103. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients. Hepatology 2009;49:729‐738. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-174"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200903000-00005.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200903000-00005.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/19072828" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/19072828');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.22694" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.22694');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Clinical%2c+virologic%2c+histologic%2c+and+biochemical+outcomes+after+successful+HCV+therapy%3a+a+5%e2%80%90year+follow%e2%80%90up+of+150+patients&publication_year=2009&author=SL+George&author=BR+Bacon&author=EM+Brunt&author=KL+Mihindukulasuriya&author=J+Hoffmann&author=AM.+Di+Bisceglie" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Clinical%2c+virologic%2c+histologic%2c+and+biochemical+outcomes+after+successful+HCV+therapy%3a+a+5%e2%80%90year+follow%e2%80%90up+of+150+patients&publication_year=2009&author=SL+George&author=BR+Bacon&author=EM+Brunt&author=KL+Mihindukulasuriya&author=J+Hoffmann&author=AM.+Di+Bisceglie');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0104" class="article-references__item js-article-reference">104. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver‐related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280‐288. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-174"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/19948249" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/19948249');return false">PubMed</a> | <a href="https://doi.org/10.1016%2Fj.cgh.2009.11.018" onclick="javascript:window.open('https://doi.org/10.1016%2Fj.cgh.2009.11.018');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=A+sustained+viral+response+is+associated+with+reduced+liver%e2%80%90related+morbidity+and+mortality+in+patients+with+hepatitis+C+virus&publication_year=2010&author=AG+Singal&author=ML+Volk&author=D+Jensen&author=AM+Di+Bisceglie&author=PS.+Schoenfeld" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=A+sustained+viral+response+is+associated+with+reduced+liver%e2%80%90related+morbidity+and+mortality+in+patients+with+hepatitis+C+virus&publication_year=2010&author=AG+Singal&author=ML+Volk&author=D+Jensen&author=AM+Di+Bisceglie&author=PS.+Schoenfeld');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0105" class="article-references__item js-article-reference">105. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open‐label study. Gastroenterology 2014;148:100‐107. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-195"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25261839" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25261839');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sofosbuvir+and+ribavirin+prevent+recurrence+of+HCV+infection+after+liver+transplantation%3a+an+open%e2%80%90label+study&publication_year=2014&author=MP+Curry&author=X+Forns&author=RT+Chung&author=NA+Terrault&author=R+Brown&author=JM+Fenkel" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sofosbuvir+and+ribavirin+prevent+recurrence+of+HCV+infection+after+liver+transplantation%3a+an+open%e2%80%90label+study&publication_year=2014&author=MP+Curry&author=X+Forns&author=RT+Chung&author=NA+Terrault&author=R+Brown&author=JM+Fenkel');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0106" class="article-references__item js-article-reference">106. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt‐Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7‐11, 2014; Boston, MA. Abstract 8. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-199"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=KR+Reddy&author=GT+Everson&author=SL+Flamm&author=JM+Denning&author=S+Arterburn&author=T+Brandt%e2%80%90Sarif" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=KR+Reddy&author=GT+Everson&author=SL+Flamm&author=JM+Denning&author=S+Arterburn&author=T+Brandt%e2%80%90Sarif');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0107" class="article-references__item js-article-reference">107. Mantry PS, Kwo PY, Coakley E, Te H, Vargas H, Brown RS Jr, et al. High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT‐450/r/ombitasvir+dasabuvir plus ribavirin [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. Abstract 198. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-200"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=PS+Mantry&author=PY+Kwo&author=E+Coakley&author=H+Te&author=H+Vargas&author=RS+Brown" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=PS+Mantry&author=PY+Kwo&author=E+Coakley&author=H+Te&author=H+Vargas&author=RS+Brown');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0108" class="article-references__item js-article-reference">108. Pungpapong S, Werner KT, Aqel B, Leise M, Murphy JL, Henry TM, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation [Abstract]. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7‐11, 2014; Boston, MA. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-200"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=S+Pungpapong&author=KT+Werner&author=B+Aqel&author=M+Leise&author=JL+Murphy&author=TM+Henry" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=S+Pungpapong&author=KT+Werner&author=B+Aqel&author=M+Leise&author=JL+Murphy&author=TM+Henry');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0109" class="article-references__item js-article-reference">109. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end‐stage renal disease: the RUBY‐1 study [Abstract]. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22‐26, 2015; Vienna, Austria. Abstract LO1. <div> <ul class="article-references__item-links"> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=PJ+Pockros&author=KR+Reddy&author=PS+Mantry&author=E+Cohen&author=M+Bennett&author=MS+Sulkowski" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=PJ+Pockros&author=KR+Reddy&author=PS+Mantry&author=E+Cohen&author=M+Bennett&author=MS+Sulkowski');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0110" class="article-references__item js-article-reference">110. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450‐456. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-220"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00005407-200007260-00034.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00005407-200007260-00034.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/10904508" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/10904508');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=The+natural+history+of+hepatitis+C+virus+infection%3a+host%2c+viral%2c+and+environmental+factors&publication_year=2000&author=DL+Thomas&author=J+Astemborski&author=RM+Rai&author=FA+Anania&author=M+Schaeffer&author=N+Galai" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=The+natural+history+of+hepatitis+C+virus+infection%3a+host%2c+viral%2c+and+environmental+factors&publication_year=2000&author=DL+Thomas&author=J+Astemborski&author=RM+Rai&author=FA+Anania&author=M+Schaeffer&author=N+Galai');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0111" class="article-references__item js-article-reference">111. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC 2nd, et al. End‐stage liver disease in persons with hemophilia and transfusion‐associated infections. Blood 2002;100:1584‐1589. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-220"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/12176875" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/12176875');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=End%e2%80%90stage+liver+disease+in+persons+with+hemophilia+and+transfusion%e2%80%90associated+infections&publication_year=2002&author=JJ+Goedert&author=ME+Eyster&author=MM+Lederman&author=T+Mandalaki&author=P+De+Moerloose&author=GC+White" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=End%e2%80%90stage+liver+disease+in+persons+with+hemophilia+and+transfusion%e2%80%90associated+infections&publication_year=2002&author=JJ+Goedert&author=ME+Eyster&author=MM+Lederman&author=T+Mandalaki&author=P+De+Moerloose&author=GC+White');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0112" class="article-references__item js-article-reference">112. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690‐695. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-220"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01451459-199610000-00002.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01451459-199610000-00002.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/8843204" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/8843204');return false">PubMed</a> | <a href="https://doi.org/10.1093%2Finfdis%2F174.4.690" onclick="javascript:window.open('https://doi.org/10.1093%2Finfdis%2F174.4.690');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+human+immunodeficiency+virus+on+hepatitis+C+virus+infection+among+injecting+drug+users&publication_year=1996&author=DL+Thomas&author=JW+Shih&author=HJ+Alter&author=D+Vlahov&author=S+Cohn&author=DR+Hoover" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Effect+of+human+immunodeficiency+virus+on+hepatitis+C+virus+infection+among+injecting+drug+users&publication_year=1996&author=DL+Thomas&author=JW+Shih&author=HJ+Alter&author=D+Vlahov&author=S+Cohn&author=DR+Hoover');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0113" class="article-references__item js-article-reference">113. Torriani FJ, Rodriguez‐Torres M, Rockstroh JK, Lissen E, Gonzalez‐García J, Lazzarin A, et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection in HIV‐infected patients. N Engl J Med 2004;351:438‐450. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-220"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00006024-200407290-00007.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00006024-200407290-00007.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/15282351" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/15282351');return false">PubMed</a> | <a href="https://doi.org/10.1056%2FNEJMoa040842" onclick="javascript:window.open('https://doi.org/10.1056%2FNEJMoa040842');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Peginterferon+alfa%e2%80%902a+plus+ribavirin+for+chronic+hepatitis+C+virus+infection+in+HIV%e2%80%90infected+patients&publication_year=2004&author=FJ+Torriani&author=M+Rodriguez%e2%80%90Torres&author=JK+Rockstroh&author=E+Lissen&author=J+Gonzalez%e2%80%90Garc%c3%ada&author=A+Lazzarin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Peginterferon+alfa%e2%80%902a+plus+ribavirin+for+chronic+hepatitis+C+virus+infection+in+HIV%e2%80%90infected+patients&publication_year=2004&author=FJ+Torriani&author=M+Rodriguez%e2%80%90Torres&author=JK+Rockstroh&author=E+Lissen&author=J+Gonzalez%e2%80%90Garc%c3%ada&author=A+Lazzarin');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0114" class="article-references__item js-article-reference">114. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon‐alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346‐355. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-220"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-200403020-00010.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-200403020-00010.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/14996676" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/14996676');return false">PubMed</a> | <a href="https://doi.org/10.7326%2F0003-4819-140-5-200403020-00010" onclick="javascript:window.open('https://doi.org/10.7326%2F0003-4819-140-5-200403020-00010');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Peginterferon%e2%80%90alpha2a+and+ribavirin+combination+therapy+in+chronic+hepatitis+C%3a+a+randomized+study+of+treatment+duration+and+ribavirin+dose&publication_year=2004&author=SJ+Hadziyannis&author=H+Sette&author=TR+Morgan&author=V+Balan&author=M+Diago&author=P+Marcellin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Peginterferon%e2%80%90alpha2a+and+ribavirin+combination+therapy+in+chronic+hepatitis+C%3a+a+randomized+study+of+treatment+duration+and+ribavirin+dose&publication_year=2004&author=SJ+Hadziyannis&author=H+Sette&author=TR+Morgan&author=V+Balan&author=M+Diago&author=P+Marcellin');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0115" class="article-references__item js-article-reference">115. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312:353‐361. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-220"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00005407-201407230-00025.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00005407-201407230-00025.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/25038354" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25038354');return false">PubMed</a> | <a href="https://doi.org/10.1001%2Fjama.2014.7734" onclick="javascript:window.open('https://doi.org/10.1001%2Fjama.2014.7734');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sofosbuvir+and+ribavirin+for+hepatitis+C+in+patients+with+HIV+coinfection&publication_year=2014&author=MS+Sulkowski&author=S+Naggie&author=J+Lalezari&author=WJ+Fessel&author=K+Mounzer&author=M+Shuhart" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sofosbuvir+and+ribavirin+for+hepatitis+C+in+patients+with+HIV+coinfection&publication_year=2014&author=MS+Sulkowski&author=S+Naggie&author=J+Lalezari&author=WJ+Fessel&author=K+Mounzer&author=M+Shuhart');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0116" class="article-references__item js-article-reference">116. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159:86‐96. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-220"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00000605-201307160-00003.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00000605-201307160-00003.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23685940" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23685940');return false">PubMed</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Combination+therapy+with+telaprevir+for+chronic+hepatitis+C+virus+genotype+1+infection+in+patients+with+HIV%3a+a+randomized+trial&publication_year=2013&author=MS+Sulkowski&author=KE+Sherman&author=DT+Dieterich&author=M+Bsharat&author=L+Mahnke&author=JK+Rockstroh" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Combination+therapy+with+telaprevir+for+chronic+hepatitis+C+virus+genotype+1+infection+in+patients+with+HIV%3a+a+randomized+trial&publication_year=2013&author=MS+Sulkowski&author=KE+Sherman&author=DT+Dieterich&author=M+Bsharat&author=L+Mahnke&author=JK+Rockstroh');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0117" class="article-references__item js-article-reference">117. Khatri A, Wang T, Wang H, Podsadecki T, Trinh R, Awni W, et al. Drug–drug interactions of the direct‐acting antiviral regimen of ABT‐450/r, ombitasvir, and dasabuvir with HIV protease inhibitors [Abstract]. Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 5‐9, 2014; Washington, DC. Abstract V‐484. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-221"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=A+Khatri&author=T+Wang&author=H+Wang&author=T+Podsadecki&author=R+Trinh&author=W+Awni" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=A+Khatri&author=T+Wang&author=H+Wang&author=T+Podsadecki&author=R+Trinh&author=W+Awni');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0118" class="article-references__item js-article-reference">118. Khatri A, Wang T, Wang H, Podsadecki T, Trinh R, Awni W, et al. Drug–drug interactions of the direct‐acting antiviral regimen of ABT‐450/r, ombitasvir, and dasabuvir with emtricabine + tenofovir, raltegravir, rilpivirine, and efavirenz [Abstract]. Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 5‐9, 2014; Washington, DC. Abstract V‐483. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-221"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2014&author=A+Khatri&author=T+Wang&author=H+Wang&author=T+Podsadecki&author=R+Trinh&author=W+Awni" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2014&author=A+Khatri&author=T+Wang&author=H+Wang&author=T+Podsadecki&author=R+Trinh&author=W+Awni');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0119" class="article-references__item js-article-reference">119. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co‐infection. JAMA 2015;31:1232‐1239. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-222"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/00005407-201503240-00024.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00005407-201503240-00024.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/25706232" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25706232');return false">PubMed</a> | <a href="https://doi.org/10.1001%2Fjama.2015.1373" onclick="javascript:window.open('https://doi.org/10.1001%2Fjama.2015.1373');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Virologic+response+following+combined+ledipasvir+and+sofosbuvir+administration+in+patients+with+HCV+genotype+1+and+HIV+co%e2%80%90infection&publication_year=2015&author=A+Osinusi&author=K+Townsend&author=A+Kohli&author=A+Nelson&author=C+Seamon&author=EG+Meissner" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Virologic+response+following+combined+ledipasvir+and+sofosbuvir+administration+in+patients+with+HCV+genotype+1+and+HIV+co%e2%80%90infection&publication_year=2015&author=A+Osinusi&author=K+Townsend&author=A+Kohli&author=A+Nelson&author=C+Seamon&author=EG+Meissner');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0120" class="article-references__item js-article-reference">120. Naggie S, Cooper C, Saag M, Yang J, Stamm L, Pang PS, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV‐1 [Abstract]. Proceedings of the Conference on Retroviruses and Opportunistic Infections; February 23‐26, 2015; Seattle, WA. Abstract 152LB. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-222"> Cited Here</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?publication_year=2015&author=S+Naggie&author=C+Cooper&author=M+Saag&author=J+Yang&author=L+Stamm&author=PS+Pang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?publication_year=2015&author=S+Naggie&author=C+Cooper&author=M+Saag&author=J+Yang&author=L+Stamm&author=PS+Pang');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0121" class="article-references__item js-article-reference">121. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co‐dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co‐infected with HIV‐1: a randomized trial. JAMA 2015;313:1223‐1231. <div> <ul class="article-references__item-links"> <li><a href="https://journals.lww.com/academicmedicine/00005407-201503240-00023.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/00005407-201503240-00023.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/25706092" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25706092');return false">PubMed</a> | <a href="https://doi.org/10.1001%2Fjama.2015.1328" onclick="javascript:window.open('https://doi.org/10.1001%2Fjama.2015.1328');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Ombitasvir%2c+paritaprevir+co%e2%80%90dosed+with+ritonavir%2c+dasabuvir%2c+and+ribavirin+for+hepatitis+C+in+patients+co%e2%80%90infected+with+HIV%e2%80%901%3a+a+randomized+trial&publication_year=2015&author=MS+Sulkowski&author=JJ+Eron&author=D+Wyles&author=R+Trinh&author=J+Lalezari&author=C+Wang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Ombitasvir%2c+paritaprevir+co%e2%80%90dosed+with+ritonavir%2c+dasabuvir%2c+and+ribavirin+for+hepatitis+C+in+patients+co%e2%80%90infected+with+HIV%e2%80%901%3a+a+randomized+trial&publication_year=2015&author=MS+Sulkowski&author=JJ+Eron&author=D+Wyles&author=R+Trinh&author=J+Lalezari&author=C+Wang');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0122" class="article-references__item js-article-reference">122. Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co‐infected with HIV (PHOTON‐2): a multicentre, open‐label, non‐randomised, phase 3 study. Lancet 2015;385:1098‐1106. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-223"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25659285" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/25659285');return false">PubMed</a> | <a href="https://doi.org/10.1016%2FS0140-6736%2814%2962483-1" onclick="javascript:window.open('https://doi.org/10.1016%2FS0140-6736%2814%2962483-1');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Sofosbuvir+plus+ribavirin+for+treatment+of+hepatitis+C+virus+in+patients+co%e2%80%90infected+with+HIV+(PHOTON%e2%80%902)%3a+a+multicentre%2c+open%e2%80%90label%2c+non%e2%80%90randomised%2c+phase+3+study&publication_year=2015&author=JM+Molina&author=C+Orkin&author=DM+Iser&author=FX+Zamora&author=M+Nelson&author=C+Stephan" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Sofosbuvir+plus+ribavirin+for+treatment+of+hepatitis+C+virus+in+patients+co%e2%80%90infected+with+HIV+(PHOTON%e2%80%902)%3a+a+multicentre%2c+open%e2%80%90label%2c+non%e2%80%90randomised%2c+phase+3+study&publication_year=2015&author=JM+Molina&author=C+Orkin&author=DM+Iser&author=FX+Zamora&author=M+Nelson&author=C+Stephan');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0123" class="article-references__item js-article-reference">123. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection. Hepatology 1999;29:908‐914. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-243"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-199903000-00040.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-199903000-00040.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/10051497" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/10051497');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.510290311" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.510290311');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Persistence+of+viremia+and+the+importance+of+long%e2%80%90term+follow%e2%80%90up+after+acute+hepatitis+C+infection&publication_year=1999&author=SA+Villano&author=D+Vlahov&author=KE+Nelson&author=S+Cohn&author=DL.+Thomas" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Persistence+of+viremia+and+the+importance+of+long%e2%80%90term+follow%e2%80%90up+after+acute+hepatitis+C+infection&publication_year=1999&author=SA+Villano&author=D+Vlahov&author=KE+Nelson&author=S+Cohn&author=DL.+Thomas');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0124" class="article-references__item js-article-reference">124. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community‐acquired acute‐phase hepatitis C virus infection. Clin Infect Dis 2005;40:951‐958. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-243"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/15824985" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/15824985');return false">PubMed</a> | <a href="https://doi.org/10.1086%2F428578" onclick="javascript:window.open('https://doi.org/10.1086%2F428578');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Prospective+evaluation+of+community%e2%80%90acquired+acute%e2%80%90phase+hepatitis+C+virus+infection&publication_year=2005&author=AL+Cox&author=DM+Netski&author=T+Mosbruger&author=SG+Sherman&author=S+Strathdee&author=D+Ompad" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Prospective+evaluation+of+community%e2%80%90acquired+acute%e2%80%90phase+hepatitis+C+virus+infection&publication_year=2005&author=AL+Cox&author=DM+Netski&author=T+Mosbruger&author=SG+Sherman&author=S+Strathdee&author=D+Ompad');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0125" class="article-references__item js-article-reference">125. Grebely J, Page K, Sacks‐Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014;59:109‐120. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-243"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-201401000-00016.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-201401000-00016.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/23908124" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/23908124');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.26639" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.26639');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=The+effects+of+female+sex%2c+viral+genotype%2c+and+IL28B+genotype+on+spontaneous+clearance+of+acute+hepatitis+C+virus+infection&publication_year=2014&author=J+Grebely&author=K+Page&author=R+Sacks%e2%80%90Davis&author=MS+van+der+Loeff&author=TM+Rice&author=J+Bruneau" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=The+effects+of+female+sex%2c+viral+genotype%2c+and+IL28B+genotype+on+spontaneous+clearance+of+acute+hepatitis+C+virus+infection&publication_year=2014&author=J+Grebely&author=K+Page&author=R+Sacks%e2%80%90Davis&author=MS+van+der+Loeff&author=TM+Rice&author=J+Bruneau');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0126" class="article-references__item js-article-reference">126. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T‐cell exhaustion. J Infect Dis 2012;205:763‐771. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-243"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01451459-201203010-00011.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01451459-201203010-00011.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/22293431" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/22293431');return false">PubMed</a> | <a href="https://doi.org/10.1093%2Finfdis%2Fjir835" onclick="javascript:window.open('https://doi.org/10.1093%2Finfdis%2Fjir835');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Spontaneous+clearance+of+chronic+hepatitis+C+virus+infection+is+associated+with+appearance+of+neutralizing+antibodies+and+reversal+of+T%e2%80%90cell+exhaustion&publication_year=2012&author=S+Raghuraman&author=H+Park&author=WO+Osburn&author=E+Winkelstein&author=BR+Edlin&author=B.+Rehermann" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Spontaneous+clearance+of+chronic+hepatitis+C+virus+infection+is+associated+with+appearance+of+neutralizing+antibodies+and+reversal+of+T%e2%80%90cell+exhaustion&publication_year=2012&author=S+Raghuraman&author=H+Park&author=WO+Osburn&author=E+Winkelstein&author=BR+Edlin&author=B.+Rehermann');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0127" class="article-references__item js-article-reference">127. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short‐term interferon‐alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004;39:1213‐1219. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-243"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200405000-00007.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200405000-00007.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/15122749" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/15122749');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.20196" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.20196');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Short%e2%80%90term+interferon%e2%80%90alfa+therapy+for+acute+hepatitis+C%3a+a+randomized+controlled+trial&publication_year=2004&author=H+Nomura&author=S+Sou&author=H+Tanimoto&author=T+Nagahama&author=Y+Kimura&author=J+Hayashi" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Short%e2%80%90term+interferon%e2%80%90alfa+therapy+for+acute+hepatitis+C%3a+a+randomized+controlled+trial&publication_year=2004&author=H+Nomura&author=S+Sou&author=H+Tanimoto&author=T+Nagahama&author=Y+Kimura&author=J+Hayashi');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0128" class="article-references__item js-article-reference">128. Gerlach JT, Diepolder HM, Zachoval R, Gruener H, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment‐induced viral clearance. Gastroenterology 2003;125:80‐88. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-243"> Cited Here</a> | </li> <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/12851873" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/12851873');return false">PubMed</a> | <a href="https://doi.org/10.1016%2FS0016-5085%2803%2900668-1" onclick="javascript:window.open('https://doi.org/10.1016%2FS0016-5085%2803%2900668-1');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Acute+hepatitis+C%3a+high+rate+of+both+spontaneous+and+treatment%e2%80%90induced+viral+clearance&publication_year=2003&author=JT+Gerlach&author=HM+Diepolder&author=R+Zachoval&author=H+Gruener&author=MC+Jung&author=A+Ulsenheimer" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Acute+hepatitis+C%3a+high+rate+of+both+spontaneous+and+treatment%e2%80%90induced+viral+clearance&publication_year=2003&author=JT+Gerlach&author=HM+Diepolder&author=R+Zachoval&author=H+Gruener&author=MC+Jung&author=A+Ulsenheimer');return false">Google Scholar</a></li> </ul> </div> </div> <div id="hep27950-bib-0129" class="article-references__item js-article-reference">129. Ghany MG, Strader DB, Thomas DL, Seeff LB; for the American Association for the Study of Liver Diseases . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335‐1374. <div> <ul class="article-references__item-links"> <li class="internal-links"><a href="#JCL-P-245"> Cited Here</a> | </li> <li><a href="https://journals.lww.com/academicmedicine/01515467-200904000-00031.fulltext" onclick="javascript:window.open('https://journals.lww.com/academicmedicine/01515467-200904000-00031.fulltext');return false">View Full Text</a> | <a href="http://www.ncbi.nlm.nih.gov/pubmed/19330875" onclick="javascript:window.open('http://www.ncbi.nlm.nih.gov/pubmed/19330875');return false">PubMed</a> | <a href="https://doi.org/10.1002%2Fhep.22759" onclick="javascript:window.open('https://doi.org/10.1002%2Fhep.22759');return false">CrossRef</a> | </li> <li><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis%2c+management%2c+and+treatment+of+hepatitis+C%3a+an+update&publication_year=2009&author=MG+Ghany&author=DB+Strader&author=DL+Thomas&author=LB+Seeff" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Diagnosis%2c+management%2c+and+treatment+of+hepatitis+C%3a+an+update&publication_year=2009&author=MG+Ghany&author=DB+Strader&author=DL+Thomas&author=LB+Seeff');return false">Google Scholar</a></li> </ul> </div> </div> <div class="article-references__button-container"></div></section><section class="ej-article-copyright">© 2015 by the American Association for the Study of Liver Diseases</section></div><button class="ejp-toggle-fulltext-button js-ejp-toggle-fulltext-button">View full article text</button></article> </div> </div> <div id="article-metrics"> <div id="article-metrics-container"> </div> </div> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_divOutlineHTML"></div> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/SlideShowPopup.js?v=05.24.00.023" defer="true"> </script> <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/zoom.js?v=05.24.00.023" defer="true"> </script> <script> var sample = 6; var smPos = 153; var spPos = 153; var sW; var sH; var articleImageDialogModal = $('#ArticleImageDialogModal'); function setImage(imageUrl) { var $container = $("#zoom_container"); var width = $container.width(); $container.z("destroy") .css("background-image", "url(/_layouts/1033/images/oaks.journals/preloader.gif)") .z({ width: width, image_url: imageUrl, responsive: true, responsive_maintain_ratio: true, max_WIDTH: '1200', max_HEIGHT: '1200', initial_ZOOM: 100, initial_POSITION: '0,0' }); return false; } </script> <div id="ArticleImageModal" class="wk-modal wk-modal-slideshow horizontally-centered large fixed-vertical ejp-modal" role="dialog" style="display: none;"> <div class="modal-dialog"> <section class="modal-content wk-modal-content wk-modal-slideshow__content"> <header class="wk-modal-header ejp-modal-header"> <button onclick="return displaySlideShowModal(false);" aria-label="close dialog" class="wk-button-icon wk-modal-close ejp-modal-close" data-dismiss="wk-modal"><i class="fa fa-times"></i></button> </header> <div class="modal-body wk-modal-body wk-modal-slideshow__body flex flex-column"> <div id="zoom_container" class="wk-modal-slideshow__zoom-container"></div> <div id="ZoomContainerDetails" class="wk-modal-slideshow__zoom-container-details pa3"> <h3> <div class="wk-modal-slideshow__title"></div> </h3> <div class="wk-modal-slideshow__description"></div> <h4>Source</h4> <div class="wk-modal-slideshow__source-article mb4"> <a href="javascript:void(0);" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_sourceArticleUrl" onclick="HideSlideShow();">Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus</a> </div> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_citationdiv" class="wk-modal-slideshow__source-citation mb4"> Hepatology62(3):932-954, September 2015. </div> </div> </div> <div class="modal-footer wk-modal-footer wk-modal-slideshow__footer pa2 flex flex-column flex-wrap"> <div class="wk-modal-slideshow__zoom-controls flex justify-between items-center mb2"> <div id="zoom_buttons" class="wk-modal-slideshow__zoom-buttons flex justify-between"> <a href="#" onmousedown="$('#zoom_container').z('zoomIn')" onclick="return false" title="Zoom In" class="ph3"><i class="fa fa-plus-square white"></i></a> <a href="#" onmousedown="$('#zoom_container').z('zoomOut')" onclick="return false" title="Zoom Out" class="ph3"><i class="fa fa-minus-square white"></i></a> </div> <div class="wk-modal-slideshow__list-pager flex pr3"> <a href="javascript:void(0);" onclick="MovePrevious();" id="anchorPrev" title="Previous"><i class="fa fa-arrow-circle-left white"></i></a> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_imageCountStatus" class="wk-modal-slideshow__list-pager-text mh3 tc white"></span> <a href="javascript:void(0);" onclick="MoveNext();" id="anchorNext" title="Next"><i class="fa fa-arrow-circle-right white"></i></a> </div> </div> <ul class="wk-modal-slideshow__action-controls flex justify-between"> <li class="pv2 ph3"> <a href="javascript:void(0);" onclick="ShowFullSize('01515467-201509000-00029');" class="white tc"> <i class="fa fa-arrows-alt mb2 db white"></i> <span class="wk-modal-slideshow__action-controls-text">Full-Size</span> </a> </li> <li id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_lnkEmailToColleague" class="pv2 ph3"> <a href="javascript:void(0);" onclick="slideShow_EmailLinkClicked(imageIndex);" class="white tc"> <i class="fa fa-envelope mb2 db white"></i> <span class="wk-modal-slideshow__action-controls-text">Email</span> </a> </li> <li id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_lnkFavorites" class="pv2 ph3"> <button class="user-menu__link user-menu__link--add-to-favorites js-ejp-login-btn white tc" type="button" data-config="{"eventName":"AddToFavoritesFromSlideShow","eventDetail":{"items":["Image|hep:2015:09000:00029|{0}|"],"an":"01515467-201509000-00029"},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":false,"promptLogin":true,"loginPromptText":"To save this item, login or register"},"isNull":false}"> <i class="fa fa-folder mb2 db white"></i> <span class="wk-modal-slideshow__action-controls-text">+ Favorites</span> </button> </li> <li class="pv2 ph3"> <button class="user-menu__link user-menu__link--ppt-download js-ejp-login-btn" type="button" data-config="{"eventName":"PPTDownload","eventDetail":{"url":"https://journals.lww.com:443/hep/fulltext/2015/09000/hepatitis_c_guidance__aasld_idsa_recommendations.29.aspx?Ppt=Article|hep:2015:09000:00029|10.1002/hep.27950|","gating":false},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}"> <i class="fa fa-file-powerpoint-o mb2 db white"></i> <span class="wk-modal-slideshow__action-controls-text">Export</span> </button> </li> <li class="wk-modal-slideshow__view-gallery pv2 ph3"> <a href="javascript:void(0);" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_imageGalleryUrl" class="white tc" onclick="slideShow_NavigateToUrl('/hep/pages/imagegallery.aspx?year=2015&issue=09000&article=00029')"> <i class="fa fa-th-large mb2 db white"></i> <span class="wk-modal-slideshow__action-controls-text">View in Gallery</span> </a> </li> </ul> </div> </section> </div> </div> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$callShowImage" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_callShowImage" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$popupImageId" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_popupImageId" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$IsExportToPPT" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_IsExportToPPT" value="false" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$keyword" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_keyword" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_url" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_url" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_description" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_description" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_sourceTitle" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceTitle" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_sourceUrl" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceUrl" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_sourceInfo" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceInfo" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_key" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_key" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_fullSizeUrl" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_fullSizeUrl" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_imageGalleryUrl" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_imageGalleryUrl" /> <input type="hidden" id="NoOfImages" name="NoOfImages" value="0" /> <script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/EmailToColleague.js?v=05.24.00.023" defer="true"> </script> <a id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hypEmailToColleague" href="javascript:" style="display:none;"></a> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlEmailToColleague" class="wk-modal-table" style="display: none"> <div class="wk-modal-cell"> <div id="ej-box-modal-drop-shadow" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal email-to-colleague" tabindex="-1" role="dialog" style="position: static;"> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlMain" class="js-main-panel" onkeypress="javascript:return WebForm_FireDefaultButton(event, 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_btnSend')"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"> <strong> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblEmailToColleague">Email to Colleague</span></strong> </div> <button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "> <i class="fa fa-times"></i> </button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <div class="wk-field-header"> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_divErrorMessage" class="js-error-message-div ej-error-message-panel" style="display: none; color: red; font-style: italic"> <p class="ej-error-message-icon"> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblErrorMessage" class="js-error-message-label">Colleague's E-mail is Invalid</span> </p> </div> </div> </div> <div class="wk-field-item"> <div class="wk-field-header"> Your Name: </div> <div class="wk-field-body"> <input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$txtYourName" type="text" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtYourName" class="js-name" /> </div> </div> <div class="wk-field-item"> <div class="wk-field-header"> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblColleaguesEmail" class="js-collegaues-email-lbl">Colleague's Email:</span> </div> <div class="wk-field-body no-bottom-margin"> <input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$txtColleaguesEmail" type="text" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtColleaguesEmail" class="js-collegaues-email" /> </div> <div class="wk-field-header"><span class="ej-form-comments">Separate multiple e-mails with a (;).</span></div> </div> <div class="wk-field-item"> <div class="wk-field-header"> Message: </div> <div class="wk-field-body"> <textarea name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$txtMessage" rows="2" cols="20" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtMessage" class="js-message"> Thought you might appreciate this item(s) I saw in Hepatology.</textarea> </div> </div> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$btnSend" value="Send" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_btnSend" class="js-send-button primary-button grecaptcha-email-colleague-ae001ce86af640b9a39d3b6ca941426f" /> <input type="button" value="Cancel" id="btnCancel" class="secondary-button js-close" /> </div> </div> <div class="wk-field-item wk-email-colleague-captcha-bar"> <div class="wk-field-body"> <div id="div-recaptcha-ae001ce86af640b9a39d3b6ca941426f" class="div-recaptcha-container" data-uniqueclassidentifier="grecaptcha-email-colleague-ae001ce86af640b9a39d3b6ca941426f" data-sitekey="6LeeoSAUAAAAACFv8yNuINPv8IWyXHJ6uN447qEK" data-callback="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_captchaCallBack" data-badge="inline" data-size="invisible" data-type="image" > </div> </div> </div> </div> </section> </div> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlSuccessMessage" class="js-success-message-panel" style="display: none;"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"></div> <button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button> </header> <div class="wk-modal-body"> <div class="wk-field-item"> <br /> <p> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblMessageSent">Your message has been successfully sent to your colleague.</span> </p> <br /> </div> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="button" value="Close Window" id="btnClose" class="primary-button js-close" /> </div> </div> </div> </section> </div> <div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlErrorMessage" class="js-error-message-panel" style="display: none;"> <section class="wk-modal-content"> <header class="wk-modal-header ejp-modal-header"> <div class="wk-modal-title ejp-modal-title"></div> <button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button> </header> <div class="wk-modal-body"> <br /> <div class="wk-field-item"> <span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblInvalidEmail" style="color:Red;">Some error has occurred while processing your request. Please try after some time.</span> </div> <br /> <div class="wk-button-bar"> <div class="wk-button-group-left"> <input type="button" value="Close Window" id="btnEClose" class="primary-button js-close" /> </div> </div> </div> </section> </div> </div> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$hiddenEmailToColleague" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenEmailToColleague" /> <input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$hiddenIsUser" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenIsUser" /> </div> </div> <script type="text/javascript"> window.emailToColleaguePopups = window.emailToColleaguePopups || []; var ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_captchaCallBack = function () { ejpAnalytics.track('emailColleaguereCAPTCHA'); ejpAnalytics.track('emailColleagueComplete'); __doPostBack('ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$btnSend','') }; var initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague = function () { window.emailToColleaguePopups['ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague'] = new EmailToColleagueComponent('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlEmailToColleague', 'div-recaptcha-ae001ce86af640b9a39d3b6ca941426f', 'grecaptcha-email-colleague-ae001ce86af640b9a39d3b6ca941426f', 'emailToColleaguePopupExtender_579494353', 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenEmailToColleague', 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenIsUser', '01515467-201509000-00029' ); } Sys.WebForms.PageRequestManager.getInstance().add_pageLoaded(initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague); </script> <input type="hidden" id="selectedItems" name="selectedItems" value="" /> </div><div class="ms-clear"></div></div> </div> </div> </div></div> <div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutColumnRepeater_ctl01_ResponsiveLayoutColumn" class=" wk-column-12 wk-column-4-m wk-column-4-l wk-column-4-xl wk-column-4-xxl"> <div class="ms-webpart-zone ms-fullWidth"> <div id="MSOZoneCell_WebPartWPQ1" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="32bb86ac-479e-413d-a966-f55007095b64" HasPers="false" id="WebPartWPQ1" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_32bb86ac_479e_413d_a966_f55007095b64"> <div id="ctl00_ctl29_g_32bb86ac_479e_413d_a966_f55007095b64_ctl00_adContainer" class="ej-advertisement ej-advertisement-middle"> <div class="ej-advertisement-content"> <div> <div id="ga_016739cf-fe35-4dbe-b291-fe2f8039207a" class="ad-slot-container ad-slot-container-ga_016739cf-fe35-4dbe-b291-fe2f8039207a" data-sizemap="[[[0, 0], [[300, 250]]]]" data-adpath="/15726702761/Desktop/hep/Article/Right" data-autoload="no" data-outofpage="no" data-sticky="no" data-slottargeting='' data-displayslug="yes" data-sticky-duration="0" data-name="Right"></div> </div> </div> </div> </div><div class="ms-clear"></div></div> </div><div class="ms-PartSpacingVertical"></div> </div><div id="MSOZoneCell_WebPartWPQ2" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="aafef93a-60d4-4d6f-a190-4cfc0e5a1711" HasPers="false" id="WebPartWPQ2" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_aafef93a_60d4_4d6f_a190_4cfc0e5a1711"> <div class="js-advanced-recommendation-widget" data-config="{"serviceUrl":null,"displayMode":"ListView","headerText":"Related Articles","hash":"1","itemsPerPage":6,"renderOnServer":false,"showConsoleLog":false,"shouldShowSpeciality":"0","kind":"Article","title":"Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","meshTerms":["Hepatitis C","Hepacivirus","Infections","Hepatovirus","Communicable Diseases","HIV","HIV Infections","Americas","Glomerular Filtration Rate","Alanine Transaminase"],"wkmrid":"JOURNAL/hepa/04.03/01515467-201509000-00029/root/v/2024-01-14T174203Z/r/text-xml","imageHandlerUrl":"https://images.journals.lww.com/hep","accessionNumber":"01515467-201509000-00029","fontSize":"small","displayImage":false,"showJournalTitle":false,"showPublicationDate":false}"></div> </div><div class="ms-clear"></div></div> </div><div class="ms-PartSpacingVertical"></div> </div><div id="MSOZoneCell_WebPartWPQ3" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="f8dbebef-5133-4869-9c15-1309ceb7f1b8" HasPers="false" id="WebPartWPQ3" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_f8dbebef_5133_4869_9c15_1309ceb7f1b8"> <div id="ctl00_ctl29_g_f8dbebef_5133_4869_9c15_1309ceb7f1b8_ctl00_adContainer" class="ej-advertisement ej-advertisement-middle"> <div class="ej-advertisement-content"> <div> <div id="ga_f1eef85a-d43c-4089-a5c5-9c3660c97538" class="ad-slot-container ad-slot-container-ga_f1eef85a-d43c-4089-a5c5-9c3660c97538" data-sizemap="[[[0, 0], [[300, 250]]]]" data-adpath="/15726702761/Desktop/hep/Article/Right" data-autoload="no" data-outofpage="no" data-sticky="no" data-slottargeting='' data-displayslug="yes" data-sticky-duration="0" data-name="Right"></div> </div> </div> </div> </div><div class="ms-clear"></div></div> </div><div class="ms-PartSpacingVertical"></div> </div><div id="MSOZoneCell_WebPartWPQ4" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="d72f615e-1372-4fb5-8072-8dd9848345b1" HasPers="false" id="WebPartWPQ4" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_d72f615e_1372_4fb5_8072_8dd9848345b1"> <div data-config="{"serviceUrl":null,"displayMode":null,"hash":"1","itemsPerPage":40,"renderOnServer":false}"></div><section id="ctl00_ctl29_g_d72f615e_1372_4fb5_8072_8dd9848345b1_ctl01_divRecentActivity" class="content-box cb-collapsible"> <div class="ejp-uc--small"> <header class="ejp-heading-2"> <h2 aria-expanded="false"> Readers Of this Article Also Read </h2> </header> <div id="ej-box-01-body"> <div id="ej-articlesWithTerms"> <ul> <li class="ejp-uc__list-item"> <h3 class='ejp-uc__article-title'><a title href="https://journals.lww.com/hep/fulltext/2024/05000/aasld_practice_guidance_on_risk_stratification_and.22.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis', 'Kaplan David E.; Ripoll, Cristina; Thiele, Maja; Fortune, Brett E.; Simonetto, Douglas A.; Garcia-Tsao, Guadalupe; Bosch, Jaime', 'Hepatology', 'May 2024', '79', '5' , 'p 1180-1211');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">AASLD Practice Guidance on risk stratification and management of portal...</a></h3></li> <li class="ejp-uc__list-item"> <h3 class='ejp-uc__article-title'><a title href="https://journals.lww.com/hep/fulltext/2018/04000/update_on_prevention,_diagnosis,_and_treatment_of.39.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance', 'Terrault Norah A.; Lok, Anna S.F.; McMahon, Brian J.; Chang, Kyong‐Mi; Hwang, Jessica P.; Jonas, Maureen M.; Brown, Robert S. Jr.; Bzowej, Natalie H.; Wong, John B.', 'Hepatology', 'April 2018', '67', '4' , 'p 1560-1599');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD...</a></h3></li> <li class="ejp-uc__list-item"> <h3 class='ejp-uc__article-title'><a title href="https://journals.lww.com/hep/fulltext/2020/02000/hepatitis_c_guidance_2019_update__american.23.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection', 'Ghany Marc G.; Morgan, Timothy R.; AASLD‐IDSA Hepatitis C Guidance Panel', 'Hepatology', 'February 2020', '71', '2' , 'p 686-721');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Hepatitis C Guidance 2019 Update: American Association for the Study of Liver...</a></h3></li> <li class="ejp-uc__list-item"> <h3 class='ejp-uc__article-title'><a title href="https://journals.lww.com/hep/fulltext/2020/08000/diagnosis_and_management_of_autoimmune_hepatitis.24.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases', 'Mack Cara L.; Adams, David; Assis, David N.; Kerkar, Nanda; Manns, Michael P.; Mayo, Marlyn J.; Vierling, John M.; Alsawas, Mouaz; Murad, Mohammad H.; Czaja, Albert J.', 'Hepatology', 'August 2020', '72', '2' , 'p 671-722');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019...</a></h3></li> <li class="ejp-uc__list-item"> <h3 class='ejp-uc__article-title'><a title href="https://journals.lww.com/hep/fulltext/2021/08000/diagnosis,_evaluation,_and_management_of_ascites,.38.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases', 'Biggins Scott W.; Angeli, Paulo; Garcia‐Tsao, Guadalupe; Gin\u00E8s, Pere; Ling, Simon C.; Nadim, Mitra K.; Wong, Florence; Kim, W. Ray', 'Hepatology', 'August 2021', '74', '2' , 'p 1014-1048');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial...</a></h3></li> </ul> </div> </div> </div> </section> </div><div class="ms-clear"></div></div> </div><div class="ms-PartSpacingVertical"></div> </div><div id="MSOZoneCell_WebPartWPQ5" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="88b6780f-ddf0-4eb6-a222-0ad6973af05c" HasPers="false" id="WebPartWPQ5" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_88b6780f_ddf0_4eb6_a222_0ad6973af05c"> <div id="ctl00_ctl29_g_88b6780f_ddf0_4eb6_a222_0ad6973af05c_ctl00_adContainer" class="ej-advertisement ej-advertisement-bannercombo"> <div class="ej-advertisement-content"> <div> <div id="ga_a4b22233-3e9e-4b77-a36a-f5db3fa1df06" class="ad-slot-container ad-slot-container-ga_a4b22233-3e9e-4b77-a36a-f5db3fa1df06" data-sizemap="[[[1050, 200], [[300, 600], [300, 250], [160, 600]]], [[730, 600], [[300, 600], [300, 250]]], [ [ 0, 0 ], [ [300, 250] ] ] ]" data-adpath="/15726702761/Desktop/hep/Article/Right1" data-autoload="no" data-outofpage="no" data-sticky="no" data-slottargeting='' data-displayslug="yes" data-sticky-duration="0" data-name="Right1"></div> </div> </div> </div> </div><div class="ms-clear"></div></div> </div><div class="ms-PartSpacingVertical"></div> </div><div id="MSOZoneCell_WebPartWPQ6" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth "> <div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth "> <div WebPartID="532eb91a-d961-4c77-9820-2c9418dc1e03" HasPers="false" id="WebPartWPQ6" width="100%" class="ms-WPBody noindex " allowDelete="false" style="" ><div id="ctl00_ctl29_g_532eb91a_d961_4c77_9820_2c9418dc1e03"> <div class="js-ejp-universalMostPopular-webpart" data-config="{"serviceUrl":"https://services.journals.lww.com/IntegrationServices/MostPopularDataService.svc/GetMostPopularItems?timeframe=90d&journalIds=hep&publisher=LWW&results=5&numberOfSymbolsInSubtitle=275&hash=1&displayCustomIndicator=False","headerText":"Most Popular","headerUrl":null,"displayMode":"ListView","hash":"1","shouldShowImage":false,"shouldShowSpeciality":"JournalSpeciality","showArticleDescription":false,"showJournalTitle":false,"viewAllLink":null,"fontSize":"small","showSpecialitySection":false,"showPublicationDate":false,"showIndicators":false}"></div> </div><div class="ms-clear"></div></div> </div> </div> </div></div> </div> </div> <div class="wk-grid-container-no-margin" id="AddRowBottomContainer"> </div> </div> <div style='display:none' id='hidZone'><menu class="ms-hide"> <ie:menuitem id="MSOMenu_Help" iconsrc="/_layouts/15/images/HelpIcon.gif" onmenuclick="MSOWebPartPage_SetNewWindowLocation(MenuWebPart.getAttribute('helpLink'), MenuWebPart.getAttribute('helpMode'))" text="Help" type="option" style="display:none"> </ie:menuitem> </menu></div> </div> <div id="DeltaFormDigest"> <script type="text/javascript">//<![CDATA[ var formDigestElement = document.getElementsByName('__REQUESTDIGEST')[0]; if (!((formDigestElement == null) || (formDigestElement.tagName.toLowerCase() != 'input') || (formDigestElement.type.toLowerCase() != 'hidden') || (formDigestElement.value == null) || (formDigestElement.value.length <= 0))) { formDigestElement.value = '0x76CA10295F4D5707D43E4BB7145BC3574B8DE098AB5892EE747E18A287ED8E71D2459A52660F70B3F34094751D55E5C2F02E1790E9A5B8C69BB31E8A5E0628FC,28 Mar 2025 09:13:48 -0000';_spPageContextInfo.updateFormDigestPageLoaded = new Date(); } //]]> </script> </div> </div>  <footer class="ejp-footer"> <div class="container wk-grid-page-container"> <a class="ejp-footer__back-to-top-link"><i class="fa fa-angle-up b ejp-footer__back-to-top-link-icon"></i>Back to Top</a> <div class="ejp-footer__main-content">  <div class="ejp-footer__smart-control-section"> <section class="ejp-footer__smart-control-section-wrapper js-section-alert"> <div class="ejp-footer__smart-control-section-image-container"> <img src="https://images.journals.lww.com/hep/XLargeThumb.01515467-202504000-00000.CV.jpeg" id="ctl00_ctl56_FooterSmartControl_ctl00_imgAlertControl" alt="Current Issue Cover Image" class="" /> </div> <div class="ejp-footer__smart-control-section-text-holder"> <h4 id="ctl00_ctl56_FooterSmartControl_ctl00_headerAlertControl">Never Miss an Issue</h4> <div class="js-section-alert__content"> <span id="ctl00_ctl56_FooterSmartControl_ctl00_spanBodyAlertControl" class="ejp-footer__smart-control-section-info">Get new journal Tables of Contents sent right to your email inbox</span> <input name="ctl00$ctl56$FooterSmartControl$ctl00$userEmailAlertControl" type="text" id="ctl00_ctl56_FooterSmartControl_ctl00_userEmailAlertControl" class="js-section-alert__email" placeholder="Type your email" /> <span class="js-section-alert--error"></span> <button id="ctl00_ctl56_FooterSmartControl_ctl00_buttonAlertControl" type="button" class="js-section-alert__subscribe-button" data-alert-type="Etoc" data-subscribed-msg="You are now subscribed to receive eTOC alerts whenever new issues are published">Get New Issue Alerts</button> </div> </div> </section> <script type="text/javascript"> (function($) { $("#smartWpMostPopularLink").on('click', function() { window.location = "https://journals.lww.com/hep/pages/viewallmostpopulararticles.aspx?WT.mc_id=HPxADx20100319xMP"; }); })(jQuery); </script> </div> <div class="ejp-footer__info-holder"> <div id="ctl00_ctl56_divLeftColumn" class="ejp-footer__info-left-wrapper"> <div class="ejp-footer__info-block"> <h4 class="ejp-footer__info-block-header">Browse Journal Content</h4> <ul class="ejp-footer__info-block-two-col-list"> <li id="ctl00_ctl56_liRegister"><a id="ctl00_ctl56_lnkRegister" href="https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2015%2f09000%2fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx">Register on the website</a></li> <li id="ctl00_ctl56_liSubscribe" role="presentation"><a id="ctl00_ctl56_lnkSubscribe" href="https://shop.lww.com/p/0270-9139" target="_blank">Subscribe</a></li> <li id="ctl00_ctl56_liHyperSubscribeToEtoc"><a rel="nofollow" title href="javascript:javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');;" onclick="javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');"><span id="ctl00_ctl56_alertLinkControl_defaultText" class="hideOnFixed">Get eTOC Alerts</span></a> </li> </ul> </div> </div> <div id="ctl00_ctl56_divRightColumn" class="ejp-footer__info-right-wrapper"> <div class="ejp-footer__info-block ejp-footer__info-block--custom-service"> <h4 class="ejp-footer__info-block-header">Customer Service</h4> <ul> <li><span class="ejp-footer--show-on-mobile">Contact us at:</span> <ul> <li class="ejp-footer__contacts-wrapper ejp-footer__email-settings"> <div class="ejp-footer--show-on-mobile">Support:</div> <a href="https://www.tfaforms.com/4966570" id="ctl00_ctl56_custSupport" target="_blank">Submit a Service Request</a> </li> <li class="ejp-footer__contacts-wrapper ejp-footer__phone-settings"> <div class="ejp-footer--show-on-mobile ejp-footer__phone-settings--version"> <div id="ctl00_ctl56_telMobileCustom">TEL:</div> </div> <div class="ejp-footer__phone-settings--holder"> <div>800-638-3030 (within the USA)</div> <div>301-223-2300 (outside of the USA)</div> </div> </li> </ul> </li> </ul> <ul><li> <button id="ot-sdk-btn" class="ot-sdk-show-settings ot-ejp-btn" onclick="return false;">Cookie Settings</button> </li> </ul> </div> </div> </div> <span id="ctl00_ctl56_FooterConfiguration" class="js-config-provider" data-config="{"loginConfiguration":{"serviceUrl":"https://services.journals.lww.com/IntegrationServices/AccountService.svc/Login","registerUrl":"https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2015%2f09000%2fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx","forgotPasswordUrl":"https://journals.lww.com/hep/pages/forgotpassword.aspx?ContextUrl=%2fhep%2ffulltext%2f2015%2f09000%2fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx","redirectUrl":"https://journals.lww.com/hep/pages/login.aspx?ContextUrl=%2fhep%2ffulltext%2f2015%2f09000%2fhepatitis_c_guidance__aasld_idsa_recommendations.29.aspx","tokenKey":"AppSsoToken","ssoLoginOptions":[{"loginHref":"https://login.journals.lww.com/OneID/Login.aspx?PartnerIdpId=https://my.aasld.org&Login_type=SocietySso&returnUrl=https%3a%2f%2fjournals.lww.com%2fhep%2fpages%2farticleviewer.aspx%3fyear%3d2015%26issue%3d09000%26article%3d00029%26type%3dFulltext","imageSrc":"/aasldpubs/PublishingImages/logos/Logo.jpg","linkPrefixText":"AASLD members log in here","linkText":"AASLD members log in here"}],"customerService":{"customerServiceUSPhone":"(800) 638-3030","customerServiceInternationalPhone":"301-223-2300","customerServiceEmail":"customerservice@lww.com"},"useAlternativeAccountLinks":false},"commonConfiguration":{"commonEndpoints":{"addToFavoritesServiceUrl":"https://journals.lww.com/hep/_layouts/15/OAKS.Journals/UserCollectionsService.svc/AddToFavorites","saveSearchServiceUrl":"https://journals.lww.com/hep/_layouts/15/OAKS.Journals/UserCollectionsService.svc/SaveSearch","counterDataServiceUrl":"https://journals.lww.com/hep/_layouts/15/OAKS.Journals/DualAccessService.svc/SendCounterDataRequestByAN"},"kaltura":{"partnerId":"1315631","playerId":"52253872","kalturaWidgetUrl":"https://cdnapisec.kaltura.com/p/1315631/embedPlaykitJs/uiconf_id/52253872"},"brightCove":{"brightCoveScriptUrl":"https://players.brightcove.net/2324982687001/HyP0JSARx_default/index.min.js","dataAccount":"2324982687001","dataPlayer":"HyP0JSARx"},"math":{"libUrl":"https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"},"recoWidget":{"journals":[{"Id":"hep","Version":"04.03","ProductCode":"hepa"}],"pubFilter":{},"clientId":"ejp_v3","libUrl":"https://assets.ovid.com/widget/v3/widget.js"},"sciteBadge":{"libUrl":"https://cdn.scite.ai/badge/scite-badge-latest.min.js"}}}"></span> </div> <div class="ejp-footer__bottom-links"> <ul class="ejp-footer__useful-links"> <li><a id="ctl00_ctl56_hlkPrivacy" href="https://journals.lww.com/hep/_layouts/oaks.journals/privacy.aspx">Privacy Policy</a></li> <li><a id="ctl00_ctl56_hlkLegal" href="https://journals.lww.com/hep/_layouts/oaks.journals/disclaimer.aspx">Legal Disclaimer</a></li> <li><a id="ctl00_ctl56_hlkTermsOfUse" href="https://journals.lww.com/hep/_layouts/oaks.journals/terms.aspx">Terms of Use</a></li> <li><a id="ctl00_ctl56_hlkNIHPublicAccess" href="https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access">Open Access Policy</a></li> <li><a id="ctl00_ctl56_hlkCAPrivacyChoices" href="https://privacyportal-de.onetrust.com/webform/2217e117-526b-4696-8a98-8c402f8f2b81/5b049ba3-0106-4b77-a7da-5d12238c90a4">Your California Privacy Choices</a> <img src="/_layouts/1033/IMAGES/OAKS.Journals/CAPrivacyPolicy.png" id="ctl00_ctl56_imgCAPrivacyPolicyChoices" class="wk-footer__ca-privacy-logo" alt="California Consumer Privacy Act (CCPA) Opt-Out Icon" /> </li> </ul> <ul class="ejp-footer__copyright-block"> <li><span>Copyright © 2025</span></li> <li><span><span>American Association for the Study of Liver Diseases -</span> <a href="https://www.wolterskluwer.com/en/health" target="_blank">Wolters Kluwer Health, Inc. All rights reserved.</a></span></li> </ul> </div> </div> </footer> </div> </div>   <script> $(document).on('click', '.yamm .dropdown-menu', function (e) { e.stopPropagation(); }); </script>   <div id="ctl00_ctl59_adContainer" class="ej-advertisement ejp-advertisement-highimpact js-advertisement-highimpact"> <div class="ej-advertisement-content"> <div> <div id="ga_470ea678-8f69-4a2e-bacd-cfbf4a2d7ca5" class="ad-slot-container ad-slot-container-ga_470ea678-8f69-4a2e-bacd-cfbf4a2d7ca5" data-sizemap="[[[992, 500], [[300, 250]]], [[768, 180], [[728, 90]]], [[0, 0], [[300, 50]]]]" data-adpath="/15726702761/Desktop/hep/HighImpact" data-autoload="yes" data-outofpage="no" data-sticky="yes" data-slottargeting='' data-displayslug="yes" data-sticky-duration="10" data-name="HighImpact"></div> </div> </div> </div>    <script type="text/javascript"> //<![CDATA[ var Page_Validators = new Array(document.getElementById("ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError")); //]]> </script> <script type="text/javascript"> //<![CDATA[ var ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError = document.all ? document.all["ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError"] : document.getElementById("ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError"); ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError.display = "Dynamic"; ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError.validationGroup = "EmailValidationGroup"; ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError.evaluationfunction = "CustomValidatorEvaluateIsValid"; //]]> </script> <script type="text/javascript"> //<![CDATA[ var _spFormDigestRefreshInterval = 1440000;window.SPThemeUtils && SPThemeUtils.ApplyCurrentTheme(true); IsSPSocialSwitchEnabled = function() { return true; };var _fV4UI = true; function _RegisterWebPartPageCUI() { var initInfo = {editable: false,isEditMode: false,allowWebPartAdder: false,listId: "{b807cb8a-3cdf-4126-b475-cf89c1612eb3}",itemId: 77,recycleBinEnabled: true,enableMinorVersioning: false,enableModeration: false,forceCheckout: false,rootFolderUrl: "\u002fhep\u002fPages",itemPermissions:{High:0,Low:200769}}; SP.Ribbon.WebPartComponent.registerWithPageManager(initInfo); var wpcomp = SP.Ribbon.WebPartComponent.get_instance(); var hid; hid = document.getElementById("_wpSelected"); if (hid != null) { var wpid = hid.value; if (wpid.length > 0) { var zc = document.getElementById(wpid); if (zc != null) wpcomp.selectWebPart(zc, false); } } hid = document.getElementById("_wzSelected"); if (hid != null) { var wzid = hid.value; if (wzid.length > 0) { wpcomp.selectWebPartZone(null, wzid); } } }; function __RegisterWebPartPageCUI() { ExecuteOrDelayUntilScriptLoaded(_RegisterWebPartPageCUI, "sp.ribbon.js");} _spBodyOnLoadFunctionNames.push("__RegisterWebPartPageCUI");var __wpmExportWarning='This Web Part Page has been personalized. As a result, one or more Web Part properties may contain confidential information. Make sure the properties contain information that is safe for others to read. After exporting this Web Part, view properties in the Web Part description file (.WebPart) by using a text editor such as Microsoft Notepad.';var __wpmCloseProviderWarning='You are about to close this Web Part. It is currently providing data to other Web Parts, and these connections will be deleted if this Web Part is closed. To close this Web Part, click OK. To keep this Web Part, click Cancel.';var __wpmDeleteWarning='You are about to permanently delete this Web Part. Are you sure you want to do this? To delete this Web Part, click OK. To keep this Web Part, click Cancel.';var lblColleaguesEmail = $get('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblColleaguesEmail'); var Page_ValidationActive = false; if (typeof(ValidatorOnLoad) == "function") { ValidatorOnLoad(); } function ValidatorOnSubmit() { if (Page_ValidationActive) { return ValidatorCommonOnSubmit(); } else { return true; } } //]]> </script> <script type='text/javascript'>SP.SOD.set_prefetch(0);</script> <script type="text/javascript"> //<![CDATA[ WPSC.Init(document); var varPartWPQ1 = WPSC.WebPartPage.Parts.Register('WPQ1','32bb86ac-479e-413d-a966-f55007095b64',document.getElementById('WebPartWPQ1')); var varPartWPQ2 = WPSC.WebPartPage.Parts.Register('WPQ2','aafef93a-60d4-4d6f-a190-4cfc0e5a1711',document.getElementById('WebPartWPQ2')); var varPartWPQ3 = WPSC.WebPartPage.Parts.Register('WPQ3','f8dbebef-5133-4869-9c15-1309ceb7f1b8',document.getElementById('WebPartWPQ3')); var varPartWPQ4 = WPSC.WebPartPage.Parts.Register('WPQ4','d72f615e-1372-4fb5-8072-8dd9848345b1',document.getElementById('WebPartWPQ4')); var varPartWPQ5 = WPSC.WebPartPage.Parts.Register('WPQ5','88b6780f-ddf0-4eb6-a222-0ad6973af05c',document.getElementById('WebPartWPQ5')); var varPartWPQ6 = WPSC.WebPartPage.Parts.Register('WPQ6','532eb91a-d961-4c77-9820-2c9418dc1e03',document.getElementById('WebPartWPQ6')); WPSC.WebPartPage.WebURL = 'https:\u002f\u002fjournals.lww.com\u002fhep'; WPSC.WebPartPage.WebServerRelativeURL = '\u002fhep'; var g_clientIdDeltaPlaceHolderMain = "DeltaPlaceHolderMain"; var g_clientIdDeltaPlaceHolderUtilityContent = "DeltaPlaceHolderUtilityContent"; WebForm_AutoFocus('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtYourName');Sys.Application.add_init(function() { $create(AjaxControlToolkit.ModalPopupBehavior, {"BackgroundCssClass":"Popup-Overlay","DropShadow":true,"PopupControlID":"ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pnlunSubscribeToAlerts","dynamicServicePath":"/hep/pages/articleviewer.aspx","id":"unSubscribeToAlerts"}, null, null, $get("ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_dummyTargetControl")); }); Sys.Application.add_init(function() { $create(AjaxControlToolkit.ModalPopupBehavior, {"BackgroundCssClass":"Popup-Overlay","DropShadow":true,"PopupControlID":"ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlSubscribeToEtoc","dynamicServicePath":"/hep/pages/articleviewer.aspx","id":"subscribeToEtoc"}, null, null, $get("ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_dummyTargetControl")); }); document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError').dispose = function() { Array.remove(Page_Validators, document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError')); } g_QuickLaunchControlIds.push("zz1_TopNavigationMenu");_spBodyOnLoadFunctionNames.push('QuickLaunchInitDroppable'); var g_zz1_TopNavigationMenu = null; function init_zz1_TopNavigationMenu() { if (g_zz1_TopNavigationMenu == null) g_zz1_TopNavigationMenu = $create(SP.UI.AspMenu, null, null, null, $get('zz1_TopNavigationMenu')); } if(g_spPreFetchKeys) {{ g_spPreFetchKeys.push('SP.Core.js');}}EnsureScriptFunc('SP.Core.js', 'SP.UI.AspMenu', init_zz1_TopNavigationMenu); Sys.Application.add_init(function() { $create(AjaxControlToolkit.ModalPopupBehavior, {"BackgroundCssClass":"Popup-Overlay","PopupControlID":"ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlEmailToColleague","dynamicServicePath":"/hep/pages/articleviewer.aspx","id":"emailToColleaguePopupExtender__1604761164"}, null, null, $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hypEmailToColleague")); }); Sys.Application.add_init(function() { $create(AjaxControlToolkit.ModalPopupBehavior, {"BackgroundCssClass":"Popup-Overlay","PopupControlID":"ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlExportTo","dynamicServicePath":"/hep/pages/articleviewer.aspx","id":"OpenExportToPopupExtender_1745200279"}, null, null, $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hypExportToCitationManager")); }); Sys.Application.add_init(function() { $create(AjaxControlToolkit.ModalPopupBehavior, {"BackgroundCssClass":"Popup-Overlay","PopupControlID":"ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlEmailToColleague","dynamicServicePath":"/hep/pages/articleviewer.aspx","id":"emailToColleaguePopupExtender_579494353"}, null, null, $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hypEmailToColleague")); }); //]]> </script> </form> <span id="DeltaPlaceHolderUtilityContent"> </span> <script type="text/javascript">// <![CDATA[ var g_Workspace = "s4-workspace"; // ]]> </script> <div id="ctl00_ctl64_divAdConfig" data-adconfig="{"adTitle":"Advertisement","slotClass":"ad-slot-container","topBanner":{"sticky":"false","stickyDuration":"5000"},"lazyLoadingEnabled":false,"npiHash":"","pageTargeting":{"ArticleId":"01515467-201509000-00029"}}" data-videoadconfig="{"serverURL":"https://pubads.g.doubleclick.net/gampad/ads","sizes":"320x180|640x360","overlayUnitPath":"/15726702761/Desktop/hep/Video/overlay","prerollUnitPath":"/15726702761/Desktop/hep/Video/pre-roll","postrollUnitPath":"/15726702761/Desktop/hep/Video/post-roll"}" class="js-ad-config"> </div> <div id="ctl00_ctl64_divScripts"><script type="text/plain" async="async" src="https://securepubads.g.doubleclick.net/tag/js/gpt.js" class="optanon-category-C0004"></script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/ads.js?v=05.24.00.023" defer="true"> </script> </div>  <script type="text/javascript"> (function($) { if (true) { $(".top-microbar-container").addClass('top-microbar-container-moved').insertAfter(".advertisement-content_top"); } $(function () { if (false) { $( '<div class="top-banner-verify-email">Be sure to check your email to verify your new user account! Thanks!</div>') .insertAfter(".top-microbar-container"); } }); })(jQuery); </script> <script type="text/javascript"> window.twttr = (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0], t = window.twttr || {}; if (d.getElementById(id)) return t; js = d.createElement(s); js.id = id; js.src = "https://platform.twitter.com/widgets.js"; fjs.parentNode.insertBefore(js, fjs); t._e = []; t.ready = function(f) { t._e.push(f); }; return t; }(document, "script", "twitter-wjs")); </script> <script type="text/javascript" src="https://lww.com/_layouts/15/oaks.journals/core/ee.js?v=05.24.00.023" defer="true"> </script> <script type="text/javascript"> function OTScriptExecutedEventHandler(e) { if (window.WKTracker && window.TrackingSetup) { window.TrackingSetup.api = window.TrackingSetup.api || {}; window.TrackingSetup.api.baseUrl = 'https://apim-hlrp-ejp-prod.azure-api.net/ee'; window.TrackingSetup.api.log = window.TrackingSetup.api.log || {}; window.TrackingSetup.api.resolve = window.TrackingSetup.api.resolve || {}; window.TrackingSetup.gdpr = window.TrackingSetup.gdpr || {}; window.TrackingSetup.gdpr.cookieUsageConsent = window.cookieUsageConsent || false; window.WKTracker.configure(window.TrackingSetup); window.WKTracker.track(); // Remove the event listener window.removeEventListener('OTScriptExecuted', OTScriptExecutedEventHandler); } } window.addEventListener('OTScriptExecuted', OTScriptExecutedEventHandler); </script> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9276037a1dacfd9b',t:'MTc0MzE1MzIyOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html>